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An exploration of influences and changes in the diagnosis and 
management of symptoms of GOR (gastro-oesophageal reflux) in infants 
aged 0-1 year of age.   
 
Gastro-oesophageal reflux (GOR) is common in infants. According to NICE 
(2015), it affects 40% or more of infants and generally resolves naturally without 
the need for medical treatment. However, preliminary indications suggest that 
there has been a rise in the use of medicines to manage GOR in young infants 
under the age of twelve months. This is particularly evident for acid suppressant 
medicines such as ranitidine and omeprazole – drugs that are currently not 
licensed for use in the 0-1 age group in the UK (BNFC, 2019).  
 
To gain a greater understanding of the extent to which this rise in prescribing 
rates is manifest in Scotland, and what underpins this shift in prescribing 
patterns, this thesis adopted a two-stage research approach to the study. Stage 
one of this study analysed national prescribing data from the Information 
Services Division of NHS Scotland (ISD), to explore how patterns of prescribing 
for alginate, domperidone, omeprazole and ranitidine have changed over time, 
and how they differ between NHS Board areas in Scotland. Findings from stage 
one confirmed that the prescribing of alginate, omeprazole and ranitidine 
increased significantly in Scotland over a 7-year period between 2010 and 
2016. Prescribing of alginate increased from 15.7 per 100 infants in 2010 to 
24.7 per 100 infants in 2016, whilst the prescribing rate for ranitidine increased 
over four-fold from 2.3 per 100 infants in 2010 to 9.7 per 100 infants in 2016, 
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and for omeprazole the prescribing rate increased over three-fold from 0.9 per 
100 infants in 2010 to 3.2 per 100 infants in 2016. Furthermore, the data 
revealed regional variation in the drugs prescribed. 
 
Stage two sought to investigate what underpinned this change in prescribing 
patterns in greater depth. Focusing on one NHS Board in Scotland that had a 
high prescribing rate for ranitidine, stage two adopted a qualitative approach 
and used in-depth interviews to explore issues contributing to this shift in 
prescribing patterns from the perspectives of health visitors, general 
practitioners and parents. Semi-structured interview schedules were used to 
guide in-depth interviews with 22 participants. Issues of adherence to national 
guidelines, the shift away from conservative to more pharmaceutical treatments 
for GOR and shifts in knowledge and power between clinicians and parents 
were explored.  While general practitioners and health visitors remain the key 
players in diagnosing and treating GOR in infants in Scotland, general 
practitioners often rely on the expertise of health visitors whom they see as the 
experts in this field, whilst health visitors are often influenced by parental 
pressures. Parents were thus found to play an important role in influencing the 
diagnosis and the treatment approach offered, with the prescribing of medicines 
often seen by parents as the first-line of approach to the treatment of GOR. 
Parental pressures placed on clinicians was seen to arise from changing 
attitudes and expectations of parenthood, shifts in family support structures, 
and the growing accessibility of a wealth of health information from (both reliable 
and unreliable) sources on the worldwide web, as well as the subtle (and not so 
subtle) advertising of medicines to manage GOR on social media. These factors 
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all play a key role in the pharmaceuticalisation of treatment for GOR and is likely 
to go some way toward accounting for changes in prescribing patterns over 
time. Theoretically, therefore, this study points to the medicalisation of everyday 
care practices for infants, especially the management of symptoms of GOR. 
Importantly, it is possible that some infants are being prescribed unlicensed acid 
suppressant medicines unnecessarily and this has financial implications for the 
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CHAPTER 1: INTRODUCTION  
 
1.0 Background and Rationale for the Study 
I am a Registered Health Visitor, and at the onset of the study I was employed 
as a lecturer and programme leader for a Specialist Community Public Health 
Nursing – Health Visiting course at a university in the north east of Scotland. To 
maintain credibility in this academic role I worked half a day each week as 
health visitor in clinical practice. This involved me working in several clinical 
settings and with a variety of health visiting colleagues. An observation during 
these sessions related to a perceived increase in the number of infants 
diagnosed with, and prescribed medicine for gastro-oesophageal reflux (GOR) 
compared to when I work full-time as a health visitor. Anecdotal evidence from 
discussions with health visitors also suggested an increase in the number of 
infants presenting with symptoms of GOR. When in full-time employment as a 
health visitor 15 - 20 years previously, it seemed to me that less infants were 
being presented with symptoms of GOR and very few were prescribed medicine 
to manage the symptoms. At that time conservative management strategies 
were advised as the first line of treatment, and few infants were prescribed 
medicine. Gaviscon (alginate) was the medicine of choice and it was only 
prescribed to infants with severe symptoms of GOR such as weight loss or very 
poor weight gain. Now, it seems that many infants are diagnosed with GOR and 
prescribed ranitidine (H2-receptor antagonist) or omeprazole (proton pump 
inhibitor). 
 
Gastro-oesophageal reflux (GOR) is defined as the backflow of stomach 
contents into the oesophagus (Rosen et al, 2018; NICE, 2016). Gastro-
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oesophageal reflux in infants, however, differs from that in adults. In young 
infants the condition is physiological, innocuous and resolves over time and as 
the infant grows, whereas, in adults the condition is pathological as the 
regurgitated stomach contents in adults is normally acidic causing heartburn 
and oesophagitis (NICE, 2019; NICE, 2016; Bhasvar et al., 2011; Toila and 
Vandenplas, 2009).  Pathological symptoms of GOR in both adults and infants 
that cause complications such as oesophagitis and haematemesis are 
diagnosed as gastro-oesophageal reflux disease (GORD) (Rosen et al., 2018; 
NICE, 2015). Whilst the prevalence of GORD in the general population is 
estimated between 10% and 20%, epidemiological data pertinent to GOR and 
GORD in young infants is lacking (El-Serag et al., 2014; Dent et al.,2005). Most 
epidemiological studies such as that by Ruigomez et al. (2010), and Gold (2004) 
focus on children older than 1 year of age. According to Rosen et al. (2018) and 
NICE (2015), the lack of epidemiological data is due the difficulty differentiating 
symptoms of GOR from symptoms of GORD in young infants. Nevertheless, 
NICE (2015) consider the prevalence of GORD in children to be low, but 
symptoms of GOR in infants to be common and go on to report regurgitation of 
feeds to occur in 40% or more infants and to resolve naturally in 90% of cases 
by the time the infant is 1 year old.  
 
The observations from practice referred to above prompted my interest in 
learning more about the condition and management strategies in order to 
determine if there really was an increase in the number of infants diagnosed 
with, and treated for symptoms of GOR as assumed, and if this was the case, 
why this was happening and what had changed. Further investigation of the 
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condition revealed the evidence base supporting the use of medicines to 
manage symptoms GOR to be weak. This spurred my inquiry as to why infants 
were now prescribed medicines of unproven efficacy to manage a condition that 
in previous years was considered benign and managed conservatively and 
generally resolved of its own accord. Moreover, further investigation revealed 
that two of the main drugs prescribed, ranitidine and omeprazole, are not yet 
licensed for oral use in infants under one year of age in the UK (BNFC, 2019). 
This seemed quite a notable change in practice, and the need to find out what 
had instigated this shift in practice provided the impetus for this study. It also 
raised the notion of the ‘medicalisation of normality’ and suggests that gastro-
oesophageal reflux, a normal physiological condition in infants has become 
medicalised and is now considered, and accepted, as a condition requiring 
medical treatment. The concept of ‘medicalisation’, therefore, frames the 
theoretical underpinning of this study. 
 
The study used a two-stage research design to address the following research 
aim and objectives: 
 
Stage One: 
Aim: To explore patterns of prescribing of alginate, domperidone, omeprazole 
and ranitidine in Scotland over time and place. 
Objective: 






Aim: To explore factors influencing and underpinning how health professionals 




1. Understand how health professionals approach their diagnosis of GOR 
in infants. 
2. Explore factors influencing health professional’s decision-making in the 
diagnosis of GOR in infants. 
3. Explore factors influencing health professional’s prescribing decisions 
about GOR 
4. Assess changes over time in the management strategies for dealing with 
GOR in infants and what underpins these changes 
5. Understand parent/ carer experiences and expectations with regard to 
the management of GOR in infants. 
 
The study took a two-staged approach using quantitative techniques in stage 
one to analyse changes in patterns of prescribing over time and place, and 
qualitative research methods in stage two to explore and understand what 
influenced diagnostic and prescribing decisions by health professionals. 
 
1.1 Context and Geographical Location of the Study 
The study takes place in Scotland where responsibility for healthcare is 
devolved from Westminster and is the responsibility of the Scottish 
Government. Although responsibility for healthcare is devolved to the Scottish 
Parliament, the regulatory bodies of health professionals, such as the Nursing 
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and Midwifery Council and the General Medical Council are UK wide. Also, 
clinical guidelines such as that from the National Institute for Health Care 
Excellence (NICE) are sometimes referred to if no equivalent guideline is 
available from the Scottish Intercollegiate Guidelines Network (SIGN), as in the 
instance of gastro-oesophageal reflux in infants.  In Scotland there are 8 Special 
National Health Service (NHS) Boards and 14 Territorial NHS Boards as 
indicated in Figure 1.01. Territorial boards have an important role in the 
provision of healthcare services, and for health protection and health promotion 
of the population within their NHS board area. 
 
 
Figure 1.01: Map of NHS Territorial Boards in Scotland 
 
 
       Scottish Government (2017a) 
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The landscape and geography of Scotland has resulted in wide variation in the 
demography and population distribution of the 14 territorial boards as detailed 
in Table 1.01. For example, Greater Glasgow and Clyde, an area of large 
conurbation, has the highest population whilst remote and rural areas such as 
the island boards of Orkney, Shetland and the Western Isles have the lowest 
populations. Furthermore, the mountainous landscape and wild terrain has led 
to variation in the density of the populations across territorial board areas. The 
Western Isles, a chain of interconnected islands off the west coast of Scotland, 
and the Highlands which has the largest land mass, both have very low 
population densities. This study examined prescribing data at a national level 
for the whole of Scotland, and territorial NHS Board level and with a particular 
focus on NHS Grampian. NHS Grampian is the fourth largest territorial board in 
Scotland with approximately 587 820 inhabitants (Table 1.01). It also has a high 
prescribing rate for ranitidine (H2RA). Geographically, the region includes both 
urban, and remote and rural areas. It also has areas of affluence and 
deprivation.  
 
Prescribing data routinely gathered by the Information Services Division (ISD 
Scotland) are used to inform this study. ISD Scotland is part of NHS National 
Services Scotland (NSS) one of the Special NHS Boards in Scotland that 
provides a variety of specialist and national services that inform decision 
making and planning in the NHS in Scotland (ISD Scotland, 2010). The decision 
to focus on infants aged 0-1-year is two-fold. Firstly, symptoms of GOR normally 
resolve by the age of 1 year (NICE, 2015), and ISD Scotland record data by 
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whole years therefore the available prescribing data was for the 0-1-year age 
group. 
 
Table 1.01: Population and demography across the territorial boards mid 2015  
(National Records of Scotland, 2016) 
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1.2 Overview of Thesis 
Chapter 2 examines the literature regarding GOR in infants and the theoretical 
framework underpinning the study. It begins by considering the definition and 
diagnosis of GOR and the prevalence of the condition in infants. Thereafter 
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management strategies are discussed starting with an overview of conservative 
management strategies. Regarding medical strategies, evidence and research 
related to a range of medicines, such as alginate, motility stimulants, H2-
receptor antagonists (H2RA) and proton pump inhibitors (PPI) is also presented 
and discussed. Theoretically, the thesis engages with Szasz’s notion of 
medicalisation and pharmaceuticalisation of everyday life as well as discussing 
the influence of the internet and social media on shifting prescribing patterns. 
 
The research methods and research design are described and discussed in 
chapter 3 and a rationale given for the two-stage research design. A quantitative 
research approach was used in stage one of the study as there was a need to 
analyse national prescribing data to determine patterns of prescribing and to 
assess if there had been an increase in prescribing over time. In stage two, 
qualitative research methods were used to explore factors influencing the 
diagnosis and prescribing of medicine for GOR. The decision to hold semi-
structured interviews with health visitors, general practitioners and parents of 
infants with symptoms of GOR is discussed as well as the approach to 
recruitment. The approach to the analysis of both the quantitative and the 
qualitative data is deliberated as well as some of the ethical issues that arose. 
Consideration is also given to positionality and reflexivity. 
 
Chapter 4 presents the findings from the quantitative analysis of national 
prescribing data from ISD Scotland. Analysis of data regarding the population 
of 0-1-year old infants prescribed Gaviscon (alginate), domperidone (motility 
stimulant), omeprazole (PPI) or ranitidine (H2RA) in each NHS board is 
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presented first. National data for the whole of Scotland is then examined and 
presented, thereafter prescribing data for each drug and for each of the 14 NHS 
territorial boards is analysed and presented. The results then centre on 
prescribing in NHS Grampian, the NHS board area of focus in stage two of the 
study. The results from the analysis of the qualitative interviews from stage two 
of the study are presented in chapter 5. Firstly, findings from the interviews with 
parents are reported followed by the analysis of the data from health visitors 
then general practitioners. 
 
Chapter 6 presents an interpretation of the results of the study and discusses 
the findings in relation to the study objectives and the underpinning theoretical 
framework. Influences on the diagnosis of GOR and prescribing of medicines 
to manage symptoms of GOR are discussed, and consideration is given to the 
influence of parents, changing social support networks and changes over time. 
The theoretical framework is also discussed in relation to the literature, and 
findings of the study. Finally, consideration is given to the strengths and 
limitations of the research study. In the concluding chapter (chapter 7) the key 




CHAPTER 2: REVIEW OF THE LITERATURE.  
 
2.0 Introduction 
This chapter examines the existing literature regarding gastro-oesophageal 
reflux (GOR) to determine what is already know about the condition, its 
diagnosis, prevalence and management in infants aged 0-1 year of age, as well 
as any gaps in knowledge. It begins with an overview of the search strategy, 
followed by an investigation of the definition, diagnosis and prevalence of the 
condition in infants. Thereafter strategies to manage GOR are appraised. This 
focuses on conservative and medical interventions. Finally, the chapter 
engages with the theoretical framework that underpins this thesis by discussing 
concepts of medicalisation and pharmaceuticalisation in a bid to understand 
why there has been a change in the management and prescribing behaviours 
for gastro-oesophageal reflux in infants and what underpins this change. 
 
2.1 Search Strategy 
The literature search was undertaken using the following databases and search 
engines: Onesearch (Lancaster University), CINAHL, EMBASE, Medline, 
Pubmed, Web of Science, Cochrane Library, Medicines Complete, Knowledge 
Network (NHS Scotland), NICE, and Google Scholar. The literature search 
focused on GOR in infants aged 0-1 year of age and conservative and medical 
management, and initially involved literature dating from 1990 (when I worked 
as a health visitor) to the present day. Relevant grey literature, such as local 
and national protocols and clinical guidelines, was also searched or obtained 
from health visiting colleagues in the practice setting. This study uses the 
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definition of ‘infant’ defined by NICE (2015) and includes all babies, children 
and infants under 1 year of age.  Key words and synonyms used to search the 
literature are presented in Table 2.01.  
 
Table 2.01: Key words, search term and alternatives. 
Key words/ terms Synonyms /alternatives 
Gastro-oesophageal reflux Gastro-esopheal reflux, Gastroesopheal reflux, reflux, GOR, 
GER, vomiting, spitting, regurgitation, posseting 
Infants (0-1-year-old) Babies, children, newborn 
Diagnosis Symptoms, back arching, crying, unsettled, 
guidelines, protocols. 
Conservative management Non-medical interventions, non-pharmaceutical 
management, feeding, feeding technique, volume of feed, 
winding, positioning, upright position, ‘kangaroo care’, 
slings, soothing, comforting. 
Medical management Drugs, pharmaceutical interventions, medical management, 
ranitidine, omeprazole, Gaviscon, domperidone, alginate, 
motility stimulants, H2receptor antagonists, H2-RA, proton 
pump inhibitors, PPI 
Efficacy Effectiveness, best practice, evidence 
Medicalisation Medicalisation of normality, pharmaceuticalisation, 
sociology of diagnosis, social diagnosis 
 
 
The titles and abstracts of the papers identified in the search were read for 
relevance to the study and pertinent full-text articles obtained. In addition, 
reference lists in key papers were searched manually and reviewed for 
references thought useful to the study. An example of the search strategy using 








Table 2.02: Search Strategy: CINAHL and Medline 
Main search area Search terms Database 
Search Term  AND AND CINAHL Medline 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
  774 2833 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies  149 562 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies Prevalence OR incidence OR 
epidemiology OR occurrence 
38 153 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies diagnosis 59 234 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies Guidelines OR protocols 
OR practice guidelines OR 
clinical practice guidelines 
16 32 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies treatment OR intervention 
OR therapy 
96 317 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies alginate OR Gaviscon 11 31 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies prokinetic OR 
domperidone 
9 42 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies H2-receptor antagonist OR 
ranitidine 
2 5 
Gastro-oesophageal reflux OR 
gastro-oesophageal reflux 
disease 
Infants OR babies Proton pump inhibitor OR 
PPI OR omeprazole 
18 46 
 
2.1.1 Inclusion Criteria 
Regarding inclusion criteria the population of interest is infants aged 0-1-year-
old. This is because physiological GOR is normal in infants in the first year of 
life and normally resolves spontaneously by the time an infant is one year old 
(Nelson et al., 1997; Martin et al., 2002). Interventions focused on conservative 
management, and the medical management of GOR and particularly the use of 
Gaviscon (alginate), domperidone (motility stimulant), omeprazole (proton 
pump inhibitor: PPI), and ranitidine (H2-receptor antagonist: H2RA). These are 
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the drugs identified in local guidelines to manage severe symptoms of GOR in 
infants and children in Scotland (NHS Lothian, 2014., NHS Grampian, 2012). 
Furthermore, Gaviscon, ranitidine and omeprazole are highlighted by the British 
National Formulae for Children (BNFC, 2019) as the preferred drugs in their 
respective drug classes to manage symptoms of gastro-oesophageal reflux 
disease in infants and children. At the outset of the study domperidone was the 
prokinetic/ motility stimulant drug of choice, however following advice from the 
European Medicines Agency (2014), domperidone is no longer recommended 
in the management of symptoms of gastro-oesophageal reflux disease in 
children. The focus of the outcome measure concerns the effectiveness of 
these drugs in alleviating symptoms of GOR in young infants. GOR is described 
by NICE (2015) as the backflow, or regurgitation, of stomach contents into the 
oesophagus or mouth. When the symptoms of GOR become severe and lead 
to complications such as oesophagitis and require medical treatment, it 
becomes a pathological condition and known as gastro-oesophageal reflux 
disease (NICE, 2015). 
 
2.1.2 Exclusion Criteria 
Exclusion criteria regarding the population of interest included preterm infants 
because according to Rossen et al, (2018), and NICE (2015) preterm infants 
have an increased risk of developing pathological gastro-oesophageal reflux 
disease (GORD). Infants over 1 year of age are excluded as physiological GOR 
resolves naturally by the time the infant is 1 year of age in 90%- 95% of cases 
(NICE, 2015., Nelson et al., 1997). Infants with additional health issues or 
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complex needs such, as cystic fibrosis or neurological impairment, also have a 
higher risk of developing GORD and therefore are excluded. 
 
Regarding the intervention, drugs other than Gaviscon (alginate), domperidone 
(motility stimulant), omeprazole (PPI) and ranitidine (R2RA) were excluded as 
these are the medicines most commonly used in the UK (NHS Lothian, 2014., 
NHS Grampian, 2012., BNFC, 2019). Surgical management was also excluded 
as this involves infants with very severe or complex symptoms of GOR or 
GORD and this study is concerned with prescribing of medicines in the 
management of symptoms of GOR. Other studies that were not relevant to this 
research, for example, studies that focused on pharmacokinetic outcomes for 
these four medicines were also excluded. Studies not available in English were 
also excluded. 
 
The search strategy included international studies, primarily from the United 
States, Australia or Europe and included quantitative studies, and systematic 
literature reviews. No pure qualitative studies were identified in the literature 
search, however one mixed methods study (Dahlen et al, 2018) included a 
qualitative stage. The quality of the research studies was assessed using the 
Critical Appraisal Skills Programme (CASP) checklists that included 10 
questions for appraisal of systematic reviews, and 11 questions for randomised 
controlled studies. Examples of these can be found in Appendix 1.   
Thirty-nine quantitative studies were included in this literature review plus six 
items of grey literature. These are presented in a table in Appendix 2 with details 
of the year, publication, age of infant, intervention, research method and quality. 
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2.2  Definition, Diagnosis and Prevalence of Gastro-oesophageal reflux 
(GOR) 
In recent years there has been general agreement that gastro-oesophageal 
reflux (GOR) in infants is a physiological condition whereby the contents of the 
stomach flow back into the oesophagus or mouth (National Institute for Clinical 
Excellence [NICE], 2015; Tighe et al, 2014; DTB, 2010; Vandenplas et al., 
2009). This involuntary back flow of gastric contents is sometimes described as 
regurgitation, posseting, spilling or spitting up (Schellack, 2012; Vandenplas et 
al, 2009). The condition is benign and normally resolves over time and as the 
infant grows and develops (Cohen et al., 2015; Hassell, 2012; Bhavsar et al., 
2011).  
 
Determining the prevalence of GOR and GORD in infants is difficult. In part due 
to the lack of epidemiological data (Dent et al., 2005; El-Serag et al., 2014) and 
in part due to difficulty in determining the prevalence of GOR and GORD 
because of the lack of specificity of the presenting symptoms (Kolimarala et al., 
2018). Nevertheless, in their seminal study Nelson et al. (1997) reported 50% 
of infants to posset after feeding at least once per day whilst a later study by 
Martin et al. (2002) found the regurgitation of most feeds on a daily basis to be 
commonplace amongst young infants. More recently, a population-based study 
in Australia, found 23% of parents reported their infant had GOR (Sun et al., 
2015).While the evidence indicates a large proportion of infants under 12 
months experience symptoms of GOR, a number of studies (Miyazawa et al., 
2002; Hegar et al., 2009; Campanozzi et al., 2009) found regurgitation to be 
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most common in the first five months of life and to resolve spontaneously by the 
age of 1 year. 
 
The cause of GOR in infants has been attributed to factors such as the shorter 
oesophagus in infants, relaxation of the immature lower oesophageal sphincter, 
over feeding and an over distended stomach, delayed gastric emptying, and 
cow’s milk allergy or sensitivity (Tighe et al., 2014; Drugs and Therapeutic 
Bulletin [DTB], 2010; Lawson, 2003). Whilst physiological GOR is essentially 
innocuous, in a small number of infants complications may develop leading to 
the diagnosis of gastro-oesophageal reflux disease (Lightdale, 2013; DTB, 
2010; McLennan et al., 2010). 
 
In contrast, gastro-oesophageal reflux disease (GORD) is a pathological 
condition of greater concern. It has been defined by Sherman et al. (2009), and 
also recognised internationally, as the gastro-oesophageal reflux of stomach 
contents that causes troublesome symptoms or complications that impairs 
quality of life. In writing this definition Sherman et al. (2009) considered severe 
symptoms or complications that may impair quality of life to include weight loss, 
oesophagitis, and haematemesis (Shellack, 2012). Nevertheless, the definition 
proposed by Sherman et al. (2009) can be argued to be vague and to result in 
some ambiguity in the diagnosis and differentiation between physiological GOR 
and its pathological counterpart GORD. For example, Vandenplas et al. (2005) 
indicate that the progression of GOR to GORD is evident when the severity and 
occurrence of the reflux increases, whilst according to NICE (2015), GORD 
occurs when symptoms of GOR are severe enough to merit medical 
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intervention. Diagnosis, therefore, is subjective and open to interpretation as 
there is no clarity of what is meant by the terms ‘severe’, ‘severity’ and 
‘occurrence’, nor of what constitutes an increase of significance that would 
warrant the diagnosis of GORD. Orenstein (2010) highlights that the definition 
of GORD offered by Sherman et al. (2009) does little to clarify the situation and 
argues that the word ‘troublesome’ could be construed in a multitude of ways. 
Orenstein (2010) draws attention to the challenge of determining the extent to 
which a symptom is troublesome in infants who are unable to communicate 
verbally. Whilst crying, back arching, irritability, refusing to feed and sleep 
disturbance are all symptoms associated with GORD, and could be used to 
determine ‘troublesomeness’, they are also common baby behaviours indicative 
of other childhood conditions such as infant colic or a distended stomach 
(Hassell, 2012; Patience, 2012). Furthermore, relying on the parent or carer to 
denote the nature and extent of the ‘troublesomeness’ may present another 
dilemma. Orenstein (2010) questions who the symptoms are more troublesome 
to, and suggests that rather than the infant being troubled, it is the parent who 
has to deal with the upset infant and clean up the mess created by the reflux 
and regurgitation. Consequently, this lack of clarity in defining and diagnosing 
GOR and GORD from presenting symptoms can pose a challenge to health 
professionals confronted with concerned parents of infants who show signs of 
regurgitation and potential GOR and GORD. In turn this may lead to 
misdiagnosis, or confusion, in the diagnosis of physiological GOR and 
pathological GORD in practice. Interestingly, although a range of investigations 
to determine GORD in infants are available in secondary care these tend to be 
limited in their specificity and sensitivity and therefore are not wholly reliable in 
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formulating an accurate diagnosis (Rosen et al., 2018). This suggests that 
further information or research is needed to determine the factors that influence 
the diagnosis of GOR and GORD in daily practice, particularly amongst health 
professionals in primary care settings. As there is no clear delineation between 
GOR and GORD, in this study the term GOR will be used to describe the full 
continuum of symptoms ranging from physiological GOR to the more severe 
and pathological symptoms associated with GORD. 
 
Gastro-oesophageal reflux (GOR) is a common concern among parents of 
young infants (Bell et al., 2018; Bhavsar et al., 2011; Campanozzi et al., 2009). 
Although it is recognised as a normal physiological condition that generally 
resolves of its own accord, with or without conservative management (Pettinger, 
2017; Chellani et al., 2015), evidence suggests that over the last 15 years, or 
more, there has been an increase in the prescribing of medication for the 
condition in infants in the United States (Hassell, 2012; Chen et al, 2012; Barron 
et al, 2007), Australia (Bell et al., 2018), Belgium (De Bruyne et al., 2014) and 
New Zealand (Blank and Parkin, 2017). This evidence largely relates to the 
prescribing of proton pump inhibitors (i.e. Omeprazole), and H2-receptor 
antagonists (i.e. Ranitidine).  Anecdotally health visitors in the UK have 
observed a rise in the prescribing of Gaviscon (alginate) and H2-receptor 
antagonists (ranitidine) in young infants. Therefore, in trying to explain this shift 
in the management and prescribing behaviours for gastro-oesophageal reflux 
in infants by health professionals, background literature regarding the diagnosis 




2.3  Management of GOR  
In the UK the lack of reliable criteria or guidelines to determine a definitive 
diagnosis of GOR in infants leads to challenges for health professionals and a 
reliance on their intuition and professional judgement. Furthermore, evidence 
suggests that GOR is being over diagnosed in practice in Australia (Bell et al., 
2018), India (Chellani et al., 2015), Belgium (De Bruyne. et al, 2014). and the 
United States (Hassell, 2012; Khoshoo et al., 2007), therefore unclear 
guidelines may be a key predisposing factor for this. This lack of clarity and 
blurring of the parameters surrounding the diagnosis of physiological GOR and 
pathological GORD may also be a predisposing factor in the over prescribing of 
medication in the United States, Australia and Belgium (Bell et al., 2018; De 
Bruyne et al., 2014; Hassell, 2012, 2008; DTB, 2010; Chellani et al., 2015; 
Barron et al, 2007). 
 
The management of GOR in infants essentially fall into two categories, that is 
conservative and medical that follow. 
 
2.3.1 Conservative Management 
Conservative management of GOR is recognised as the first line of treatment 
in the management of GOR in the UK, the United States and Europe (Rosen et 
al., 2018; NICE, 2015; Vandenplas et al., 2009; Orenstein and McGowan, 
2008). This involves reassuring parents that the symptoms will improve over 
time and providing advice on the volume of feeds, feeding techniques, 
positioning of the infant, massage therapy, and use of feed thickeners (Rosen 
et al., 2018; NICE, 2015; Neu et al. 2014; Orenstein and McGowan, 2008). The 
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rationale for reducing the volume of feeds is based on the work of Sutphen and 
Dillard (1988) and Khoshoo et al. (2000) who found that a reduction in the 
volume of feeds led to a reduction in GOR in infants.  NICE (2015) and Rosen 
et al. (2018) also recommend a reduction in the volume of feeds in infants that 
are clearly being overfed. Overfeeding may lead to an overstretched and 
distended stomach that has reached its capacity and the oesophageal sphincter 
acting as a pressure valve at risk of a blowout resulting in reflux and 
regurgitation. A small study by Neu et al. (2014) found massage therapy to be 
beneficial in relieving stress in infants but did not affect symptoms of GORD. 
 
The efficacy of thickening agents, for formula fed infants, has been debated for 
many years. For example, a systematic review by Horvath et al. (2008) found 
thickening agents to be moderately effective in the treatment of GOR, but the 
systematic review by Huang et al. (2009) that focused on infants up to one 
month old, did not find sufficient evidence to support or discredit the use of 
thickeners. Thickened feeds were found to reduce the frequency of 
regurgitation in a multi-National (Greece, Morocco, France and Belgium), 
prospective randomized intervention study by Xinias et al. (2005), in a 
prospective randomized controlled study in Taiwan and Belgium by Chao and 
Vandenplas (2007), and in a prospective, blinded, randomized Indonesian 
study by Hegar et al. (2009). All three studies included infants up to 3 months 
old. More recently a Cochrane Review by Kwok et al. (2017), reported thickened 
feeds to be moderately effective in reducing episodes of regurgitation in formula 
fed infants. However, it should be noted that alginate is included as a feed 
thickener in the study by Kwok et al. (2017), and the age of the infants extended 
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from 3 to 6 months. Rosen et al. (2018), NICE (2015) and local guidelines (NHS 
Grampian (2012) all recommend the use of thickening agents in the 
management of GOR.  
 
Early studies (Meyers and Herbst, 1982) have shown positioning of the baby, 
particularly lying prone, to be beneficial in the management of GOR. However 
due to the increased risk of sudden infant death syndrome to babies when 
sleeping in the prone position, this practice is not recommended (Rosen et al., 
2018; NICE, 2015; Vandenplas et al., 2009). According to Kinny and Thach 
(2009) lying infants in the prone position can treble the risk of sudden infant 
death syndrome in infants.  
 
2.3.2 Medical Management 
Whilst medical management is generally concerned with pharmaceutical 
interventions, it may involve surgery in very severe cases of GORD. As surgery 
is at the severe end of the continuum of treatments for GOR in infants, and this 
study is concerned with increases in medical prescribing, literature regarding 
surgery is excluded from the literature review.  
 
A range of pharmaceutical preparations are currently available and used in the 
treatment of GOR in infants. These can be categorised as antacids, alginates, 
H2-receptor antagonists, prokinetics or motility stimulants, and proton pump 
inhibitors (Rosen et al., 2018; DTB, 2010; Tighe et al., 2014, 2009). Antacids 
are no longer recommended or used to manage gastro-oesophageal reflux due 
to the potential risks associated with raised plasma aluminum levels in young 
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infants, and therefore these will not be discussed further (Lightdale et al., 2013; 
Vandenplas et al., 2009; Tighe et al., 2009). The 2009 Clinical Knowledge 
Summary (CKS, 2009) did not recommend initiation and use of motility 
stimulants, H2-receptor antagonists (H2RA), and proton pump inhibitors (PPI) 
in primary care in the UK. Nevertheless, evidence suggests that they are used 
regularly by colleagues in the United States (Barron et al., 2007; Hassall, 2012) 
and therefore worthy of further discussion. More recently, guidance from the 
National Institute of Clinical Excellence (NICE, 2015) in the UK recommends a 
4-week trial of ranitidine (H2RA), or omeprazole (PPI) in infants with overt 
regurgitation that is accompanied by distressed behaviour, faltering growth or 
unexplained feeding difficulties. 
 
2.3.3  Use of Alginates (Gaviscon) 
Regarding the use of alginates, such as Gaviscon, in the management of GOR 
in infants, the available evidence is both limited and conflicting (Tighe et al., 
2014; Clinical Knowledge Summary, 2009). For example, the largest study by 
Millar (1999) found Gaviscon to be effective in alleviating and reducing bouts of 
regurgitation and vomiting in infants, however it is noted that the age range of 
the subjects was 0 - 12 months. As it is well recognised that GOR generally 
resolves independent of treatment in most infants by the age of 12 - 14 months 
(NICE, 2015; Nelson et al., 1997; Martin et al., 2002), it is questionable if the 
improvement in this instance can in fact be attributed to the use of the alginate, 
Gaviscon. Findings of a, later but smaller, study by Del Buono et al. (2005) were 
weak and suggested that there was no perceived benefit of using Gaviscon to 
manage of symptoms of GOR in infants. A more recent study by Salvatore et 
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al, 2018 suggested that alginate may help reduce symptoms of GOR in infants. 
However, the study (Salvatore et al, 2018) was also small and the researchers 
acknowledge that the findings may be biased and resulted in a false positive 
effect due to parents under-reporting symptoms of GOR in infants following 
commencement of treatment with alginate. For more definitive results, the 
researchers advise that a placebo-controlled double-blind randomized 
controlled study be conducted. Nevertheless, Gaviscon is the most commonly 
used alginate and is said to work by reacting with gastric acid to thicken the 
gastric contents making reflux more difficult due to the increased viscosity, and 
also to form a protective layer over the distal oesophagus (DTB, 2010; Corvaglia 
et al., 2011). Due to the inconclusive evidence of its efficacy, the use of alginate 
in the treatment of symptoms of GOR is not supported in the Pediatric 
Gastroesophageal Reflux Clinical Practice Guideline developed by (Rosen et 
al., 2018) on behalf of the North American Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European 
Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). 
However, it is advocated as a treatment option for breast fed infants, and in the 
stepped care approach for formula fed infants with symptoms of GOR in the UK 
by NICE (2015), and also locally by NHS Grampian (2012). 
 
 
2.3.4 Use of Motility Stimulants (Domperidone) 
Motility stimulants, also known as prokinetics, claim to relieve reflux by 
stimulating stomach emptying (DTB, 2010; Vandenplas et al., 2009; Tighe et 
al., 2009) and include drugs such as domperidone, metoclopramide and 
cisapride. Several systematic reviews found insufficient evidence in infants to 
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support the use of metoclopramide (Hibbs and Lorch, 2006), domperidone 
(Pritchard et al., 2005) and cisapride (McLennan et al., 2010) in practice (Tighe 
et al., 2014). Furthermore, a study in Italy by Cresi et al (2008) that focused on 
infants aged between 24 and 30 days old found evidence of the use of 
domperidone to manage symptoms of GOR in this age group to be 
unconvincing and therefore did not recommend it’s use. In addition, the findings 
of a systematic review by Scott (2012) did not find domperidone effective in the 
management of symptoms of GOR in infants. Motility stimulants, however, are 
not without their adverse effects and despite being the drug of choice and used 
widely some years ago, cisapride was withdrawn from the market due to its 
association with cardiac arrythmias and sudden death (DTB, 2010). Since 
commencing this study, the European Medicines Agency (2014) issued advice 
warning of an increased risk of cardiac problems with the use of domperidone, 
therefore domperidone is not recommended for the management of symptoms 
of GOR in infants. Furthermore, Vandenplas et al. (2009) did not recommend 
the use of motility stimulants in the management of gastro-oesophageal reflux 
in infants, a view that is also shared in the UK by NICE (2015) and in Europe 
and the US (Rosen et al., 2018).  
 
2.3.5 Use of H2-Receptor Antagonists (Ranitidine) 
H2-receptor antagonists (H2RA) aim to reduce gastric acid secretion (DTB, 
2010; Vandenplas et al., 2009; Tighe et al., 2009). Ranitidine and Cimetidine 
are examples of H2RA drugs. However, despite evidence (Cucchiara et al, 
1989) of cimetidine being effective in the treatment of reflux oesophagitis (a 
complication of GOR indicative of GORD), there was insufficient evidence to 
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support its safe use in children (DTB, 2010), therefore it is not recommended in 
the British National Formulary for Children (BNFC, 2019). An Italian study by 
Cucchiara et al. (1993) found ranitidine to be effective in the treatment of reflux 
oesophagitis or GORD in infants. However, it should be noted that the sample 
population is small and the method of randomization is not clear. Azizollahi et 
al (2016) in a small randomized double-blind trial and parallel-group study, 
involving 60 infants also found ranitidine to be effective in the treatment of 
GORD. Nevertheless, a study of oesophageal acid exposure and gastric acid 
secretion in infants older than 1 year concluded that the infants that did not 
respond to treatment with ranitidine either required better acid suppression 
management, or their lack of response to the medication was because their 
symptoms of GOR were not acid related (Salvatore et al., 2006). A systematic 
review by Tighe et al (2014) did not find any randomised controlled trials 
evaluating the effectiveness of ranitidine to manage symptoms of GOR or 
GORD in infants. This situation appears largely unchanged as no further studies 
were revealed when searching the literature. Furthermore, a Clinical Knowledge 
Summary (CKS, 2009) did not advocate the use of H2RA medicine in primary 
care, considering these drugs to be more appropriate for infants with severe 
symptoms and complications of GOR such as oesophagitis and mucosal 
erosion that can impair quality of life (Lightdale et al., 2013; DTB, 2010). Such 
infants were recommended to be referred to secondary care for further 
investigation and diagnosis of GORD (CKS, 2009). Nevertheless, an analysis 
of data gathered by the UK National Poisons Information Service by Crawford 
et al. (2018) identified that among the recorded overdoses of ranitidine in the 0-
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5-year age group (100%=517), 79% (410) were in infants under 6 months of 
age. 
In the UK, oral ranitidine is not licensed for use in children under 3-years of age 
(BNFC, 2019). According to the General Medical Council (GMC, 2013), and the 
Medicines and Healthcare Products Regulatory Agency (2014), unlicensed 
medicines refer to drugs that are prescribed outside of the terms of use defined 
by the marketing authority or manufacturer. For example, regarding prescribing 
of ranitidine (H2RA) in the UK, the license does not include infants under 1 year 
of age. The reason being that the efficacy, safety, and quality of these 
unlicensed drugs has not been assessed to the appropriate quality standard for 
use in the 0-3-years age group in the UK, therefore their efficacy and safety is 
in doubt (Medicines and Healthcare Products Regulatory Agency, 2014). 
Nevertheless, the GMC (2013), and the Medicines and Healthcare Products 
Regulatory Agency (2014) both recognise there will be situations where 
unlicensed medicines may be prescribed. For example, The British Pain Society 
(2005) give the example of antidepressant medicine not being licensed to 
manage pain, but in some instances used for this purpose. Unlicensed 
medicines are sometimes used in palliative care, psychiatry and paediatrics 
where conducting randomised controlled trials to provide evidence of efficacy 
may be challenging (Medicines and Healthcare Products Regulatory Agency, 
2014). 
 
Interestingly, NICE (2015) advise that a 4-week trial of an H2RA, such as 
ranitidine, may be given to infants with overt regurgitation accompanied by 
distressed behaviour, faltering growth or feeding difficulties. However, the 
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interpretation of the perceived distress of the infant and their feeding difficulties 
remains subjective. In contrast, Rosen et al. (2018) referring to the NASPGHAN 
and ESPGHAN guideline do not recommend the use of H2RA in distressed 
infants with overt regurgitation who are generally healthy, and a systematic 
review by Tighe et al. (2014) did not find sufficient evidence to support the use 
of H2RA medication in infants under one year of age. Furthermore, studies 
concerning preterm infants and neonates highlight an association of ranitidine 
(H2RA) use with increased risk of infection (Santana et al., 2017; Terrin et al., 
2012) and advise caution in the use of ranitidine in young infants.  
 
2.3.6 Use of Proton Pump Inhibitor (Omeprazole) 
Proton pump inhibitors (PPI) are also acid suppressant drugs and like H2RA 
medicines they are not licensed for use in infants under 1-year of age in the UK 
(DTB, 2010; BNFC, 2019). Nevertheless, PPI medicines have gained in 
popularity in recent years, particularly in the United States where Chen et al. 
(2012) and Barron et. (2007 indicate that their use in infants under 12 months 
of age has increased over the last 20 years. Barron et al (2007) reported that, 
in the United States, prescribing of PPI medicines to manage symptoms of GOR 
in infants increased four-fold between the years 1999 and 2004. An analysis of 
prescribing data in Belgium by De Bruyne et al (2014) found that prescribing of 
PPI and H2RA medicines to children aged 0-2-years increased seven-fold 
between the years 1997 and 2009 . A national study in New Zealand, by Blank 
and Parkin (2017) also revealed an increase in prescribing of PPI medicines to 
manage symptoms of GOR in infants from 2.5% in 2005 to 5.2% of infant in 
2012. This suggests that the increase in prescribing of PPI medicines is not just 
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a Scottish phenomenon but is occurring more widely across a number of 
western countries. 
 
Only one study was identified that assessed the efficacy of omeprazole in 
managing symptoms of GOR and GORD in infants. This was a small 
randomized, double blind placebo-controlled crossover study undertaken in 
Australia by Moore et al. (2003) that reported omeprazole to be ineffective in 
alleviating symptoms of GOR such as irritability and unsettledness. Moore et al. 
(2003) suggested that omeprazole should only be administered to infants with 
proven acid reflux, oesophagitis or GORD. Other studies regarding omeprazole 
tended to focus on older children or compared omeprazole with other acid 
suppressant drugs in the treatment of severe symptoms of GORD or 
oesophagitis as in the study by Cucchiaria et al. (1993). 
 
Focusing on PPI drugs, Chen et al., (2012) conducting a review on behalf of the 
US Food and Drug Administration did not find sufficient evidence of the efficacy 
of PPI drugs to support their use in the treatment of symptoms of GOR. Other 
systematic reviews by van der Pol et al. (2011), Kierkus et al. (2014) and 
Gieruszczak-Bialek et al. (2015) also found evidence to support the use of PPI 
in infants under 1 year of age to be weak. However, Kierkus et al. (2014) 
Gieruszczak-Bialek et al. (2015) and De Bruyne and Ito (2018) also warned of 
the risk of adverse effects of long-term PPI use, such as an increased risk of 
infection. This is also supported by Rosen at al. (2018) in the updated 
NASPGHAN and ESPGHAN guideline. Furthermore, the systematic review by 
Tighe et al. (2014) found the research evidence concerning PPI medicines to 
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be weak but were of the view that omeprazole (PPI) may help infants with acid 
induced oesophagitis as typical of GORD.  Nevertheless, despite the lack of 
evidence supporting the use of PPIs, in the UK, NICE (2015) do not appear to 
have dismissed their use entirely, rather they suggest a 4-week trial of a PPI 
medicine in infants with overt regurgitation that is accompanied by distressed 
behaviour, faltering growth or feeding difficulties. Again, the interpretation of 
distressed behaviour and feeding difficulties in infants is subjective.  
 
It is also interesting to note that Hassell (2012) highlights an increase, in the 
Unites States, of PPI medicines being used in the management of GOR in 
infants under 6 months of age. Furthermore, a study by Khoshoo et al (2007) in 
the United States concluded that most infants prescribed prokinetic, H2RA or 
PPI medicines did not have acid related pathology such as GORD or 
oesophagitis. More recently, a study by Bell et al. (2018) suggests that in 
Australia, general practitioners may be overprescribing acid suppressants such 
as PPI to infants aged 0-1 year. According to Hassell (2012) the increase in 
prescribing of PPI is partly due to the increasing workloads of doctors, the 
reduced time to consult with, and to take a more in-depth history from patients, 
as well as parental pressure to alleviate the symptoms of GOR.  However, it 
may also reflect the difficulty in differentiating symptoms of physiological GOR 
from pathological GORD in infants. Another reason posed by Hassell (2012) 
relates to the relaxation in the regulations regarding marketing in the US that 
has led to pharmaceutical companies advertising directly to the consumer. 
Furthermore, in their advertising the pharmaceutical companies use terms such 
as ‘acid reflux’ to justify the need for medicines to counteract or neutralise the 
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acid. Whilst such advertising is essentially aimed at symptoms of GOR in the 
adult population, Hassell (2012) believes that the notion of ‘acid reflux’ has 
filtered down and now influences perceptions of GOR in the younger age group 
of children and infants with some parents believing that gastric reflux in young 
infants is acidic. This suggest that the physiological symptoms of GOR in infants 
are becoming medicalized. Given that marketing of remedies aimed at ‘acid 
reflux’ are evident in the advertisements shown on UK television there is the 
potential that this trend will develop in the UK and increase over time. 
Subsequently this may lead to the medicalization of GOR and a greater demand 
and expectation for medicines to be prescribed for GOR in infants. 
 
2.4 Medicalisation of Normality: A Conceptual Framework 
The reason for the increase in prescribing of medicines to manage symptoms 
of GOR in young infants is not clear, however to try and understand the 
underpinning reasons for this change in practice, the concepts of medicalisation 
and diagnosis will be explored. Although other theoretical frameworks are 
relevant, it was felt that they do not resonate with the aim, objectives and subject 
matter of this study as well as that of ‘medicalisation of normality’. For example, 
the focus of social constructionism concerns the influence of culture, social 
interactions and the experience of illness (Conrad and Barker, 2010). In this 
study, those experiencing the ‘illness’ (infants with symptoms of GOR) are 
unable to express or share that experience, instead it is the parent’s 
interpretation and experience of caring for the infant that is explored. Whilst the 
influence of social interactions, culture and other socio-cultural factors on the 
experience of the illness are recognized, this study is concerned with what is 
44 
 
driving the shift from conservative to medicalised strategies in the management 
of GOR in infants. This, therefore, lends itself to concepts around ‘the 
medicalisation of normality’. Furthermore, using ‘medicalisation of normality’ as 
a theoretical framework allows other concepts such as pharmaceuticalisation to 
be explored. 
 
The concept of ‘medicalisation of normality’ is not new with early writing on the 
subject by Szasz dating back to the 1960’s (Szasz, 1960, 2007). However, 
according to Conrad et al. (2010) and Clarke (2013), interest in the 
‘medicalisation of normality’ has gained in momentum over the last thirty to forty 
years. The concept has been described in many different ways.  For example, 
Kanieski (2010), describes medicalisation as the increasing use of medical 
terminology to explain a range of conditions and behaviours that individuals 
may exhibit, whilst Conrad (1992) considers it as the identification, and 
subsequent management, of common everyday ailments and concerns as 
medical illnesses or disorders. Medicalisation, therefore, could be argued to be 
the interpretation, diagnosis and treatment of natural human functions and 
ordinary bodily activities as medical problems requiring medicinal treatment. 
Reflecting on the possible medicalisation of GOR in infants, the lack of 
specificity and differentiation between the symptoms of GOR and GORD in 
clinical guidelines (Rosen et al.,2018; NICE, 2015) may have led to some 





In exploring the concept further, Zola (1972) considered diagnosis, and 
assigning the labels of ‘health’ or ‘illness’ to symptoms, to be a critical feature 
of medicalisation in practice. The ability to diagnose or assign a label to a 
condition conveys a degree of power and control, however whilst recognising 
this elitism, Zola (1972) did not deem medical authority or supremacy to be a 
key determinant underpinning the notion of ‘medicalisation’. Instead, he 
considered the concept of illness to be defined and shaped by social and 
environmental factors that continually evolve and influence the daily life of 
individual people as well as the population at large. In other words, he believed 
‘health’ and ‘illness’ to be influenced by wider social and environmental factors, 
such as air pollution or poverty, impacting on a person and their health and that 
diagnosis should not be limited to the presenting symptoms alone. 
 
Focusing on diagnosis, Jutel (2011a), highlights the work of Friedson (1970), 
inferring that in practice, diagnosis is the ability to decipher various signs and 
symptoms presented by a patient to form clinical meaning that allows an illness, 
or label, to be assigned. From this clinical picture and diagnosis, medical 
interventions and treatments can then be planned and prescribed. Diagnosis, 
therefore, is viewed as a supreme skill as well as a very powerful classification 
tool within medicine (Jutel, 2009). Diagnosis confirms and legitimises ‘ill health’ 
and as a result can bestow certain privileges such as sick leave or access to 
services, and additional support (Jutel, 2011a, 2011b). Alternatively, 
confirmation of a diagnosis can have a negative impact. For example, some 
diagnoses, or labels, such as AIDS, chronic fatigue syndrome or Huntington’s 
Disease may be stigmatizing or affect insurance cover or job prospects for the 
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person. However, there are also instances whereby presenting symptoms 
cannot be classified or labeled within the available diagnostic frameworks. Such 
conditions, because there is no identified organic pathology, are considered to 
be medically unexplained and according to Jutel (2009) are often branded as 
psychogenic in origin. Some symptoms of GOR in infants, such as crying and 
irritability, are often unexplained. Furthermore, diagnostic criteria differentiating 
between symptoms of GOR and GORD in clinical guidelines (Rosen et al., 
2018; NICE, 2015) are vague. Medically unexplained symptoms may result in 
misery and suffering for many people who, feeling unbelieved and being without 
a legitimate diagnosis, are deprived of appropriate treatment and access to 
resources and support (Nettleton, 2006). Diagnosis, therefore, not only 
legitimises illness and reinforces the individual’s belief that they are ill, but it 
confirms greater knowledge, status and power on those diagnosing. This is 
generally undertaken by a physician or doctor.  
 
The notion of a power imbalance between patient and doctor is supported by 
Cornwell (1984) who highlighted medicalisation to be concerned with an 
interaction or relationship between two groups with differing health beliefs. 
According to Cornwell (1984) lay people or patients generally have more 
traditional or intuitive health beliefs, whereas doctors are from the world of 
medicine and therefore embrace empiricism and scientific beliefs. Over time the 
traditional and intuitive health beliefs of lay people have become overshadowed 
by science and technology, leading to some conditions becoming medicalised 




Whilst agreeing that the concepts of diagnosis and medicalisation are inherently 
linked, Jutel (2009) emphasizes that they are also very different. Jutel (2009) 
argues that medicalisation incorporates much more than mere diagnosis. For 
example, entwined within medicalisation is the notion of pharmaceuticalisation 
(Williams et al., 2008). Pharmaceuticalisation refers to social, behavioural and 
bodily conditions, such as addiction, obesity and baldness in men, deemed as 
ailments or problems that require medical treatment (Abraham, 2010). 
Nevertheless, Jutel (2009) suggests that there is an iterative relationship 
between the concepts of medicalisation and diagnosis, in that diagnosis has a 
key role in medicalisation, whilst medicalisation has an influence on the 
sociology of diagnosis.  
 
On reviewing the sociology of diagnosis in more depth, Brown et al. (2011) 
proposed the concept of ‘social diagnosis’ whereby the diagnosis of an illness 
encompasses more than the physical presentation and considers wider 
influences on health such as social, economic, and environmental factors. For 
example, damp housing may affect the health of a child with asthma. According 
to Brown et al. (2011) there is a link between the process of diagnosis and/or 
the illness itself, to political, economic, cultural and social factors. Furthermore, 
Brown et al. (2011) perceive a variety of social players to be involved in social 
diagnosis with the activities of one group of players affecting the actions of other 
players. Social actors could include medical professionals, researchers, 
government bodies, private organisations and so forth. In simple terms, social 
diagnosis involves consideration of social factors, or determinants of health 
when formulating a diagnosis, as well as consideration of the influence of social 
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players, other disciplines and professional groups, such as policy makers, 
employers, and health and social care professionals (Brown et al., 2011). 
 
Reflecting on the situation in Scotland, it is plausible that the process of 
diagnosing and managing GOR in infants has become medicalised. Traditional 
beliefs regarding childrearing are argued by Apple (1995) to have been eroded 
over time.  Apple (1995) refers to this phenomenon as the move towards 
‘scientific motherhood’ and describes the emergence of scientific motherhood 
in the United States and the dichotomy faced by women who, as mothers, were 
responsible for the health and wellbeing of their family but encouraged to rely 
on medical advice rather than their own maternal intuition. According to Apple 
(1995) the ideology of scientific motherhood denied mothers control over the 
upbringing of their children by favouring scientific and medical advice from 
doctors over maternal instinct. Over time, therefore, the medical profession 
clearly had power and authority to exert social control and to determine 
boundaries of what is, and what is not, accepted as being normal. 
 
2.4.1 Changing Focus of Health Care with Examples of ‘Medicalisation’ 
The focus of health care has changed over time, for example, Clarke (2010) 
highlights how attitudes to death and dying have changed over the years. 
According to Clarke (2010), traditionally death and dying was seen as a rite of 
passage that had great social significance for the individual and their family. For 
example, up until the twentieth century most people died at home cared for and 
surrounded by family and friends. Death, therefore, was a natural event 
presided over by priests or other religious leaders of the time. In contrast the 
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twentieth century was a time of change. According to Howarth (2007), the 
increasing interest and advances in medical science led to religious leaders 
gradually being replaced at the bedside by physicians who had more control 
over pain and could offer greater physical comfort to the patient. Death, a 
natural phenomenon, became medicalised. Nevertheless, it is interesting to 
note that by the mid twentieth century the notion of respect and dignity in the 
lead up to death, and indeed in the process of dying, gained momentum with 
the development of the hospice movement (Clarke, 2010). This was in contrast 
to the cold and stark approach to caring for dying patients in hospitals that 
epitomized the medical approach to death. According to Clarke (2010), attitudes 
to death and dying were evolving and changing from the influence and 
dominance of theology, then medicine, to being more individual and person-
centred and taking account of the psychological needs of the dying person. 
More recently, however, it could be argued that the medicalisation of death is 
again coming to the fore with growing interest in assisted suicide and 
euthanasia (Hains & Hulbert-Williams, 2013; Shekhar and Goel, 2012). 
 
Another natural life event that has become increasingly dominated by the 
medical profession is childbirth (Christiaens et al., 2013; Clarke, 2010; 
Johanson et al., 2002).  Whilst Christiaens et al. (2013) laud the contribution of 
medical interventions to safeguard women and their infants when complications 
and pathological problems during pregnancy and labour arise, they also 
highlight that unnecessary obstetrical intervention in otherwise healthy pregnant 
women can lead to increased risks that may jeopardize the health of both the 
mother and baby. Nevertheless, medical intervention in pregnancy and 
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childbirth has increased over the years. According to Clarke (2010) childbirth 
has become firmly rooted in the medical domain and become an intensely 
technical matter. Johanson et al. (2002), highlight that the increase in medical 
involvement in childbirth has led to an increase in caesarean sections with 
Walsh (2006) indicating that globally 20% of infants are delivered by caesarean 
section. More recent data from ISD Scotland (2018) indicates that caesarean 
section rates in Scotland have risen from 9% in 1976, to 32% in 2018. Whilst 
most caesarian sections are performed for clinical reasons, ISD Scotland 
(2018) acknowledge that in some instances there is no clinical indication for the 
procedure and the reason for the caesarean section is due to the preference 
and choice of the woman. This suggests changing attitudes and expectations 
of childbirth. 
 
Traditionally the Netherlands was a country where natural child birth dominated 
and medical intervention was resisted, however Johanson et al. (2002), and 
Christiaens et al. (2013), both highlight the increasing trend and movement 
towards medical interventions such as induction and augmentation of labour. In 
some instances, this may be desired by women who find the pain, 
inconvenience, and unpredictability of labour and childbirth to be incongruent 
with their plans, schedules and lifestyle (Christiaens et al., 2013). This is in 
contrast to the earlier work of Oakley (1979; 1980) that found that women did 
not feel in control of their labour due to medical dominance and wanted a more 
natural birth and greater autonomy and empowerment over the decisions 
regarding their pregnancy and birth. From this it could be conferred that 
attitudes to childbirth and medical intervention are changing, and that in some 
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quarters medicalisation of childbirth has been welcomed with parents knowing 
the sex of their unborn baby as well as being involved in decisions regarding 
the proposed date of induction of labour, or indeed caesarean section. This 
suggests that the medicalisation of childbirth, rather than being abhorred, has 
been embraced by some women and permitted them to have some influence 
over the date of induction of labour or mode of delivery. Some women, 
therefore, may perceive that they have some control over their delivery and 
childbirth.  
 
As discussed by Szasz (2007) in the context of psychiatry, assessment and 
decisions regarding childbirth, could be argued to have become more subjective 
and linked to what society now accepts as being normal. For example, 
compared to previous generations, few women in the UK opt for a home birth 
(McLaren, 2015) and it has become normal for births to take place in a hospital 
setting. However, this trend may be at a turning point as according to NICE 
(2014), for women with low risk of complications, giving birth at home is safe 
and associated with less medical intervention compared to giving birth in 
hospital. Regarding symptoms of GOR in infants, it is possible that societal 
norms are also changing with parents viewing what was previously seen as 
common baby behaviours such as regurgitation, crying and unsettledness as requiring 
medical treatment. 
 
Power to determine the boundaries of what is, and is not, accepted as being 
normal may influence the process of diagnosis. For example, Szasz (2007) 
(focusing on psychiatry) proposes that the process of diagnosing mental ill-
health is very different from that of physical illness. Szasz (2007) argues that 
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the medical diagnosis of physical illness is objective and often based on 
measurable changes in bodily functions and physical state (eg Blood Pressure, 
temperature, urinary output, blood tests etc.), whereas the diagnosis of mental 
illness is more subjective. In making a diagnosis in the field of mental health, 
psychiatrists assess and judge a person’s behaviour in light of their own 
perception of reality and on what society currently accepts as normal behaviour 
(Szasz, 2007). Psychiatrists, therefore, have tremendous power and ability to 
exert social control, particularly when making a diagnosis.  According to Szasz 
(2007), diagnoses in psychiatry that are not diseases include kleptomania 
(shoplifting and stealing), pyromania (setting fires) and compulsive gambling 
(Szasz, 2007). For example, Lenz and MagShamhráin (2012) highlight that 
kleptomania came to the fore at the start of the twentieth century when 
department stores were first introduced. Department stores provided a socially 
acceptable venue for middle and upper class women to wander safely and to 
meet other like-minded women. The employment of women to work in such 
stores also gave women a new sense of independence and freedom. 
Consequently, this new freedom for women was not welcomed by all in society 
and therefore, according to Lenz and MagShamhráin (2012), had to be 
repressed. To this end, Lenz and MagShamhráin (2012) highlight that the 
medical profession, that is physicians and psychiatrists, pulled rank to create 
the new illness of kleptomania, or shoplifting, and according to Lenz and 
MagShamhráin (2012) this aimed to thwart the freedom of middle and upper 
class women. This supports the view of Szasz (2007), that the medical 
profession, including psychiatrists were developing a higher authority and rise 
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in status that gave them great power to exert social control by means of creating 
a medical diagnosis. 
 
The concept of social control is interesting. For example, myalgic 
encephalomyelitis and chronic fatigue syndrome are conditions that could be 
argued to be influenced by social control. Although recognised as illnesses by 
the US Centers for Disease Control and Prevention (2017), the cause of illness 
remains unclear and, to date, no specific diagnostic tests are available (CDC 
2017; NHS Inform, 2019). Diagnosis, therefore, is subjective and under the 
control of the physician. Furthermore, in previous years, the media influenced 
public perception of the condition by branding it as ‘yuppie flu’ and implying the 
symptoms are psychosomatic and the sufferers weak-willed or work-shy (Siegel 
et al., 2018; Tuller, 2007). The lack of a legitimate diagnosis denied sufferers of 
myalgic encephalomyelitis treatment and support (Jutel, 2011; Nettleton, 2006). 
Diagnosis of GOR and GORD in infants may also be influenced by changing 
social attitudes. According to Rosen et al. (2018), there is no single diagnostic 
test for GOR or GORD in infants. Diagnosis appears to be intuitive and as 
highlighted by Szasz (2007) may be based on what society considers as normal 
baby behaviours, or on health professionals’ perception of reality. 
 
Alternatively, some behaviours considered deviant and labelled as mental 
illnesses in years gone by are now accepted as normal. McColl (1994) and 
Conrad et al. (2010) highlight the case of homosexuality that was considered a 
disease and homosexual people mentally ill or disturbed. However, over the 
years, attitudes and perceptions have changed and society has become more 
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open-minded, sympathetic and accepting of homosexuality. Furthermore, 
Szasz (2007) highlights how, after much protest by gay groups, homosexuality 
was demedicalised in 1967 with gay people no longer being branded as 
mentally ill. This supports the concept of ‘social diagnosis’, presented by Brown 
et al. (2011), in that social and cultural factors as well as action from social 
players, such as gay and homosexual support groups, have instigated this 
change of view and diagnosis of homosexuality as an illness. Szasz (2007), 
therefore, suggests that in contrast to the notion of ‘medicalisation’, in some 
cases such behaviours have become demedicalised and accepted as normal.  
 
2.4.2 Pharmaceuticalisation 
Interestingly Bell and Figert (2012) and Williams et al. (2011) highlight a growing 
interest in the role and dominance of the pharmaceutical industry on 
‘medicalisation’ and how the use of medicines has increased dramatically over 
the last 20 - 30 years. The concept of ‘pharmaceuticalisation’ as an element of 
medicalisation has gained much attention (Williams et al., 2008). In contrast to 
‘medicalisation’, ‘pharmaceuticalisation’ is the perception that some normal 
physical conditions and human characteristics and capabilities are opportunities 
for pharmaceutical intervention and capitalisation (Williams et al., 2008).  
 
Unlike the definition of medicalisation given by Conrad (1992), that focused on 
identifying, and treating everyday ailments as medical conditions, 
pharmaceuticalisation has its focus on finding potential conditions that are 
normal and disease free, such as baldness in men (Harvey, 2013), and 
marketing them as problems requiring pharmaceutical treatment. In other 
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words, pharmaceutical companies being commercial enterprises utilise 
innovative and ingenuous marketing strategies to bolster their sales and 
subsequent profits (Busfield, 2010).  
 
In exploring the concepts of medicalisation and pharmaceuticalisation further, 
Harvey (2013), Bell and Figert (2012), and Williams et al. (2008, 2011) highlight 
concerns that medicalisation and pharmaceuticalisation have become akin to 
disease mongering. The notion of disease mongering being that it is ‘diseases’ 
and ‘illnesses’ that are being marketed and sold to the public rather than drugs. 
The underpinning psychology appears to be that once the seed has been 
planted and an individual believes that he or she has a recognised ‘illness’ or 
condition for which a treatment happens to be available, he or she will either 
buy the product from a pharmacy or seek a prescription from their general 
practitioner. Selling the ‘illness’ or condition, therefore, sells the pharmaceutical 
product. Moreover, Fox and Ward (2008) discuss ‘lifestyle drugs’ and describe 
a group of pharmaceutical products that are linked to lifestyle choices giving the 
examples of nicotine replacement therapy for smokers, and weight reducing 
drugs for the obese. Medicalisation, pharmaceuticalisation, disease mongering 
and life style drugs could be argued to be firmly rooted and established within 
modern life. For example, the rising demand, or market, for cosmetic surgery 
and aesthetic procedures suggests that increasingly people are dissatisfied with 
their appearance, and desire to look beautiful. Indeed, beauty parlors, cosmetic 
products and aesthetic procedures such as the use of botulinum toxin type A, 
or Botox, to reduce the appearance of facial wrinkles has become more 
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commonplace, and more accessible. (Edmonds, 2013; Berer, 2010; Friedman, 
2004).  
 
Whilst direct to consumer advertising by pharmaceutical companies has been 
established in several countries such as the United States and New Zealand for 
quite some time, it is a relatively new concept in the UK (Hassell, 2012; 
Medicines and Healthcare Products Regulatory Agency (MHRA), 2014; 
Abraham, 2009). According to the MHRA (2014), in the UK pharmaceutical 
companies are only permitted to advertise ‘over the counter drugs’, that is 
pharmaceutical products that do not require a medical prescription and can be 
bought from pharmacies. The form of permitted advertising is quite diverse and 
includes the use of the media, television, newspapers, magazines and the 
internet as well as medical journals (MHRA, 2014). The media, particularly the 
television and internet, however, are easily accessible and very powerful 
advertising mediums (Fox and Ward, 2008). Whilst it is recognised that the 
media can both promote and disparage pharmaceutical companies and their 
products (Williams et al., 2008), Hassell (2012) argues that advertising can also 
strongly influence beliefs about health and ill-health and the need for 
pharmaceutical intervention. In discussing the issue of gastro-oesophageal 
reflux in infants Hassell (2012) highlighted how subtle advertising aimed at 
adults in the United States changed perceptions of reflux by creating the new 
condition of ‘acid reflux’. In marketing this new ‘illness’ as suggested by Busfield 
(2010) there was a perceived need to seek medicine to neutralise the acid 
(Hassell, 2012). Common usage of the term by adults then lends itself to be 
used to describe normal reflux or regurgitation in infants thereby reinforcing the 
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notion of medicalisation and pharmaceuticalisation by reinventing the disease 
or condition, only this time involving the younger age group.  
 
2.4.3 Knowledge Acquisition 
The rise in the use of the internet to access and acquire health related 
information (Dumit, 2012; McMullen, 2006; Wald et al., 2007) may have aided 
pharmaceuticalisation and influenced the doctor-patient relationship. For 
example, McMullen (2006) and Wald et al. (2007) report the increasing use of 
the internet to have impacted on the role of the patient during a consultation, 
and the doctor-patient relationship. They believe the power balance to be 
shifting with patients becoming active consumers of health information rather 
than passive participants (McMullen, 2006; Wald et al., 2007). This supports 
the recommendations of the Scottish Government (2018), Da Silva (2012), and 
Waneless (2002) who believe that shared decision making between health 
professionals and patients / clients can improve patient satisfaction and 
concordance with any prescribed treatment. Alternatively, Anderson (2004) 
considers the evolving ‘active consumer’ role to be due to factors such as 
patients being frustrated or unhappy with the service and information provided 
by doctors, and their unrealistic expectations of health care provision as a result 
of the continual advancement of medicine. In some instances, Anderson (2004) 
indicates that patients believe that internet sources can actually provide better 
health related information. Furthermore, Hassell (2012) highlights that in the 
United States pharmaceutical companies can promote and advertise their 
products direct to the consumer, however by advertising on the internet and 
world wide web the reach of pharmaceutical companies is infinite. Subtle, and 
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not so subtle, advertising on the internet by pharmaceutical companies may 
influence consumers perceptions of health and treatment strategies and this 
may be a factor influencing the medicalisation of GOR and the increasing use 
of medicines to manage GOR in infants. 
 
Wald et al. (2007), however, explored the patient-doctor relationship in light of 
the increased internet use and proposed a tri-partite model consisting of the 
patient, the internet and the doctor. In this consumer-focused model, Wald et 
al. (2007) indicate that information gleaned from the internet can be used to 
supplement the information provided by the doctor, and also facilitate informed 
decision-making by patients. In turn this is thought to promote concordance with 
any prescribed treatment (Wald et al., 2007). Britten (2008) views this positively 
as patients, or ‘informed consumers’, seeking to enter a partnership with the 
health professional regarding their diagnosis and subsequent management. 
Nevertheless, whilst an informed patient or ‘consumer’ can be advantageous in 
diagnosing and managing presenting symptoms and illnesses, it can also pose 
a challenge to the authority and power balance of the medical profession. This 
is particularly the case if the health information acquired is of poor quality or 
misleading (Britten, 2008). Consequently, direct to consumer advertising by 
pharmaceutical companies, especially in countries such as the United States, 
may have a key role in both informing and misleading consumers, and in shifting 
the balance of power between patient and doctor (Arney and Merjivar, 2014; 
Britten, 2008). However, it is not only pharmaceutical companies that can 
influence consumers, but also the increasing use of the internet, and the 
growing number of social media sites and self-help groups (Prasad 2013). For 
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example, the seeds of pharmaceuticalisation could be argued to be sown in 
websites such as ‘Healthline’, ‘Baby Centre’ and ‘Netmums’ as they all refer to 
regurgitation in infants as ‘acid’ reflux, suggesting that medicine is needed to 
neutralise the ‘acid’ reflux. Furthermore, ‘Netmums’ indicates that treatment 
with domperidone, omeprazole and/or ranitidine may be required. This 
suggests that multiple players (Brown et al., 2011) operate independently and 
together and are continually evolving, developing and influencing each other in 
the process. These social players can also influence the knowledge up-take of 
active consumers in pursuit of information about their health. Social and cultural 
changes have resulted in the internet being used more widely and by more 
people (Eckler et al., 2010). Furthermore, the internet permeates peoples 
personal and home life and can act as a conduit or channel for a multitude of 
players to provide health information and to engage in discussion forums and 
chat rooms. The internet, therefore, has a notable and powerful role in 
influencing people’s knowledge and understanding of health-related issues 
including GOR in infants.  
 
In reviewing the literature, it would appear that regurgitation in infants, a 
common everyday ailment, has been given a medical label and diagnosis, and 
therefore the condition medicalised. However, many factors could have 
influenced this change. The perceived authority of ‘medicine’ in exerting social 
control particularly over women is clear, especially in regard to ‘scientific 
motherhood’ and the creation of the diagnosis of kleptomania early in the 
twentieth century. It is also evident in pregnancy and childbirth, a natural 
phenomenon that has become a highly technical affair and therefore 
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medicalised. However there also seems to be a change in attitude, with modern 
women embracing, rather than thwarting medical intervention. With this change 
in attitude comes a change in the power balance with some women requesting 
medical intervention, such as caesarean section, in the delivery of their baby as 
a lifestyle choice rather than a medical need (ISD Scotland, 2018a). Indeed, 
lifestyle and the use of drugs to address lifestyle needs, is very important to 
some women as highlighted by Fox and Ward (2008) who indicated that some 
women have sought a prescription for contraceptive medication to disrupt or 
postpone menstruation prior to going on holiday or attending an important 
function or event. The term ‘medicalisation’ therefore is associated with both 
positive and negative connotations. However, as suggested by Brown et al. 
(2011), there are also many social, cultural, economic and political forces and 
social players to be considered. For example, pharmaceuticalisation, disease 
mongering and direct to consumer advertising also influence the knowledge up-
take by lay people as well as their attitudes and perceptions of health and their 
expectations of health care and this may be happening regarding the situation 
of GOR in infants. The use of internet and social media to source health related 
information is growing and permeates practically every aspect of everyday life 
via computers, tablets, and smart phones (Prasad, 2013). The internet and 
social media therefore are very powerful forces that can also impact on the 
patient-doctor relationship. Whilst information from the internet can be 
harnessed by health professionals to strengthen their position, authority and 
power with regard to health care, it can also weaken or shift this balance of 




2.4.4  Professional Decision Making 
Given the increasing use of the internet to gain medical knowledge and the 
changing power balance between doctors and patients, how decisions are 
made in health care also merits some consideration and discussion. Thomson 
and Dowding (2002) identify three categories of decision-making: Normative 
approaches which are concerned with the impact of, and the quality and worth 
of decisions made. Normative decisions are founded on scientific and 
mathematical evidence and generally considered rational and logical. However, 
evidence regarding gastro-oesophageal reflux and pharmaceutical 
management in infants identified earlier in this chapter is weak. Alternatively, 
prescriptive approaches aim to enhance decisions and facilitate effective 
decision-making. Protocols, guidelines and algorithms are common tools used 
to support prescriptive decision-making in practice. Although international, 
national and local protocols and guidelines are available to guide decision 
making regarding the diagnosis and management of GOR in infants (Rosen et 
al, 2018; NICE, 2015; NHS Grampian, 2012) international studies (Manasfi et 
al., 2017; Quitadamo et al., 2015; Quitadamo et al., 2014) found that such 
guidelines were not always followed. This may be the same in Scotland, 
therefore the use of guidelines by health professionals in Scotland needs to be 
explored further. Finally, descriptive approaches are concerned with judgmental 
and decision-making processes that inform how decisions are made, for 
example the use of intuition or tacit knowledge (Standing, 2010; Thomson and 
Dowding, 2002). Limited use of clinical guidelines by health professionals 
(Quitadamo et al.,2014: 2015; Manasfi et al., 2017), combined with the lack of 
specificity in the criteria guiding the diagnosis of GOR and GORD within clinical 
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guidelines (NICE, 2015; Rosen et al., 2018) and the weak evidence supporting 
the use of medicines to manage symptoms of GOR, may have influenced 
decision-making regarding the diagnosis and management of GOR in infants. 
It may be that such decisions are based on tacit knowledge and subjectivity, 
however this requires further exploration to identify what influences health 
professionals’ decision-making in the diagnosis and management of GOR in 
infants. Nevertheless, all three approaches aim to be evidence based and, 
therefore, are relevant in primary care and informing decision-making in daily 
practice. 
 
Evidence based practice is important in health care and refers to the diligent 
use of the best evidence obtainable to inform clinical practice and decisions 
about patient / client care (Sackett et al., 1996). The process of decision making 
is complex and multifactorial, however according to Flemming and Fenton 
(2002), the four key influences on evidence informed decision-making concern 
the clinical experience of the practitioner, the research evidence, patient/ client 
preferences, and the availability of resources. These concepts are all very 
pertinent to decision making in this instance. For example, much research 
evidence regarding the management of GOR in infants is weak, and although 
resources such as NICE (2015) guidelines are available, Orenstein (2010) 
considers diagnosis guidance within such guidelines to lack clarity and be open 
to interpretation. Furthermore, the increasing use of the internet and social 
media (McMullen, 2006; Wald et al., 2007) may influence social diagnosis and 
parent preferences regarding their infant and symptoms of GOR. As a 
consequence, the clinical experience of the practitioner may have a crucial 
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influence on the decisions made regarding the diagnosis and management of 
GOR in infants. 
 
In addition, McKay et al. (2016) discussed the impact of human factors on health 
professional’s decision making and clinical practice. Human factors that may 
impact on practitioners’ clinical practice and decision making in primary care 
include work related stress such as high workload, time pressures, interruptions 
and distractions, physical and emotional demands, and fatigue (Mackay et al., 
2016). Numerous factors, therefore may influence health visitors and general 
practitioner’s decision-making in practice.  
 
2.5 Strengths and Limitations  
At the time of undertaking this doctoral research there was no requirement to 
undertake a systematic review approach to the literature review. It is 
acknowledged that by not following accepted systematic literature review 
processes and using recognised MeSH headings and search procedures, there 
is the potential that important literature may have been omitted. Nevertheless, 
using what were deemed to be the most appropriate data bases and search 
engines for this field of enquiry, the literature was searched using key terms, 
synonyms and Boolean operators. In addition to the initial search, the literature 
was searched regularly throughout the duration of the study and immediately 
prior to the thesis being submitted to Lancaster University. Therefore, it is 
believed that at the time of submission, key literature and research relevant to 
GOR in infants aged 0-1 year was included in this literature review. Following 
systematic literature review processes and using MeSH terms in future 
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This literature review has raised some interesting points about the diagnosis 
and management of GOR in infants and the possibility that physiological GOR 
in infants has become medicalised. For example, evidence of the efficacy of the 
key drugs (Gaviscon, domperidone, omeprazole and ranitidine) used in the UK 
for the management of GOR infants is weak (Tighe et al., 2014). Furthermore, 
omeprazole (PPI) and ranitidine (H2RA) are not licensed for use in children 
under 1 year of age (BNFC, 2019). This means these medicines have not been 
rigorously tested for safety and effectiveness in this age group (Medicines and 
Healthcare Products Regulatory Agency, 2014). Yet evidence from Belgian (De 
Bruyne et al., 2014), the US (Hassell, 2012; Barron et al., 2007), New Zealand 
(Blank and Parkin, 2017) and Australia (Bell et al., 2018) suggest that these 
medicines are increasingly being used in the management of symptoms of 
GOR. Evidence regarding the use of these medicines to manage symptoms of 
GOR in young infants in Scotland, and in the UK, is lacking, therefore this 
warrants further investigation. This study aims to establish patterns of 
prescribing regarding the use of these medicines in the 0-1-year age group in 
Scotland. Why there is an increase in the use of PPI and H2RA medicines to 
manage symptoms of GOR as identified by Bell et al. (2018), Blank and Parkin 
(2017), De Bruyne et al. (2014), and Barron et al. (2007) is unclear and 
suggests a gap in knowledge. However, management and prescribing 
decisions may be linked to diagnostic decisions as evidence from this literature 
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review highlighted that the criteria to aid the diagnosis of GOR is vague and that 
investigative tests may be unreliable (NICE, 2015; Rosen et al., 2018). This 
suggests that decision-making regarding the diagnosis of GOR may be 
subjective and based on tacit knowledge rather than empirical evidence. This 
is interesting as Zola (1972) believed ‘diagnosis’ to be a key element of 
‘medicalisation’. This merits further investigation to explore how decisions are 
made regarding the diagnosis and management of GOR in infants and what 
influences those decisions. An element of medicalisation highlighted in the 
literature review that is also of interest is pharmaceuticalisation. Hassell (2012) 
alludes to subtle advertising by pharmaceutical companies in the US that raises 
the profile of ‘acid’ reflux and the need for acid suppressant medicines thereby 
strengthening the concept of pharmaceuticalisation and medicalisation. This is 
worth investigating in the UK, as Dumit (2012), McMullen (2006), and Wald et 
al. (2007) highlight that the internet is increasingly being used to access 
information about health, therefore, this may be a factor influencing diagnostic 
and management decisions regarding GOR in infants. Evidence in the literature 
review also highlighted that the focus of health care is constantly changing and 
evolving, again this is worth exploring in relation to GOR in infants as changing 
attitudes may influence parental expectations of parenthood as well as 
decision-making regarding the diagnosis and management of GOR in infants 
by health professionals. 
 
In concluding, medicalisation of normality is a useful framework to help 
understand the issues raised in this literature review. It also resonates well with 
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the two-stage research design and pragmatic approach to this study that is 




CHAPTER 3: RESEARCH METHODS   
 
3.0 Introduction  
Evidence from the previous chapter suggests that prescribing of medicines for 
the management of GOR in infants is increasing in the US (Hassell, 2012; 
Barron et al., 2007), Belgium (De Bruyne et al., 2014) and Australia (Bell et al., 
2018). However, although it is assumed that prescribing of medicines to 
manage symptoms of GOR is rising in Scotland and the UK, currently there is 
very little evidence to validate this assumption. As the previous chapters have 
illustrated, the existing evidence base (Bell et al.,2018; De Bruyne, 2014; Tighe 
et al., 2014) highlights a rise in prescribing but also the lack of evidence around 
efficacy of medicines to manage GOR. This raises an important question about 
why prescribing rates continue to rise. Theoretically, commentators (Harvey, 
2013; Jutel, 2011a; Williams et al., 2008; Apple, 1995) have suggested, that as 
medical treatments become available, symptoms previously dealt with through 
non-medical interventions become medicalised. In order to explore how these 
issues are being played out in the Scottish setting, it was decided to develop a 
two-stage research study. Stage one aimed to explore patterns of prescribing 
of alginate, domperidone, omeprazole and ranitidine in Scotland over time, 
whilst the aim of stage two was to explore factors influencing and underpinning 
how health professionals and parents perceive and manage symptoms of GOR 
in infants aged 0-1 year. 
 
This chapter will discuss the research design and research methods used in 
this study. The rationale for the two-stage design, and the epistemological and 
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philosophical assumptions that underpin the study will also be discussed. 
Thereafter, the chosen two-stage research design, the research methods used, 
including their validity and trustworthiness, will be examined. Finally, the 
positionality of the researcher and the ethical considerations for the study will 
be reviewed. 
 
3.1 Two Stage Research Design 
The decision to use a two-stage research approach was pragmatic and chosen 
in a bid to effectively address the research objectives as one method alone 
would not have been sufficient. In this instance, anecdotal evidence suggested 
that the prescribing of medicines to manage GOR in infants in Scotland had 
increased over time, but at the outset of the study the evidence to support this 
was not yet known, therefore a quantitative research strategy was required in 
stage one to interrogate the data in order to support or refute this assumption. 
The quantitative data on its own, however, provided limited information, 
therefore to gain a more in-depth understanding of the situation and explore 
reasons for the potential increase in prescribing, qualitative research 
techniques were used in stage two. 
 
The underpinning epistemological assumption of the two-stage methods 
research is pragmatism (Adamson, 2005; Robson, 2011) which focuses on the 
problem to be researched and the consequences of the research, rather than 
the philosophical and epistemological assumptions and constraints (Feilzer, 
2010). In this study, stage one and stage two are two independent studies, 
therefore a two-stage study research design is appropriate. 
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Stage one took a quantitative approach, therefore the epistemological position 
is that of positivism. Positivism favours an empirical approach to research that 
focuses on cause and effect relationships, and deduction or the testing of 
theories (Doyle et al 2009). A quantitative approach was appropriate as the 
purpose of stage one of the study was to identify patterns of prescribing of 
medicines in the management of GOR in infants aged 0-1 year in Scotland. 
From an ontological perspective the orientation of quantitative research is that 
of objectivism in that objective reality exists independently of the influence of 
the researcher (Sale et al, 2002). The concept of objectivity is relevant to stage 
one of this study as secondary numerical data were obtained from routine 
survey data gathered on a national level by ISD Scotland. Although I was not 
directly involved in the collection of the original data, I conducted the secondary 
analysis of these datasets.  The chosen research method and quantitative 
approach was appropriate for stage one of this study, as a large and robust set 
of factual and numerical data from ISD Scotland was used to describe the 
pattern of prescribing behaviours across Scotland, observe changes over time 
and address the research aim and objective of stage 1.  
 
In stage two of the study a qualitative research approach was chosen. The 
epistemological underpinning of the qualitative paradigm is founded on 
interpretivism and constructivism that is characterised by a focus on subjectivity 
and a quest for deeper meaning and understanding (Bryman, 2008; Sale et al, 
2002). The qualitative paradigm believes that the construction of reality is based 
on numerous truths or realities that are constantly changing (Sale et al, 2002; 
Bryman, 2008; Doyle et al., 2009). In other words, there are many internal 
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and/or external influences that can have an impact on the findings of qualitative 
studies, or in this instance the perceptions of GOR in infants and the impact on 
family life. Therefore, a key goal of stage two of the study was to capture the 
real-life experience, thoughts, perceptions and feelings of health visitors, 
general practitioners and parents when confronted with an infant suffering from 
symptoms of GOR. The researcher, therefore, and the participants (health 
visitors, general practitioners and parents) are generally inextricably linked, 
mutually interactive, and not separate entities as in the quantitative paradigm 
(Sale et al. 2002).  
 
3.2 Stage 1: Quantitative Research Method 
The study undertook secondary analysis of prescribing data collected over a 
seven-year period from 2010 – 2016 (inclusive) for all 14 territorial NHS boards 
in Scotland. The data for the four key medicines (alginate/ Gaviscon, 
domperidone, omeprazole and ranitidine) prescribed and dispensed to the 0-1-
year age group was provided by the Information Services Division of NHS 
Scotland (ISD Scotland, 2012). In Scotland all NHS patients have a unique 
Community Health Indicator (CHI) number that is indicated on all prescriptions 
(ISD Scotland). This enables ISD Scotland to identify patients and the drug 
dispensed to them (ISD Scotland). The number of items or prescriptions 
dispensed includes only those with a valid CHI number and details of the CHI 
completeness for paid items is included in the data. In this study, the patient 
count refers to the number of infants aged 0-1-year prescribed a specific 
medicine within one financial year. Therefore, using CHI data infants are 
counted only once for the drug prescribed per year. In instances where infants 
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are prescribed two drugs within the year, their CHI number will be recorded 
once in both drug classes within that year. ISD Scotland also provided mid-year 
population estimates from the National Records of Scotland for children aged 
0-1 year for the whole of Scotland and across NHS Board areas. 
 
The use of this secondary data was considered appropriate for the purpose of 
stage one as ISD Scotland routinely gather data on prescribing practices across 
all NHS Boards in Scotland and were able to provide national data on 
prescribing that included the geographical distribution and pattern of prescribing 
practices, as well as variation over time. Without these data, the aim and 
objective of stage one of the study would not have been adequately addressed 
as the literature search found no studies concerned with prescribing for GOR in 
infants aged 0-1 year in the UK. National data sources such as ISD Scotland 
are considered invaluable on several counts (Alvarez et al., 2012). Firstly, ISD 
Scotland has routinely gathered prescribing data for many years and data 
relevant to this study was available from 2010, therefore it was possible to 
observe change over time adding strength to the study. Secondly, this wider 
dataset provided a larger and more robust database through which to describe 
the situation across Scotland (Windle, 2010). Consideration was given to other 
quantitative research designs. For example, an experimental design was 
considered inappropriate as the intention of the study was to determine if the 
use of medicines to manage symptoms of GOR in infants had increased, it was 
not to test the efficacy or compare effectiveness of medicines in managing 
symptoms. Reviewing medical records from a sample of general practices was 
also deliberated, however in addition to this being a lengthy and time-
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consuming process it would only have provided a snapshot view of prescribing 
of medicines to manage symptoms of GOR in infants at one point in time. It 
would not have shown change in prescribing practice over time. It is also 
possible that the sample selected would have reflected local prescribing 
preferences and not have been representative of the general population. 
Furthermore, as the medical records would not be anonymised this would have 
required further ethical consideration and approval. Secondary data analysis in 
this instance, was not only convenient but was more effective and efficient in 
addressing the aim and objective of stage one. In this study the prescribing rate 
refers to the number of prescriptions dispensed and paid for per 100 head of 
population (infants aged 0-1 year). Prescriptions that have been dispensed and 
paid for provide accurate data (based on written prescriptions only) as not all 
prescriptions written by practitioners are taken by patients to the pharmacy for 
dispensing. 
 
The prescribing data, however, does have some limitations which need to be 
acknowledged. For example, the data does not provide insight into the reason 
why the drugs were being prescribed. Currently such detailed information is not 
available. Therefore, although it is highly likely that the drugs were prescribed 
for managing symptoms of GOR in infants not all prescriptions are written for 
this purpose. For example, omeprazole may be prescribed as part of the regime 
in the eradication of helicobacter pylori in children, in the treatment of Zollinger-
Ellis syndrome, and fat malabsorption (BNFC, 2019), whilst both omeprazole 
and ranitidine may be used in the treatment of acid related conditions such as 
gastric or duodenal ulceration (BNFC, 2019). It should also be noted that 
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domperidone (motility stimulant) is not recommended in the management of 
GOR, and that neither omeprazole (PPI), or ranitidine (H2-receptor antagonist) 
are licensed for use in children in the 0-12-month age group in the UK (BNFC, 
2019). However, despite these limitations, the ISD Scotland data does provide 
an important indication of changes in prescribing levels for infants aged under 
12 months in Scotland. 
 
3.2.1 Ethical Approval 
The protocol for this study was submitted to Lancaster University Ethics 
Committee and to the Integrated Research Application System (IRAS) and 
approval gained prior to receiving data (Appendix 9 - FHMREC:23/05/2014;  
NHS Lothian: 23/20/2014; Grampian: 07/01/2015). The data provided by ISD 
Scotland was completely anonymous and no individual patient or child health 
records were identified or involved. 
 
3.2.2 Quantitative Data Analysis 
The data analysis plan is presented in table 3.01. Overall the data set included 
a total of 404757 prescriptions for alginate, domperidone, omeprazole and 
ranitidine prescribed to 0-1year old infants across all 14 NHS boards between 
the years 2010 and 2016. The software tool Minitab 16 was used to manage 
the data provided by ISD Scotland.  
 
Stage one of this study aimed to determine patterns of prescribing for GOR in 
infants to see if there had been an increase in prescribing of the key medicines 
used to manage GOR as was assumed at the outset, therefore descriptive 
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statistics were deemed sufficient to illustrate this and to show key features of 
the data set (Robson, 2011). Descriptive statistics are essentially concerned 
with frequencies, averages, and variability (Robson, 2011). Time series plots 
were used to provide a graphical depiction of the connection or relationship 
between variables. It also allowed comparisons between the prescribing rates 
of the four drugs at a national level to be illustrated, as well as comparisons of 
the prescribing rate of each drug between the 14 NHS boards over the study 
period (Montgomery et al, 2015). 
 
Regression analysis using the ‘least squares’ method was used to identify the 
‘line of best fit’ on the time series plots and determine values for the gradient or 
slope of the line, and the intercept. The intercept being the point where the slope 
crosses the y axis. (Scott and Mazhindu, 2005/2011). Regression analysis 
measures changes in the ‘y’ variable as a result of the ‘x’ variable and, therefore, 
was used to identify trends in prescribing and to predict the likely increase in 
the prescribing of each medicine over time (Robson, 2011; Dancey and Reidy, 
2014).  
To establish the accuracy and degree of precision of the data, confidence 
intervals were calculated. These provide an upper and lower limit within which 
the researcher could be 95% confident that this is where the true prescribing 
rate lies (Gerrish and Lacey, 2006; O’Rourke, 2009). The narrower, or tighter 
the confidence interval, the less the margin of error and the greater the precision 







Table 3.01: Data Analysis Plan 
 
Research question Is prescribing of medicines to manage symptoms of GOR in infants increasing in Scotland? 
Dataset to be used • National prescribing data from the Information Services Division of NHS National Services 
Scotland. 
• The dataset involves prescribing data in the 0-1-year age group in Scotland between the 
years 2010 – 2016 for the following medicines: 
-  Alginate (Gaviscon),                                       -  Domperidone (motility stimulant),  




• Items prescribed and dispensed in Scotland 
• Items where a valid Community Health Indicator number (CHI) is captured 
• Items prescribed to infants age 0-1year 
• Medicines: alginate (Gaviscon), domperidone (motility stimulant), omeprazole (proton 
pump inhibitor) and ranitidine (H2-receptor antagonist) 
Exclusion criteria 
• Items with invalid or incomplete CHI  
• Infants older than 1 year of age 
• Medicines other than alginate (Gaviscon), domperidone (motility stimulant), omeprazole 
(proton pump inhibitor) and ranitidine (H2-receptor antagonist) 
Missing data ISD Scotland is a recognised producer of Official Statistics in Scotland and adheres to the Code of 
Practice for Official Statistics (UK Statistics Authority, 2018), that defines the principles and practises 
required to produce high quality and trustworthy statistics, therefore the national prescribing data 
provided by ISD Scotland is the most accurate and robust data available. Therefore, the data provided 
is deemed to be complete. 
Variables to be 
used in the analysis 
 
Exposure variables: 
-  Alginate (Gaviscon),                                       -  Domperidone (motility stimulant),  
                  -  Omeprazole (proton pump inhibitor),        -  Ranitidine (H2-receptor antagonist) 
Outcome variables: 
• Prescribing rate 
Stratifying variables: 
• NHS Scotland 
• NHS Territorial Boards in Scotland (14 Boards) 
Statistical Methods Trend Analysis 
• Time series plots are used to illustrate changes in prescribing rates over time 
• ‘Least squares’ regression analysis is to be used to: 
o Identify the ‘line of best fit’ for the regression of prescribing rate against time 
(year), (with year = 0 ≡ 2009, year = 2 ≡ 2010, etc) 
o Model the linear trend in the prescribing rate over time, in particular, the 
coefficient of year (the gradient in the fitted regression equation) to quantify the 
average annual change in the prescribing rate over the study period. 
• The coefficient of determination R² (0 ≤ R² ≤ 1), is calculated for each plot. This statistic 
provides a measure of how well the straight line fits the data and is interpreted as the 
proportion of variation in the prescribing rate that is accounted for by the variation in year.  
Confidence Intervals: 
• While the rates obtained are population figures, they are still subject to random 
fluctuation. Hence, 95% confidence intervals are used to indicated the precision with which 
the underlying ‘true’ rates are measured (95% of intervals calculated will obtain the ‘true’ 
rate). However, such intervals are considered to be unreliable when the number of events 
(patients) is less than about 20 (Buescher, 1997; 2008) 
Ranking of NHS Board prescribing of each drug within each year (rank = 1 ≡ highest rate, etc.) and 





Key tables and/or 
figures 
• Time series plots 
• Time series plots with ‘line of best fit’ 
• Patient count table 
• Prescribing rate in Scotland and confidence intervals for each drug 
• Ranking tables of prescribing of each drug in each NHS Board. 
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The findings from stage one revealed areas where prescribing of specific 
medicines used in the management GOR was particularly high. This data was 
also used to identify study areas for stage two of the research.   
 
 
3.2.3 Reliability and Validity 
ISD Scotland is part of NHS National Services Scotland (NSS) and provides 
national statistical data that informs decision making and planning within the 
national health service in Scotland (ISD Scotland, 2010). It has a key role in 
gathering routine prescribing data on behalf of NSS Practitioner services and 
therefore, provides the most accurate data. Moreover, ISD Scotland abide by 
the Code of Practice for Official Statistics within the UK and is a recognised 
authority by the UK Statistics Agency (ISD Scotland, 2010). The data provided 
for this study are the most valid and reliable available and provide an accurate 
reflection of prescribing practices across NHS Scotland (ISD Scotland, 2012b). 
In this study ISD Scotland provided data on all prescriptions for alginate, 
domperidone, omeprazole and ranitidine dispensed to infants aged 0-1year in 
Scotland from the year 2010 to 2016. 
 
3.3 Stage 2:  Qualitative Research Method 
Stage two of the study focused on gaining a more in-depth understanding of the 
patterns of prescribing and the changes that were evident from the analysis of 
the prescribing data from ISD Scotland in stage one. Therefore, qualitative 
research strategies were used to explain and interpret the findings and 




The initial intention was for interviews to be held with health visitors and general 
practitioners from two NHS Board areas and for comparisons to be made 
between the two board areas. Consideration was given to the use of focus 
groups to gather data, however social interaction among participants is a key 
feature of the generation of data in focus groups and this can present 
challenges to the researcher (Holloway and Galvin, 2017). For example, focus 
groups can be difficult to lead and to manage, especially if there are dominant 
participants in the group, and this may affect the outcome of the data collected 
and can lead to bias. Transcribing of discussions within focus groups can also 
be challenging as it can be difficult to decipher what is being said if more than 
one person is speaking at time therefore some valuable discussion may be lost. 
Furthermore, given the large geographical areas involved it may have been 
difficult to arrange a suitable time and venue to host a focus group. In 
comparison, one to one interview’s focus on the interviewees own personal 
experiences and therefore can produce more in-depth data (Holloway and 
Galvin, 2017). They can also be arranged at a time and place suitable to the 
participant, allowing them an element of choice and privacy within the process.  
 
 The findings from stage one, identified two NHS Boards to consistently have 
high prescribing rates. NHS Grampian consistently had the highest prescribing 
rate for ranitidine over the study period, and NHS Lothian consistently had the 
highest prescribing rate for omeprazole. Therefore, these two boards were 
selected for sampling and further exploration in stage two of the study. Neither 
of these medicines are licensed for use in infants under one year of age in the 
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UK, hence understanding the reasons behind these high prescribing was 
worthy of further investigation in stage two. 
 
Nevertheless, at an early stage of the study this decision to sample two 
geographical areas proved challenging, particularly in NHS Lothian where there 
was an acute shortage of health visitors, recruitment was via a gatekeeper and 
I did not have the same support from the Director of Nursing as I had in NHS 
Grampian. Therefore, the decision was taken to focus on one region only: NHS 
Grampian, but also to include parents of infants with symptoms of GOR. Whilst 
a comparison of these two regions with differing prescribing practices would 
have provided useful insights into why health professionals in different areas 
manage GOR differently, including parents in one area allowed for a more 
rounded picture of influences on the management of GOR within that area. This 
had an impact on the overall aim and objectives. Therefore, instead of narrowly 
focusing on health professionals the aim and objectives were revised to include 
a broader focus on factors influencing and underpinning how health 
professionals and parents perceive and currently manage GOR in infants. 
 
The aim of stage two was amended to explore parent’s perceptions and 
experiences of caring for an infant with symptoms of GOR, and what shaped 
their decisions about whether or not to seek medical advice and support. It also 
sought to understand what factors influenced the diagnosis of GOR in infants 
by health visitors and general practitioners and how this shaped their 




3.3.1 Participant Selection 
The sampling strategy in stage two was influenced by the analysis of the ISD 
Scotland data undertaken in stage one, with the geographical data and findings 
from stage one used to inform and deliberately select geographical areas for 
more qualitative research in stage two. The study focused on NHS Grampian 
for the following reasons. Firstly, findings from stage one revealed Grampian to 
be an area in which changes in prescribing rates were high, and that Grampian 
consistently had the highest prescribing rate for ranitidine over the study period. 
Secondly, although there was a national shortage of health visitors in Scotland, 
the Director of Nursing in Grampian was supportive of the study making it more 
likely that good recruitment would be possible. Thirdly, Grampian was selected 
for the pragmatic issue of proximity for me, the researcher. 
 
Health visitors and general practitioners were the professional groups selected 
to recruit to the study because they had specific qualifications, experiences and 
knowledge deemed important in addressing the research aim and objectives 
(Moule and Goodman, 2009). For example, every child in Scotland has a named 
health visitor who, in many cases, is first point of contact for families, whilst 
currently general practitioners are the key professionals in primary care that 
prescribe pharmaceutical interventions to manage GOR in infants under 1 year 
of age. Parents were included to share their perceptions, insights and 
experiences of caring for their infant with symptoms of GOR, thereby providing 






3.3.1.1 Recruitment of Health Visitors 
Regarding health visitors, the recruitment process involved the researcher 
contacting the Director of Nursing services in NHS Grampian to seek their 
approval and support in recruiting health visitors to the study. The Director of 
Nursing in NHS Grampian supported the study, leading to health visiting team 
leaders / managers in NHS Grampian being sent electronic information about 
the study to disseminate to the health visitors in their geographical areas. In 
addition, I offered and was invited to attend health visitor meetings to provide 
information about the study and to answer any queries. At the time of the data 
collection there was an estimated 230 health visitors employed in NHS 
Grampian (ISD Scotland, 2018c) and of these ten health visitors were recruited 
to the study from a range of settings that included urban and rural, and affluent 
and poor areas. 
 
3.3.1.2 Recruitment of General Practitioners 
Recruitment of general practitioners was challenging. A letter was sent to the 
GP Sub-committee to inform them of the study and harbor their support in 
recruiting participants. However, although seemingly interested in the study, the 
Chair of the group was not agreeable to disseminating information about the 
study to general practitioners in Grampian. The researcher therefore sent letters 
of invitation, participant information and other relevant information (Appendix 3) 
about the study to 43 medical practices in NHS Grampian. This included urban 
are rural areas as well as affluent and deprived areas. According to ISD 
Scotland (2018c) there were approximately 160 general practitioners working 
in medical practices in NHS Grampian at the time of the study. However, despite 
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reminder letters and offers to visit medical practices to inform them about the 
study and answer any questions or concerns, only four general practitioners 
were recruited. As three of the general practitioners worked in the same health 
centre and one was of a different gender, it was decided to use androgynous 
pseudonyms to maintain anonymity. There was also a risk that these three 




3.3.1.3  Recruitment of Parents 
Parents were recruited via parent and baby groups. Initially parent and baby 
groups in the catchment areas of the recruited health visitors and general 
practitioners were targeted and sent posters, letters of invitation, and 
information about the research (Appendix 3), but this was later opened to 
include a wider geographical area within NHS Grampian. I also offered, and 
was invited, to attend meetings and groups to share information about the study 
and to answer any queries. Initially parents with children under one year of age 
were targeted, but it later became apparent that the children of some parents 
who were agreeable to participate in the study were now older than 1 year. 
These parents had reflected on their past experiences of caring for their child 
with GOR when their infant was under 1-year-old and believed they had a 
valuable contribution to make to the study. Therefore, after discussion with my 
research supervisors it was agreed to include parents of infants up to the age 
of 30 months.  An ethics amendment to this effect was submitted to, and 
accepted by, Lancaster University Research Ethics Committee (Appendix 9: 




The parents were recruited via a variety of parent and baby groups across 
Grampian. From 32 parent and baby groups in Grampian targeted, eight 
parents were recruited to participate in the study. However, although some 
parents lived in the same catchment area as where some of the general 
practitioners and health visitors worked, it is not known if these families were 
registered at these medical centres or known to the practitioners. Whilst this 
may be a weakness of the study, it also increased the diversity of responses 
gained. 
 
3.3.2 Setting of Data Collection 
The interviews (pilot and main study) were conducted in a private environment 
and location that was familiar and comfortable to the interviewee. Health 
professionals chose their workplace, whilst parents preferred to be interviewed 
in their own homes. This was conducive to a relaxed and positive experience 
for the participant, and to a more favourable and productive outcome from the 
interview (Whiting, 2008). In keeping with the principles of lone working cited by 
the Universities and College Employers Association (2005), details of the 
venues of the interviews, and the expected time of return were left with work 
colleagues.  
 
3.3.2.1 Data Collection  
Semi-structured interviews were chosen as the main research method of data 
collection in stage 2. Firstly, because they allow the researcher to develop a 
schedule of pre-determined themes that can help guide the interview process 
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to ensure that key issues are discussed (Tod, 2009). Secondly semi-structured 
interviews permit scope for flexibility so a common set of broad themes relevant 
to the diagnosis and management of GOR could be explored. Flexibility was 
important and valuable within this study as it enabled respondents to elaborate 
and expand on any points that they felt were significant as well as introduce 
issues they considered important but were not identified by the researcher at 
the outset. It also allowed the interviewer to be responsive to unexpected but 
relevant issues, and to probe and explore these in greater depth to unravel 
factors that both influenced the diagnosis of GOR in infants, and shaped 
management and prescribing decisions. 
 
3.3.2.2 Semi-Structured Interview Schedules 
Two semi-structured interview schedules were developed (Appendix 4), one for 
health professionals (health visitors and general practitioners) and one for 
parents. Although similar in some respects, the semi-structured interview 
schedules differed and provided two broad sets of themes to guide the 
interviewer when interviewing parents, and health professionals. For example, 
the schedule for health professionals focused on finding answers to research 
objectives 2 – 5, whilst the interview schedule for parents focused on research 
objective 6 and the parents experience of caring for their infant with symptoms 
of GOR. The content of the semi-structured interview schedules was drawn 
from the evidence in the literature review regarding gastro-oesophageal reflux 
and its diagnosis and management in infants, as well as the theoretical 
underpinnings concerning medicalisation, pharmaceuticalisation, the changing 




3.3.2.3 Pilot Study 
Two former health visiting colleagues, and one parent (friend) participated in 
the pilot study. The pilot interviews highlighted several areas for improvement. 
For example, different terminology was used by the participants to describe 
GOR, and new issues such as culture and cultural differences were highlighted. 
The interviews were also much shorter than one hour. This led to the interview 
schedules being revised and whilst the themes / sections remained same, the 
order and wording of some of the questions was changed to encourage greater 
discussion. Also, to ensure that the focus of the study remained the same, the 
revised questions were reviewed and mapped against the objectives set for the 
study. Listening to the recordings allowed me to reflect on my interview 
technique and improve it in the main study by talking more slowly, using less 
leading and less medically focused questions, and allowing for silences while 
participants were thinking. During the pilot study interviews, field notes were 
taken to verify the data collected and to note any nuances within the context of 
the discussions (Tod, 2009). However, on listening to the audio recordings it 
was clear this had a detrimental impact on the flow of conversation with the 
participants waiting until I had finished writing before speaking. Taking field 
notes also distracted me, preventing me from giving my full attention to the 
interviewee and the interview. As a result, some important opportunities to 
probe and explore issues further were missed. Therefore, in the main study it 
was decided that no field notes would made during the interview, rather they 




3.3.2.4 Audio Recording and Field Notes 
With the participant’s consent, the interviews were audio recorded to ensure a 
record of the interviews were available for analysis. The recordings also allowed 
me to reflect on my questioning approach and interview technique and make 
improvements in subsequent interviews. Whilst cognisance was taken of the 
intrusive nature imposed by using recording equipment (Tod, 2009), its use led 
to a more relaxed and informal ambiance during the interviews. This enabled 
me to focus and give my full attention to the individual being interviewed. 
 
3.3.2.5 Duration of Interviews 
On average the interviews lasted around one hour in length. The longest 
interview was 1 hour, and 25 minutes and the shortest interview was 35 
minutes. Longer interviews can lead to respondent and interviewer fatigue and 
deter others from participating in the research (Robson, 2011).  
 
3.3.2.6 Data Saturation 
Due to the in-depth and intense nature of qualitative research and the wealth of 
rich and prolific data that is gleaned, sample sizes tend to be small (Procter and 
Allan, 2006). However, there is general agreement that the sample size is 
appropriate when the data analysis reveals no new data and indicates that 
thematic saturation has been achieved (Ritchie et al., 2014a; Procter and Allan, 
2006; Endacott, 2005). In this instance data saturation was reached on 
interviewing ten health visitors, and although only four GPs were interviewed, 
the emergent themes reflected that of the health visitors suggesting that 
saturation point had been achieved. Saturation point appeared to be reached 
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when eight parents were interviewed.  A total of 22 subjects were thus 
interviewed and this is in accordance with Ritchie et al. (2014a) who indicate 
the sample size in qualitative studies to range between 10 and 50 subjects. 
 
 
3.3.3 Qualitative Data Analysis 
The audio recorded interviews were transcribed verbatim and analysed 
thematically using the Framework Method (Ritchie and Spencer, 2014a). This 
approach, sometimes referred to as Framework Analysis, provides a flexible yet 
structured and rigorous way to manage qualitative data (Ward et al., 2013; 
Parkinson et al., 2016). The approach is explicit with clear steps to follow that 
support transparency in the analytical process by facilitating an audit trail of how 
the data are interpreted from the initial interview and raw transcripts, through to 
the development of theories and summary charts (Ward et al., 2013; Parkinson 
et al., 2016). The process was iterative and involved revisiting some steps in 
the framework as well as some themes, and interview data. Only when the 
findings were written up was the Framework Method of analysis considered 
complete. Furthermore, the Framework Method complements thematic 
methodology used to support the thematic analysis of the semi-structured 
interviews (Ward et al., 2013; Gale et al., 2013). Analysis of qualitative data is 
often criticised for lack of transparency, therefore the Framework Method, by 
providing a clear audit trail enhanced the dependability of the research findings. 
The steps of Framework analysis begin with familiarisation of the data, the 
development of a theoretical framework, indexing and charting, and 
summarising of data in an analytical framework and finally synthesis of data by 
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mapping and interpreting (Spencer et al., 2014a; Ward et al., 2013). The 
Framework Method was used as follows: 
 
1. Familiarisation started with transcribing the interviews then repeatedly 
reading the transcriptions and listening to the recorded interviews (Spencer 
et al., 2014a, 2014b). This was done to ensure familiarisation with each 
transcription and a full understanding of the data. Due to time constraints 
several interviews were transcribed by a professional transcriber, however 
when this happened extra vigilance was taken to repeatedly listen to the 
recordings and read the transcriptions and any field notes. This was to ensure 
accuracy in the transcriptions as well as to become immersed in, and familiar 
with the data and any nuances within the interview itself. The familiarisation 
process was considered complete when the wealth of attributes and 
elements in the data was understood (Spencer et al., 2014a, 2014b). 
Thereafter data from each transcript was coded and classified according to 
the subject group (general practitioner, health visitor or parent) and from this 
an initial list of topics for each group were identified and described. (Appendix 
5 provides an example of the initial list of themes and subthemes from the 
interviews with general practitioners) 
 
2. Theoretical framework - The list of initial topics drawn from the 
interview data from each subject group was refined, linked and sorted to form 
a hierarchy of themes and sub-themes. The interview schedule was useful in 
helping to structure the hierarchy and initial framework, however 
consideration was also given to new and emerging themes that presented. 
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In developing a meaningful and purposeful theoretical framework relevant to 
this research study, the research aims, and objectives were revisited, and 
always kept in the view of the researcher (Spencer et al., 2014a, 2014b). 
(Appendix 6 provides an example of some of the revised themes and 
subthemes mapped to research objectives and the underpinning theoretical 
framework) 
 
3. Indexing and charting was undertaken by applying the draft Framework 
to the original transcriptions to identify where specific topics relevant to the 
framework themes and sub-themes are located within the data. The 
computer assisted qualitative data analysis software (CAQDAS) package 
NVivo 10 was used to support analysis and code in step 1 (Familiarisation). 
NVivo 10 proved expedient in indexing the data and charting and sorting the 
data around key topics to allow for intensive review, and with the added 
bonus of retaining links with the original transcripts. This allowed for the 
creation of a working analytical framework that allowed for later reflection on 
the choices made. All decisions made during indexing and charting were 
recorded, and any connections to emergent themes and categories 
documented. (Appendix 7 provides an example of indexing using NVivo) 
 
4. Summarising data in an analytical framework involved reducing the 
volume of data to a manageable level whilst retaining the essence of what 
each individual subject said (Spencer et al., 2014b). Each theme was given 
its own matrix with sub-themes entered in columns and participants in rows. 
The challenge was deciding how much information to include in each cell of 
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the framework and keeping the summaries succinct. Initially this was done 
manually on a Word document, however using NVivo, made this easier and 
more efficient by tracking links back to the transcripts and the original quotes. 
This enhanced transparency of the audit trail (Ward et al., 2013). (Appendix 
8 provides an example of a Data Summary and Display) 
 
5. Synthesising of data by mapping and interpreting involved higher 
analytical and abstract thinking in order to explain and make sense of the 
data (Spencer et al., 2014a, 2014b; Ward et al., 2013). The identified themes 
and sub-themes were compared and contrasted to allow further refinement, 
merging and splitting, whilst the data summaries were continually checked 
against the original transcripts to ensure accuracy and context. Using NVivo, 
participant groups (health visitor, general practitioner and parent), and 
specific attributes within the participant groups, were explored for 
connections and differences in the data. The aim being to develop meaningful 
explanations by making logical sense of the patterns within the data (Spencer 
et al., 2014b) 
 
3.3.3.1 Trustworthiness 
Credibility, transferability, dependability and confirmability are the criteria 
(Bazeley, 2013a; Guba and Lincoln, 1986) used to determine trustworthiness 
and authenticity, the alternative to reliability and validity in qualitative studies. 
These criteria are demonstrated throughout and evidenced in the documenting 
of the steps and decisions made in undertaking this research study and reported 
in this dissertation. Furthermore, the Framework Method facilitated a clear audit 
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trail of all decisions and steps taken in the research journey, again enhancing 
transparency and dependability of the research findings. More specifically, the 
recording of interviews allowed me to repeatedly return to the original 
recordings and transcriptions in order to validate data and keep the findings 
grounded in the data and experiences of the participants and maintain credibility 
of the findings (Cope, 2014). 
 
3.3.3.2 Positionality and Reflexivity 
Reflexivity is a central feature of qualitative research that is concerned with the 
influence that the researcher wittingly or unwittingly has on the findings of a 
study (Jootun et al., 2009). The social identity of the researcher, and personal 
background such as gender, culture and life experiences can all frame the 
research questions, study design and interpretation of the data collected 
(Creswell, 2014). Cognisance, therefore, was taken of potential preconceived 
notions and biases that I may have unconsciously brought to the study. As a 
female and a health visiting lecturer there was a risk that the interviewee and I 
were known to each other. For example, some interviewees were former health 
visiting students and, therefore, may have felt intimidated by me, or alternatively 
provided responses that they perceived to be ‘the right answers’ rather than 
providing a true reflection of their own professional practice and values. To 
overcome this dilemma, I continuously reflected on my own role and position 
within the research study and how my own perceptions, personal values, and 
actions could influence the collection and analysis of data (Creswell, 2014). 
These reflections were recorded in a reflective log (Jootun et al., 2009). On the 
other hand, as an experienced health visitor, I was well acquainted with medical 
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jargon and terminology, and could have full and candid interviews with health 
professionals using medical terms and language. My health visiting expertise 
and knowledge of GOR was also useful when interviewing parents as I could 
explain the purpose of my research in a clear and simple manner. I was also 
familiar with lay terms and could adapt my questions to suit the participant as 
well as probe any pertinent issues highlighted. An interviewer without such 
specialist knowledge and understanding may have missed valuable insights, 
pertinent points or opportunities to probe matter further. 
 
3.4 Ethical Considerations  
Ethical considerations in this research study were guided by NHS Research 
Scotland (NRS) based on the Research Governance Framework for Health and 
Community Care (Scottish Executive, 2006) that states: 
 ‘the dignity, rights, safety and well-being of participants must be the 
primary consideration in any research study’ 
Lancaster University research ethics committee approved the study (Appendix 
9: FHMREC – 23/05/2014), and, via the on-line Integrated Research Application 
System (IRAS), NHS Grampian Research and Development Department also 
granted ethical approval for stage 1 and stage 2 of the study (Appendix 9: NHS 
Grampian – 07/01/205). Ethical approval therefore was granted prior to 
prescribing data from ISD Scotland being analysed in stage 1, and in stage 2 
prior to the pilot and main study (Appendix 5). In this study particular attention 
was given to the ethical areas of informed consent, anonymity and 




3.4.1 Informed consent 
Participants were given information prior to the study allowing them to make an 
informed decision of whether or not to participate. In addition, the researcher 
outlined the study and ensured that participants understood what the study 
involved, how findings would be reported, and what they were consenting to 
prior to the interview taking place. Participants were also informed of their right 
to withdraw from the study if they so wished. Details of counselling and support 
agencies was also made available to participants should they feel distressed at 
any point before, during or after the interview. None of the participants were 
distressed by the interview. 
 
3.4.2 Anonymity and Confidentiality 
All consent forms were signed by the participant and the researcher and stored 
separately from the audio recording and transcripts. In addition, and to maintain 
anonymity, participants were given a personal identification code and 
pseudonym. Audio recordings and transcriptions were stored electronically, and 
password protected with the password known only by me, the researcher. 
Furthermore, it was only me who had access to the raw data and care was 
taken to ensure anonymity and confidentiality at each stage of the research 
process and specially when writing up the findings. 
 
3.4.3 Research Governance 
At the outset, the study focused on health professionals, therefore initially 
ethical approval was gained from Lancaster University research ethics 
committee (Appendix 9: FHMREC 23/05/2014) and, via the Integrated 
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Research Application System (IRAS), from NHS Grampian, and NHS Lothian 
(NHS Grampian 07/01/2015; NHS Lothian 23/10/2014). However due to 
recruitment challenges the research study was revised with the initial plan to 
include NHS Lothian dropped and the study in NHS Grampian opened up to 
include parents. The plan was to recruit parents via NHS held baby clinics in 
the same locations as the health visitors and general practitioners, hence 
approval was needed from the North of Scotland National Research Ethics 
Service (NoSRES) was required as well as approval from Lancaster University 
research ethics committee (Appendix 9: FHMREC – 31/05/2016) . In addition 
to guidance from Lancaster University, local guidance on the formal process on 
seeking approval for this amendment was provided by a designated person in 
NHS Grampian Research and Development (NHSR&D) department. My 
understanding, therefore, was that the amendment of my study was 
straightforward and should not pose any difficulties. Subsequently, when I was 
given the opportunity to attend the NoSRES meeting the following week, I 
accepted even although my supervisors were both on leave.  
 
The experience of attending the NoSRES meeting was traumatic as the Chair 
of the meeting clearly misunderstood the role of the ethics committee regarding 
my study. Whilst I was only seeking approval for an amendment to the study to 
recruit parents via NHS clinics, the Chair chose to critique the wider study and 
was unwilling to listen to my explanation. The Chair also seemed adamant that 
the study was challenging the professionalism of medical colleagues although 
consent had already been gained for this, and this part of the study completed. 
The attitude of the Chair left me feeling demoralized and very upset. 
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Subsequently ethical approval for the amendment was denied. Fortunately, my 
research supervisors at Lancaster University supported me through this ordeal 
and a telephone meeting was set up with the Chair of NOSRES, my 
supervisors, an ethics expert at Lancaster University, and myself. The Chair of 
NOSRES acknowledged there had been a misunderstanding of the ethics 
application and agreed to a resubmission. However, given the tight timeframe 
for completing the study it was decided to recruit parents from Non-NHS parent 
and baby groups. Ethical approval for this amendment was gained from 
Lancaster University Research Ethics Committee (Appendix 9: FHMREC 
15035– 21/11/2016). A further amendment was made to include infants up to 
the age of 30 months (Appendix 9: FHMREC – 08/05/2017). 
 
 
3.5 Reflections on the Research  
The overall research experience was positive, and professionals and 
participants associated with the research were very supportive. However, 
recruitment to the study was challenging, particularly amongst general 
practitioners as evident in the literature (Hummer-Praedier et al., 2008; 
Bonevske et al., 2011). Reflecting on what could have been done differently, it 
would have been beneficial to have included parents in the study from the 
outset. Interesting and valuable data was gleaned from the interviews with 
parents. The ethical process involved in recruiting parents via NHS sources 
proved challenging, therefore seeking to recruit participants through non-NHS 
sources where feasible in the future may be more expedient and advantageous. 
Reflecting further on the study, targeting two contrasting NHS Board areas was 
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perhaps unrealistic, and the less ambitious approach focusing on one NHS 
Board area proved more achievable and realistic within the timeframe of the 
study. It may also have been useful to have targeted key medical centres and 
to have interviewed health visitors, general practitioners and parents aligned to 
specific medical practices. This may have helped to gain a better understanding 
of the situation, and to help explore and explain differences in perceptions of 
GOR, the experience of caring for an infant with symptoms of GOR, as well as 
decisions made regarding the diagnosis and management of GOR in infants 
aged 0-1 year. Consideration was given to data that appeared incongruous with 
the evidence in the main data set. For example, although Shetland was the 
highest prescriber of ranitidine in 2016, the confidence intervals were noted to 
be wide suggesting that the data may be misleading and therefore require 
greater scrutiny. In this instance the wide confidence intervals reflected the low 
population in Shetland. This was also typical of data from the other island 
boards. Reflecting on the findings from the semi-structured interviews, one 
parent commented that ranitidine had been prescribed following a telephone 
consultation and without the general practitioner examining the child. Whilst this 
was an unexpected and deviant finding and not reflected in the data from health 
visitors, general practitioners and other parents in the study, it was recognized 
as an important finding that may be a potential factor contributing to the rise in 





CHAPTER 4: STAGE ONE: FINDINGS FROM QUANTITATIVE 
ANALYSIS OF NATIONAL PRESCRIBING DATA  
 
4.0: Introduction 
This chapter presents the results from stage one which involved the quantitative 
analysis of national prescribing data in Scotland. These findings presented 
address the aim and objective of stage one: to determine patterns of prescribing 
of Gaviscon (alginate), domperidone (motility stimulant), omeprazole (PPI) and 
ranitidine (H2RA) in 0-1-year-old infants in Scotland from 2010 – 2016. It begins 
with the analysis of the population of 0-1-year old infants prescribed Gaviscon 
(alginate), domperidone (motility stimulant), omeprazole (PPI) or ranitidine 
(H2RA) in each NHS board. Thereafter, patterns of prescribing of these drugs 
in the 0-1-year age group in Scotland are presented.  
 
4.1 National Prescribing Data from ISD Scotland  
Stage one of the research study concerns the secondary analysis of 
quantitative data obtained from the Information Services Division of NHS 
Scotland (ISD Scotland). In Scotland all NHS patients have a unique 
Community Health Indicator (CHI) number that is indicated on all prescriptions. 
This enables ISD Scotland to identify patients dispensed a particular drug. In 
this study, the patient count refers to the number of infants aged 0-1-year 
prescribed a specific medicine within one calendar year. Therefore, using CHI 
data infants are counted once for the drug prescribed per year. In instances 
where infants are prescribed two drugs within the year, their CHI number will be 
recorded once in both drug classes within that year. The prescribing rate refers 
to the number of prescriptions dispensed and paid for per 100 head of 
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population (infants aged 0-1 year). Prescriptions that have been dispensed and 
paid provide the most accurate data. This is because not all prescriptions written 
by practitioners for patients are taken to the pharmacy for dispensing. For 
example, some patients may choose not to follow medical or health care advice, 
whilst other patients will only use the prescription if their condition worsens or 
they feel the medicine is required. Therefore, only prescriptions that have been 
dispensed, administered, and claimed for by pharmacies are paid for. Use of 
prescribing rates also enables comparisons to be made between populations 
over time and between NHS Board areas.  
 
4.2 Infant Population in Scotland 
According to the National Records of Scotland (NRS, 2019) on the 30th June 
2018, the mid-year population of Scotland was estimated to be in the region of 
5,438,100. In the years since 1998 (population:5,077,070) the mid-year 
estimated population of Scotland has increased by 7%. Regarding infants, 
National Records of Scotland data show that approximately 1% of the Scottish 
population is aged 0-1-year-old (NRS, 2019), and that the population of infants 
aged 0-1-year old steadily declined from 59,665 in 2009, to 55,516 infants in 
2016. This implies that the birth has fallen and that the overall growth in the 





Table 4.01: Mid-year population estimates from National Records of Scotland for infants 
aged 0-1 year across health boards in Scotland  
 
Year 2009 2010 2011 2012 2013 2014 2015 2016 
Ayrshire & Arran 3,946 3,825 3,946 3,884 3,639 3,544 3,656 3,647 
Borders 1,173 1,182 1,173 1,112 1,152 1,149 1,024 1,077 
Dumfries & Galloway 1,461 1,520 1,461 1,366 1,370 1,293 1,291 1,299 
Fife 4,218 4,235 4,218 4,075 3,911 3,866 3,879 3,737 
Forth Valley 3,382 3,467 3,382 3,317 3,085 3,027 3,043 2,996 
Grampian 6,395 6,494 6,395 6,360 6,274 6,383 6,265 6,441 
Greater Glasgow & Clyde 13,955 14,192 13,955 13,131 12,877 12,668 12,424 12,367 
Highland 3,320 3,186 3,320 3,212 2,998 2,958 3,020 2,971 
Lanarkshire 6,719 6,528 6,719 7,334 7,105 6,903 7,136 6,960 
Lothian 9,950 9,609 9,950 9,729 9,675 9,689 9,470 9,431 
Orkney 209 208 209 214 199 177 198 169 
Shetland 271 279 271 257 290 235 238 257 
Tayside 4,398 4,389 4,398 4,309 4,180 4,035 4,141 3,935 
Western Isles 258 221 258 247 244 256 216 229 
         
Scotland 59,655 59,335 59,655 58,547 56,999 56,183 56,001 55,516 
*The population estimated from NRS illustrated in table 4.01 were used by ISD Scotland to calculate the 
prescribing rate for each drug. 
 
NICE (2015) indicate that symptoms of GOR affect at least 40% of infants and 
that in most cases treatment is not required, therefore the number of infants 
aged 0-1-year prescribed medicine to manage symptoms of GOR at the NHS 
Board level is likely to be low. Furthermore, there is wide variation in the 
demography and population of the 14 territorial NHS Boards in Scotland which 
will also impact on the patient count / number of infants prescribed medicine. 
The patient count/ number of infants prescribed Gaviscon, domperidone, 
omeprazole and ranitidine at the NHS Board level over the 7-year study period 
are illustrated in tables 4.02, 4.03. 4.04, 4.05. In the low populated island boards 
of Orkney, Shetland and the Western Isles, the number of infants, and 
dispensed prescriptions are very small compared to the NHS boards on 
99 
 
mainland Scotland and may account for some variation. For example, Table 
4.05 illustrates that the patient count, or number of infants prescribed ranitidine 
in the years 2010 and 2016 in NHS Orkney were 6 and 16 respectively, 
compared to NHS Grampian with a patient count of 347 in 2010 and 899 in 
2016. On mainland Scotland, NHS Borders and NHS Dumfries and Galloway 
are rural areas that also have relatively low populations and infants aged 0-1 
year (Table 4.01). 
 
 
Table 4.02: Patient count/ number of infants aged 0-1-year prescribed alginate per NHS Board 
and Scotland per year*  
 
NHS Board 2010 2011 2012 2013 2014 2015 2016 
Ayrshire & Arran 408  457 537 669 729 773 790 
Borders 159 175 161 209 216 212 226 
Dumfries & Galloway 181 212 232 289 316 322 330 
Fife 642 753 903 899 957 925 972 
Forth Valley 596 689 783 852 842 759 745 
Grampian 1,289 1,463 1,535 1,569 1,563 1,483 1,505 
Gt Glasgow & Clyde 2,379 2,747 2,983 3,307 3,554 3,814 3,451 
Highland 462 522 614 632 679 651 596 
Lanarkshire 1,282 1,397 1,529 1,610 1,844 2,068 2,318 
Lothian 1,366 1,611 1,772 1,975 2,117 2,004 2,005 
Orkney 15 28 29 33 39 32 31 
Shetland 46 37 44 52 49 54 64 
Tayside 573 708 767 770 929 877 810 
Western Isles 21 22 14 20 40 50 41 
Scotland 9,396 10,798 11,873 12,864 13,838 13,932 13,844 
*Year refers to the end of financial year i.e. Year 2010 = 1st April 2009 – 31st March 2010.  Infants are counted once per drug 




Table 4.03: Patient count/ number of infants aged 0-1-year prescribed domperidone per NHS 
Board and Scotland per year*  
 
NHS Board 2010 2011 2012 2013 2014 2015 2016 
Ayrshire & Arran 23  42 65 58 54 16 4 
Borders 25 31 30 38 51 29 21 
Dumfries & Galloway 9 15 23 32 28 12 3 
Fife 111 138 143 131 162 100 49 
Forth Valley 35 54 70 86 96 46 6 
Grampian 63 80 85 94 90 41 22 
Gt Glasgow & Clyde 49 70 90 116 108 53 21 
Highland 16 17 21 25 36 27 12 
Lanarkshire 62 49 60 70 69 29 8 
Lothian 224 273 340 435 490 288 132 
Orkney 2 1 0 2 4 1 1 
Shetland 6 1 0 2 4 0 0 
Tayside 32 52 45 43 69 42 12 
Western Isles 0 2 1 0 0 2 1 
Scotland 655 822 969 1,129 1,259 868 291 
*Year refers to the end of financial year i.e. Year 2010 = 1st April 2009 – 31st March 2010.  Infants are counted once per drug 




Table 4.04: Patient count/ number of infants aged 0-1-year prescribed omeprazole per NHS 
Board and Scotland per year*  
 
NHS Board 2010 2011 2012 2013 2014 2015 2016 
Ayrshire & Arran 1 12 16 22 31 33 45 
Borders 9 17 18 16 25 26 27 
Dumfries & Galloway 16 21 27 38 52 42 70 
Fife 59 65 62 82 128 129 149 
Forth Valley 20 38 38 40 62 58 88 
Grampian 30 33 37 52 74 92 97 
Gt Glasgow & Clyde 88 116 157 200 274 385 404 
Highland 20 32 26 29 48 59 86 
Lanarkshire 105 107 123 169 186 184 250 
Lothian 175 249 312 413 476 532 535 
Orkney 0 1 0 2 3 0 1 
Shetland 2 1 1 1 0 1 3 
Tayside 4 20 28 25 62 78 80 
Western Isles 0 0 0 0 1 1 1 
Scotland 529 709 845 1,085 1,420 1,608 1,828 
*Year refers to the end of financial year i.e. Year 2010 = 1st April 2009 – 31st March 2010.  Infants are counted once per drug 





Table 4.05: Patient count/ number of infants aged 0-1-year prescribed ranitidine per NHS Board 
and Scotland per year*  
 
NHS Board 2010 2011 2012 2013 2014 2015 2016 
Ayrshire & Arran 39 56 89 127 166 168 278 
Borders  18 37 32 37 70 66 77 
Dumfries & Galloway 20 29 28 35 45 34 58 
Fife 104 127 174 180 257 297 316 
Forth Valley 128 135 149 189 280 316 360 
Grampian 347 476 549 665 763 775 899 
Gt Glasgow & Clyde 264 353 419 570 746 1052 1149 
Highland 65 101 111 148 202 290 326 
Lanarkshire 77 115 191 273 364 516 742 
Lothian 194 211 305 456 670 741 835 
Orkney 6 2 4 12 18 14 16 
Shetland 13 12 12 22 22 19 35 
Tayside 113 136 150 196 298 319 324 
Western Isles 4 4 3 3 2 10 8 
Scotland 1,391 1,790 2,213 2,909 3,892 4,592 5,410 
*Year refers to the end of financial year i.e. Year 2010 = 1st April 2009 – 31st March 2010.  Infants are counted once per drug 
prescribed per year. 
 
As illustrated in tables 4.02, 4.03. 4.04, 4.05, the data reveal that in the whole 
of Scotland, the number of infants prescribed alginate, omeprazole and 
ranitidine increased over the seven years of the study period, whilst population 
data presented in table 4.01 shows a steady decline in the number of infants 
aged 0-1 year. This suggests that the prescribing rate of these medicines is 
increasing. 
 
4.3 Prescribing in Scotland: The National Picture 
The data reveal a rise in the prescribing of alginate, omeprazole and ranitidine 
in infants aged 0 – 1 year between 2010 and 2016 in Scotland. Evidently the 
prescribing rate for alginate was persistently much higher than for the other 
medicines used in the management of GOR in infants (Figure 4.01). Although 
the prescribing rate for alginate shows the greatest absolute increase from 
15.75 per 100 infants in 2010 to 24.72 per 100 infants in 2016, the prescribing 
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rates for ranitidine increased over four-fold from 2.3 per 100 infants in 2010 to 
9.7 per 100 infants in 2016, and for omeprazole it increased over three-fold from 
0.9 per 100 infants in 2010 to 3.2 per 100 infants in 2016. The prescribing rate 
for domperidone also showed a steady rise until 2014 but thereafter began to 
fall. This reflects guidance from the European Medicines Agency (2014) that 
will be discussed further later. 
 
Figure 4.01: Prescribing rate (per 100 infants) for alginate, domperidone, omeprazole and 




It is interesting to note that whilst the prescribing rate of both omeprazole and 
ranitidine have risen steadily, the prescribing rate for alginate began to level out 
from 2014. To determine the degree of precision of these findings, confidence 
intervals were calculated. Confidence intervals provide a range of values within 
which the true population value lies (Bowling, 2009). Based on the standard 
normal, or Gaussian distribution and using the standard deviation of 1.96, 95% 
confidence intervals were calculated (Chinn, 2015) using the following formula: 
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95% Confidence interval = mean value ± 1.96 x Standard error of the mean 
According to Chinn (2015) and Tilling et al (2009), the standard deviation of 
1.96 is normally used to calculate 95% confidence intervals. The premise being 
that the sample size is large enough to assume a normal distribution. Buescher 
(1997) considers a sample size greater than 20, and the Scottish Government 
(2018) a sample size greater than 30, to have a normal distribution. The sample 
sizes in this instance exceeded 30. Confidence intervals for the ‘true’ 
prescribing rate of alginate, domperidone, omeprazole and ranitidine are 
presented in Table 4.06. The intervals are typically narrow indicating that the 
margin of error is small and therefore greater precision of the findings (Tilling et 
al., 2009). Furthermore, the confidence intervals show statistically significant 
increases in prescribing each year except for domperidone from 2014 and 
alginate from 2014. 
Table 4.06: Prescribing rate (per 100 infants) and upper and lower confidence interval levels for 
alginate, domperidone, omeprazole and ranitidine in Scotland (2010 -2016)  
*Prescribing rate is the patient count divided by the mid-year population estimates for the age group 0-1-year, multiplied by 100 
 
 
Prescribing rate, upper and lower confidence intervals (CI) for infants aged 0-1 year in Scotland 
(2010 -2016) 
Year  Alginate Domperidone Omeprazole Ranitidine 
2010 
 
Rate (per 100) 
(Lower - Upper CI) 
15.75 
(15.46 - 16.04) 
1.10 
(1.01 - 1.18) 
0.89 
(0.81 - 0.96) 
2.33 
(2.21 - 2.45) 
2011 
 
Rate (per 100) 
(Lower - Upper CI) 
18.20 
(17.89 - 18.51) 
1.39 
(1.29 - 1.48) 
1.19 
(1.11 - 1.28) 
3.02 
(2.88 - 3.16) 
2012 
 
Rate (per 100) 
(Lower - Upper CI) 
19.67 
(19.35 - 19.99) 
1.61 
(1.50 - 1.70) 
1.40 
(1.30 - 1.49) 
3.6 
(3.51 - 3.82) 
2013 
 
Rate (per 100) 
(Lower - Upper CI) 
21.97 
(21.64 - 22.31) 
1.93 
(1.81 - 2.04) 
1.85 
(1.74 - 1.96) 
4.97 
(4.78 - 5.15) 
2014 
 
Rate (per 100) 
(Lower - Upper CI) 
24.28 
(23.93 - 24.63) 
2.21 
(2.09 - 2.33) 
2.49 
(2.36 - 2.62) 
6.83 
(6.61 - 7.04) 
2015 
 
Rate (per 100) 
(Lower - Upper CI) 
24.80 
(24.44 - 25.15) 
1.22 
(1.13 - 1.31) 
2.86 
(2.72 - 3.00) 
8.17 
(7.94 - 8.41) 
2016 
 
Rate (per 100) 
(Lower - Upper CI) 
24.72 
(24.36 - 25.08) 
0.52 
(0.46 - 0.58) 
3.26 
(3.11 - 3.41) 
9.66 
(9.40 - 9.92) 
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Time series plots and regression analysis were used to identify any trend for 
alginate, domperidone, omeprazole and ranitidine between 2010 and 2016 
(Figures 4.02, 4.03, 4.04, 4.05).  Time series plots are useful for exploring the 
relationship between two variables, which in this instance is the prescribing rate 
and time. The time series plots for alginate, omeprazole and ranitidine all show 







































Regression analysis can provide strong visual evidence of the linear 
relationship between two variables and in this study simple linear regression, or 
sum of least squares regression, was used to find the line of best fit in the time 
series plots, and to indicate, or predict, the likely increase in prescribing of each 
medicine over time. (Robson, 2011; Gilchrist and Wright, 2009). A linear trend 
provided a very good fit for three medicines, alginate, omeprazole and 
ranitidine, with the co-efficient of determination (R2) for each drug calculated as 
R2 = 93.6% for alginate, 98.3% for omeprazole, and 97.5% for ranitidine. The 
coefficient of determination provides information about the percentage of 
variation of the data that is most close to the line of best fit. In this study these 
high R2 values indicate that the data points are close to the fitted values on the 
times series plot. The standard error of regression (S) provides further 
information on the precision of the predictions of the fitted line as it gives an 
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indication of the distance between the fitted values and the data points 
(Donnelly and Abdel-Raouf, 2016). Lower S values, as in Figures 4.02, 4.04 
and 4.05, indicate that the distance between data points and the fitted line 
values are smaller, thereby increasing the precision of the data. However, 
following the advice of the European Medicines Agency (2014) regarding the 
use of domperidone, the linear trend for domperidone changed and now shows 
the start of a downward trend with R2 = 4.1%. 
 
The regression coefficient represents the mean change of the y variable (drug), 
by one unit of change in the x variable (time). In this study the regression 
coefficients indicate estimated annual increases of 1.60% for alginate, 0.41% 
for omeprazole and 1.27% for ranitidine. The plots for omeprazole and ranitidine 
show no sign of these upwards trends being halted. However, the 2015 and 
2016 data for alginate suggest that the overall prescribing rate for alginate in 
Scotland may have peaked.  
 
4.4 Prescribing at the NHS Health Board Level 
The data were further analysed to explore patterns of prescribing for the four 
drugs in each of the 14 NHS territorial boards in Scotland. The prescribing rates 
for alginate, domperidone, omeprazole and ranitidine in each NHS board from 
2010 to 2016 are illustrated in Figures 4.06, 4.07, 4.08, 4.09. Except for 
domperidone, the prescribing rates for the drugs increased in all NHS boards 
over the seven years, however there was also clear variation between board 
areas. The variation between board areas may, in part, be due to the geography 
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and landscape, and areas of rurality in Scotland as discussed earlier in the 
Introduction (Chapter 1).  
 
The data were further analysed to describe the prescribing pattern for the four 
drugs in each of the 14 NHS territorial boards in Scotland. The prescribing rates 
and confidence intervals for these medicines in each board for each year of the 
study were calculated and are presented in Appendix 10. In addition, the 
prescribing rates in each board were ranked for each medicine between 2010 
– 2016 and can be found in Appendix 11. The confidence intervals for the top 
three ranking NHS boards for each drug were also calculated and are presented 
in Tables 4.07, 4.08, 4.09, 4.10. 
 
4.4.1 Prescribing of Alginate (Gaviscon) 
Analysis of the ISD Scotland data identified that the prescribing rate for alginate 
had risen in all health board areas over the seven years period (Figure 4.06). 
The prescribing rate was consistently much greater than for the other 
pharmaceutical products used in the management of GOR in infants. This 
higher rate in prescribing of alginate is not unexpected and is in line with NICE 
(2015) guidance that recommends a two-week trial of alginate therapy in breast 
fed babies. It is also consistent with the stepped-care approach applied to 
formula fed babies that have shown no improvement following the introduction 




Figure. 4.06: Prescribing rate for alginate per NHS Board 2010 – 2016 
 
 
The prescribing rates of alginate were ranked (appendix 11), and the top three 
ranking board areas over the study period presented in Table 4.07. Lanarkshire 
features in the top three ranks in each of the seven years except for the year 
2013 and is ranked highest in 2016. Regardless of the prescribing rate of 
alginate seeming to have stabilized at other high prescribing boards, the 
Lanarkshire rate has continued to increase approximately linearly and over the 
full study period from 19.08 per 100 infants in 2010, to 32.48 per 100 infants in 
2016. Forth Valley also features in the top three ranks for each year apart from 
2016 although the rate dropped in both of the last two study years. The 
prescribing rate at Greater Glasgow and Clyde increased sharply from 17.05 
per 100 infants in 2010 to 30.11 per 100 infants in 2015, and despite a reduction 
to 27.78 per 100 infants in 2016 still held the second top ranking. Although 
Grampian was initially the highest prescriber of alginate it does not appear in 
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the top three ranks after 2013. The increase in Grampian from 2010 to 2013 of 
4.51 is relatively low. In 2016, Shetland held third top ranking, however due to 
the low population numbers involved, the data may be misleading, and this is 
evidenced by the wide confidence intervals. 
 
 
Table 4.07: Top 3 Ranking NHS Boards for prescribing alginate in infants aged 0-1 year (2010 - 2016)  
Year Rank 1 
(Highest) 
Rank 2 Rank 3 
2010 
Rate (per 100) 
(Lower - Upper CI) 
Grampian 
20.16 
(19.17 - 21.14) 
Lanarkshire 
19.08. 
(18.14 - 20.02) 
Forth Valley 
17.62 
(16.34 - 18.91) 
2011 
Rate (per 100) 
(Lower - Upper CI) 
Grampian 
22.53 
(21.51 - 23.54) 
Lanarkshire 
21.40 
(20.40 - 22.39) 
Forth Valley 
19.87 
(18.54 - 21.20) 
2012 
Rate (per 100) 
(Lower - Upper CI) 
Forth Valley 
24.31 
(22.83 - 25.80) 
Grampian 
23.58 
(22.55 - 24.61) 
Lanarkshire 
23.35 
(22.33 - 24.38) 
2013 
Rate (per 100) 
(Lower - Upper CI) 
Forth Valley 
25.69 
(24.20 - 27.17) 
Gt Glasgow & Clyde 
25.18 
(24.44 - 25.93) 
Grampian 
24.67 
(23.61 - 25.73) 
2014 
Rate (per 100) 
(Lower - Upper CI) 
Gt Glasgow & Clyde 
27.60 
(26.83 - 28.37) 
Forth Valley 
27.29 
(25.72 - 28.86) 
Lanarkshire 
25.95 
(24.93 - 26.97) 
2015 
Rate (per 100) 
(Lower - Upper CI) 
Gt Glasgow & Clyde 
30.11 
(29.31 - 30.91) 
Lanarkshire 
29.96 
(28.88 - 31.04) 
Forth Valley 
25.07 
(23.53 - 26.62) 
2016 
Rate (per 100) 
(Lower - Upper CI) 
Lanarkshire 
32.48 
(31.40 - 33.57) 
Gt Glasgow & Clyde 
27.78 
(26.99 - 28.56) 
Shetland 
26.89 
(21.26 - 32.52) 
 
 
As alginate, or Gaviscon for infants, can be readily bought over the counter, the 
recent fall in the prescribing rate of alginate may be due to more parents buying 
the product themselves rather than seeking a prescription from their GP. 
Nevertheless, although the efficacy of alginates is weak, evidence supporting 
its efficacy is stronger than for the other drugs (Tighe, et al., 2014). Alginate is 




4.4.2 Prescribing of Domperidone 
The prescribing rate for domperidone, as illustrated in Figure 4.07, shows a 
steady increase until 2014, thereafter the prescribing rate dropped in all NHS 
Boards reflecting the national picture and the guidance given by the European 
Medicines Agency (2014), warning of the risk of cardiac side effects with the 
use of domperidone. 
 





Lothian, Fife and Borders were the highest-ranking boards for prescribing of 
domperidone over the study period (Table 4.08).  
 
Table 4.08: Top 3 Ranking NHS Boards for prescribing domperidone in infants aged 0-1 year  
  (2010 - 2016) 
Year Rank 1 
(Highest) 
Rank 2 Rank 3 
2010 
Rate (per 100) 
(Lower - Upper CI) 
Fife 
2.63 
(2.14 - 3.12) 
Lothian 
2.25 
(1.96 - 2.55) 
Shetland 
2.21 
(0.44 - 3.98) 
2011 
Rate (per 100) 
(Lower - Upper CI) 
Fife 
3.26 
(2.71 - 3.80) 
Lothian 
2.84 
(2.50 - 3.18) 
Borders 
2.62 
(1.70 - 3.55) 
2012 
Rate (per 100) 
(Lower - Upper CI) 
Fife 
3.35 
(2.80 - 3.90) 
Lothian 
3.25 
(2.90 - 3.60) 
Borders 
2.69 
(1.73 - 3.66) 
2013 
Rate (per 100) 
(Lower - Upper CI) 
Lothian 
4.47 
(4.05 - 4.89) 
Borders 
3.42 
(2.33 - 4.50) 
Fife 
3.21 
(2.66 - 3.76) 
2014 
Rate (per 100) 
(Lower - Upper CI) 
Lothian 
5.06 
(4.62 - 5.51) 
Borders 
4.43 
(3.21 - 5.64) 
Fife 
4.14 
(3.50 - 4.78) 
2015 
Rate (per 100) 
(Lower - Upper CI) 
Lothian 
2.97 
(2.63 - 3.32) 
Fife 
2.59 
(2.08 - 3.09) 
Borders 
2.52 
(1.60 - 3.44) 
2016 
Rate (per 100) 
(Lower - Upper CI) 
Borders 
2.05 
(1.17 - 2.93) 
Lothian 
1.39 





However, despite the falling trend in prescribing of domperidone, Lothian, Fife 
and Borders continued to have a prescribing rate for domperidone that 
exceeded the national average (Table 4.06). The reason for this is unclear. 
Domperidone is no longer recommended for the management of GOR which 
may explain the falling trend in prescribing (NICE, 2015; Tighe et al., 2014; 
European Medicines Agency, 2014; Vandenplas et al., 2009). However, 
domperidone is sometimes prescribed to manage nausea and vomiting in the 
0-1-year age group (BNFC, 2019). However, the trend showing a year on year 
higher than average rate of prescribing of domperidone would suggest this is 
highly unlikely. Geographically these NHS Boards are in the southeast of 
Scotland and aligned to the regional hospital in Edinburgh, therefore prescribing 
practices may have been influenced by prescribing guidelines in Lothian or the 
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recommendations of the paediatric consultants in Lothian at that time. In 
contrast, Glasgow and Clyde health board has one of the lowest prescribing 
rates for domperidone at 0.97 per 100 infants. Again, this may be linked to local 
guidelines and recommendations by paediatricians in the NHS board area. The 
reason underlying the high rate of prescribing of domperidone in Lothian and 
the marked difference in the prescribing practice between Lothian, and Glasgow 
and Clyde, the two most densely populated health board areas in Scotland, is 
worthy of further investigation especially if this trend continues.  
 
4.4.3 Prescribing of Omeprazole 
Regional variation in prescribing practice is also evident with omeprazole. As 
illustrated in Figure 4.08, Lothian, Dumfries and Galloway, Fife and Lanarkshire 
were found to have the highest prescribing rates for omeprazole. In each of 
these boards the prescribing rate for omeprazole showed an increasing trend 




Figure. 4.08:  Prescribing rate of omeprazole in NHS Boards 2010-2016
 
 
Ranking of prescribing rates for omeprazole for each NHS Board area over the 
seven-year study period is presented in appendix 11. The top three ranking 
board areas for each year of the study are presented in Table 4.09. Lothian was 
the top-ranking board in each of the seven years, with the prescribing rate rising 
from 1.76 per 100 infants in 2010, to 5.65 per 100 infants in 2016. The 
prescribing rate for omeprazole in Dumfries and Galloway rose sharply in 2016 
to 5.40 per 100 infants and was almost level with Lothian. It is also interesting 
to note that the prescribing rate for omeprazole in Lothian (5.65 per 100 infants) 






Table 4.09: Top 3 Ranking NHS Boards for prescribing omeprazole in infants aged 0-1 year 
(2010 - 2016) 
 
Year Rank 1 
(Highest) 
Rank 2 Rank 3 
2010 
Rate (per 100) 
(Lower - Upper CI) 
Lothian  
1.76 
(1.50 - 2.02) 
Lanarkshire 
1.56 
(1.26 - 1.86) 
Fife 
1.40 
(1.04 - 1.76) 
2011 
Rate (per 100) 
(Lower - Upper CI) 
Lothian  
2.59 
(2.27 - 2.91) 
Lanarkshire 
1.64 
(1.33 - 1.95) 
Fife 
1.53 
(1.16 - 1.91) 
2012 
Rate (per 100) 
(Lower - Upper CI) 
Lothian  
2.98 
(2.65 - 3.31) 
Lanarkshire 
1.88 
(1.55 - 2.21) 
Dumfries & Galloway 
1.77 
(1.10 - 2.44) 
2013 
Rate (per 100) 
(Lower - Upper CI) 
Lothian  
4.24 
(3.84 - 4.65) 
Dumfries & Galloway 
2.78 
(1.90 - 3.67) 
Lanarkshire 
2.30 
(1.96 - 2.65) 
2014 
Rate (per 100) 
(Lower - Upper CI) 
Lothian 
4.92 
(4.48 - 5.36) 
Dumfries & Galloway 
3.80 
(2.76 - 4.83) 
Fife 
3.27 
(2.71 - 3.84) 
2015 
Rate (per 100) 
(Lower - Upper CI) 
Lothian  
5.49 
(5.02 - 5.96) 
Fife 
3.34 
(2.76 - 3.91) 
Dumfries & Galloway 
3.25 
(2.27 - 4.23) 
2016 
Rate (per 100) 
(Lower - Upper CI) 
Lothian  
5.65 
(5.17 - 6.13) 
Dumfries & Galloway 
5.42 
(4.15 - 6.69) 
Fife 
3.84 
(3.22 - 4.46) 
 
 
Nevertheless, it is clear from the data that prescribing of omeprazole in the 0 – 
1-year age group is increasing in all board areas. This is a concern as proton 
pump inhibitors, such as omeprazole, are reported to increase the risk of gastric 
infections such as clostridium difficile (BNFC, 2019; Kierkus et al., 2014). This 
may have serious health implications for young infants aged 0 – 1 year. 
Furthermore, cessation of omeprazole may lead to increased sensitivity to 
gastric acid resulting in an exaggerated reaction, and rebound return of 
symptoms of dyspepsia and gastro-oesophageal reflux (BNFC, 2019).  
Consequently, to the uninformed, this may inadvertently suggest a return of 





4.4.4 Prescribing of Ranitidine 
Grampian clearly had the highest prescribing rate for ranitidine over the full 
study period with the prescribing rate rising linearly from 5.43 per 100 infants in 
2010, to 14.35 per 100 infants in 2016 (Figure 4.09). 
 




The full ranking of the prescribing rate for ranitidine in each NHS Board area is 
presented in appendix 11. The top three ranking boards for each year of the 
study are presented in Table 4.10. As well as Grampian and Forth Valley, 
Shetland also feature consistently near the top of the ranitidine rankings. Due 
to the relatively small population numbers in Shetland, the individual 
confidence intervals are wide and indicative of a wide margin for error and 




Table 4.10: Top 3 Ranking NHS Boards for prescribing ranitidine in infants aged 0-1 year (2010 - 2016) 
 
Year Rank 1 
(Highest) 
Rank 2 Rank 3 
2010 
Rate (per 100) 
(Lower - Upper CI) 
Grampian 
5.43 
(4.85 – 6.00) 
Shetland 
4.80 
(2.19 - 7.40) 
Forth Valley 
3.78 
(3.13 - 4.44) 
2011 
Rate (per 100) 
(Lower - Upper CI) 
Grampian 
7.33 
(6.67 - 7.99) 
Shetland 
4.30 
(1.87 - 6.73) 
Forth Valley 
3.89 
(3.24 - 4.55) 
2012 
Rate (per 100) 
(Lower - Upper CI) 
Grampian 
8.43 
(7.73 - 9.14) 
Forth Valley 
4.63 
(3.88 - 5.37) 
Shetland 
4.30 
(1.87 - 6.73) 
2013 
Rate (per 100) 
(Lower - Upper CI) 
Grampian 
10.46 
(9.70 - 11.21) 
Shetland 
8.56 
(4.98 – 12.14) 
Forth Valley 
5.70 
(4.89 - 6.51) 
2014 
Rate (per 100) 
(Lower - Upper CI) 
Grampian 
12.16 
(11.35 – 12.97) 
Forth Valley 
9.08 
(8.01 - 10.14) 
Orkney 
9.04 
(4.87 - 13.22) 
2015 
Rate (per 100) 
(Lower - Upper CI) 
Grampian 
12.14 
(11.34 - 12.94) 
Forth Valley 
10.44 
(9.35 - 11.53) 
Highland 
9.80 
(8.67 - 10.93) 
2016 
Rate (per 100) 
(Lower - Upper CI) 
Shetland 
14.71 
(10.21 - 19.20) 
Grampian 
14.35 
(13.48 - 15.22) 
Forth Valley 
11.83 
(10.68 - 12.98) 
 
It is also interesting to note, that in contrast to having one of the highest 
prescribing rates for omeprazole, Dumfries and Galloway has the second 
lowest prescribing rate in the mainland boards for ranitidine. Furthermore, 
Grampian has the highest prescribing rate for ranitidine but had the second 
lowest mainland board prescribing rate for omeprazole. Conversely Dumfries 
and Galloway has one of the highest prescribing rates for omeprazole, but for 
ranitidine has the second lowest prescribing rate in the mainland boards. 
Compared to most of the other board areas, Ayrshire and Arran had low 
prescribing rates for all three drugs over the study period although these still 







4.5 Prescribing in NHS Grampian  
Due to the high prescribing rate of ranitidine in NHS Grampian, the prescribing 
data was analysed further. Time series plots and regression were used to 
identify any linear trend for the prescribing rate for the four drugs in Grampian 
between 2010 – 2016 (Figure 4.10, 4.11, 4.12, 4.13). A linear trend provided a 
good fit for omeprazole and ranitidine with R2 = 94.1% for omeprazole and 
97.6% for ranitidine. However, following the advice of the European Medicines 
Agency (2014) regarding the use of domperidone, the linear trend for 



















Figure 4.11: Prescribing rate and regression line for alginate in 0-1-year infants in NHS Grampian  






















The regression coefficients indicate estimated annual increases of 1.43% for 
ranitidine, 0.20% for omeprazole and 0.51% for alginate. The estimated annual 
increase of 1.43% for ranitidine exceeds the national estimated increase of 
1.27% for the whole of Scotland (section 4.2) and is worthy of further 
investigation. The plots for omeprazole and ranitidine show no signs of these 
upwards trends being halted. However, the 2015 and 2016 data for alginate 
suggest that the overall prescribing rate for alginate in Grampian may be 
levelling (Figure 4.11). 
 
Interestingly as the prescribing rate for alginate dropped in the year 2015, the 
prescribing rate for omeprazole continued to rise. The reason for the decrease 
in the prescribing rates of alginate and ranitidine in 2015 may be revealed in the 





The findings of the analysis of the national prescribing data from ISD Scotland 
identified that the population of infants aged 0-1 year in Scotland has steadily 
declined since 2009 but the number of infants prescribed alginate, omeprazole 
and ranitidine has risen over the seven-year study period. This is reflected in 
the increase in the prescribing rate of these medicines and regression analysis 
shows no sign of this trend abating. The findings also highlight variation in the 
patterns of prescribing across NHS territorial boards and identified Lothian as 
consistently having the highest prescribing rate for omeprazole, and Grampian 
consistently the highest prescriber of ranitidine over the duration of the study. 
Furthermore, the prescribing rates for the respective drugs in these boards 
exceeded the national prescribing rates. Currently in the UK, omeprazole and 
ranitidine are not licensed for use in infants aged 0-1 year, therefore the reason 
for the high prescribing rates of these medicines in these boards is worthy of 
further investigation. To develop understanding of the reasons underpinning 
this rise in prescribing, stage two of this study will focus on NHS Grampian and 
explore factors influencing and underpinning how health professionals and 




CHAPTER 5: STAGE TWO FINDINGS FROM QUALITATIVE 




Analysis of national prescribing data in stage one, revealed a rise in prescribing 
of alginate, omeprazole and ranitidine to manage symptoms of GOR in infants 
aged 0-1 year. Stage two of the study aimed to explore why there was a rise in 
prescribing of these medicines to manage symptoms of GOR in this age group. 
This chapter, therefore, presents data from the qualitative analysis of the semi-
structured interviews held with general practitioners, health visitors and parents 
in the NHS Grampian, the territorial board identified in stage one to have the 
highest prescribing rate for ranitidine in each year of the 7-year study period. 
 
It should be noted that the health visitors and general practitioners interviewed 
in NHS Grampian reported very few infants on their caseloads to be prescribed 
omeprazole (PPI). This reflects the analysis of ISD Scotland data in stage one 
that identified Grampian as having one of the lowest prescribing rates for 
omeprazole. Furthermore, the interviews with parents revealed those infants 
that were prescribed omeprazole had been referred to the hospital and were 
prescribed omeprazole whilst under the care of a paediatrician as indicated by 
Maria below: 
 
‘Things improved for a little while, but were still not quite right – so, we were 
then referred to see a paediatrician at the hospital and he prescribed 
omeprazole alongside the ranitidine, so he is now on a combination of 




Consequently, prescribing practice in NHS Grampian and reported in this study 
primarily relates to Gaviscon (alginate) and ranitidine (H2RA).  
 
The findings from stage one identified a rise in the prescribing of medicines 
used to manage symptoms of GOR/ GORD in infants, therefore this was 
explored further in the interviews with health visitors and general practitioners 
with practitioners asked what they thought had contributed to, or instigated this 
change in practice. The interviews with parents explored their experience of 
caring for their infant with symptoms of GOR, their knowledge of GOR, the 
impact on them and their family, their support networks, and management and 
coping strategies.  The point that parents felt they needed help and support 
from health professionals was also explored and parents were encouraged to 
discuss the help, support and advice from health professionals as well as from 
family, friends, and other sources. 
 
The characteristics of the participants are presented first, thereafter the findings 
from the data gathered from parents is presented, followed by the analysis of 
the data gleaned from health visitors and finally analysis of data from the 
interviews with general practitioners.  
 
5.1 Characteristics of the Participants. 
In total 22 subjects participated in the interviews. Eight participants were 





 All eight parents were women and had partners, and four had older children. 
All parents chose to breast feed their infant, however, two later changed to 
formula feeding. Six of the parents lived in a city or urban area and two in more 
rural locations. Three parents had support from the infant’s maternal 
grandparents, the others (5) did not have family support locally. Six infants were 
prescribed ranitidine, one parent was offered medicine for her infant but 
declined it. As indicated in table 5.01 two parents were from outside the UK, 
and one Scottish parent spent the first 6 months of the infant’s life outside the 
UK. Two infants were later diagnosed with allergies (i.e. cow’s milk protein 
allergy, eggs, nuts).
  
Table 5.01: Participant Table: Parents 




Current Age of 
Children 
Partner Feeding Area Type Extended Family Support Medicine prescribed / given Other 
Louise 3-year-old and 
almost 1-year-old 
Yes Breast City None locally Choose not to give medicine  
Maria 9.5-months Yes Breast City None in first 5/6 months as 
living overseas (Norway) 
Prescribed Ranitidine and 
Omeprazole. 
Referred to RACH and 
paediatrician 
Cow’s Milk Protein Allergy, 
Allergy to eggs 
Explosive & smelly nappies 
Lived overseas (Norway) 
when child born 
Penny 3-months Yes Bottle (breast 
fed initially) 
Suburb Maternal grandmother Prescribed Gaviscon then 
Ranitidine 
 
Rachel 3-year old and 
almost 1-year-old 
Yes Breast City Maternal grandfather Tried Infacol 






Referred to dietician 
Susan 2.5-years Yes Breast Village None locally in first 6 
months 
Ranitidine prescribed from 
about 6 weeks 
Referred to paediatrician - 
RACH 
Early weaning advised 
Tanya 1-year Yes Breast Suburb None locally Gaviscon then ranitidine Polish 
Ursula 11-year-old and 
13-month-old 
Yes Breast City None locally Prescribed Infacol 
Nelsons colica granules 
Swedish 
Val 3-year-old and 4-
5months 
Yes Breast & anti-
reflux milk 




5.1.2: Health Visitors 
Regarding health visitors, and as indicated in table 5.02, four participants had 
over 10 years of experience as a health visitor, four had between 6-10 years of 
experience and two health visitors had less than 5 years of experience. All the 
health visitors in the study were female. Two health visitors worked in a city and 
the others (8) all worked in rural areas. One health visitor described their 
caseload area as being deprived, three described their caseload as affluent and 
the others (6) described their caseload as being areas of mixed affluence and 
deprivation. Three health visitors also disclosed that one of their own offspring 
had suffered symptoms of GOR as an infant. 








Location Parental experience of 
own child with symptoms 
GOR 
Ann >10 years Mixed Rural Yes 
Betty 0-5 years Mixed Rural Yes 
Carol >10 years Affluent City Not known 
Dawn >10 years Affluent Rural Not known 
Ella 6-10 years Mixed Rural Not known 
Fran 6-10 years Mixed Rural Not known 
Hannah >10 years Deprived Rural Not known 
Irene 0-5 years Affluent City Not known 
Jane 6-10 years Mixed Rural Not known 
Karen 6-10 years Mixed Rural Yes 
*All names are pseudonyms 
 
5.1.3: General Practitioners 
As indicated in table 5.03, all the general practitioners (4) in the study worked 
in urban areas and described their practice caseload areas as being affluent. 
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Three general practitioners had over 10 years of experience and one had less 
than 5 years of experience. All (4) disclosed that one of their offspring had 
suffered symptoms of GOR as an infant. Three of the general practitioners 
worked in the same medical centre. Only one general practitioner was of a 
different gender, therefore, to maintain anonymity, androgynous pseudonyms 
are used. 
Table 5.03: Participant Table: General Practitioners 
Case* 
(Pseudonym) 




Location Parental experience of 
own child with 
symptoms GOR 
Ali 0-5 years Affluent Suburb Yes 
Lee >10 years Affluent Suburb Yes 
Jo >10 years Affluent Suburb Yes 
Lesley >10 years Affluent City Yes 
*All names are pseudonyms 
 
5.2 Findings from Analysis of Data from Interviews with Parents 
Drawing on the Framework Method (Ritchie and Spencer, 2014a) described in 
chapter 3, an audit trail of how the data from the interviews were analysed, 
coded, indexed and finally interpreted within relevant themes was developed 
(Ritchie and Spencer, 2014a). 
This section presents the findings from the interviews with parents and explores 
the parents’ experiences of caring for their infant with symptoms of GOR. 
 
5.2.1 The Parent’s ‘Reflux’ Journey 
This theme focuses on the experience of caring for an infant with symptoms of 
GOR as described by parents, the parent’s expectations of parenthood and 
128 
 
caring for a young infant, and also the point or trigger that spurred them to seek 
help. 
 
Focusing on the ‘trigger’ to seek help, the interviews with parents revealed that 
the volume of vomit or regurgitated feeds was a key factor in parents seeking 
medical help as described by Penny: 
 
‘ ..... so we got to the point we thought, “This is it.”  It was no longer a mouthful, 
it was a proper throw-up, and then we spoke to the health visitor and she 
referred us to speak to the doctor.‘    Penny (Parent) 
 
However, seven of the eight parents interviewed were more concerned with the 
perceived distress and discomfort of their infant as in the excerpt from Maria: 
 
‘... pretty soon after he was born, he was really kind of agitated, very 
uncomfortable and a lot of screaming ….  basically all the time and he was 
having trouble sleeping, so we saw multiple doctors and were told it's colic, it's 
fine, it's normal, he will be ok ….  but, come three months, he will be fine; come 
four months, he'll be fine; come five months, he'll be fine … but things didn't 
really get any better.‘      Maria (Parent)  
 
Regarding expectations, the parents interviewed were all optimistic about 
parenthood. However, the parents (6) of infants with the more severe symptoms 
of GOR expressed the view that parenting their infant was more challenging 
and difficult than they had expected, whilst the parents (2) of infants with 
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relatively minor symptoms were more accepting of the symptoms considering it 
to be a normal part of life with a new baby. Nevertheless, Louise whose infant 
had symptoms of GOR that she chose to manage conservatively commented 
that it was hard to determine whether, or not, the symptoms were due to GOR. 
Speaking about GOR she said: 
 
‘…  I think it (GOR) is a normal thing, but it's hard to understand when it stops 
becoming normal. I think it's hard to decide when it's a problem, and when to 
start treating ...’       Louise (Parent)  
 
On exploring the expectation of parenting further, parents of infants with severe 
symptoms of GOR, commented that their experience was not what they 
expected. The parents understood that their infant may bring back mouthfuls of 
milk, be unsettled at times and cause them to have a period of sleepless nights. 
However, they did not anticipate the extent of the distress in their infant and the 
sheer intensity and persistence of the symptoms, or, that as parents, they could 
not console or comfort their infant. Rachel, talking about her second baby said:  
 
‘I think I felt prepared before he was born and I knew the sort of issues were 
going to be about managing his relationship with Leo (sibling). I wasn’t prepared 
for there being something physically wrong that I had to manage…. Because, 
as I said, I’d breast-fed, I was happy that I could comfort him. I knew how to 
comfort him. I knew how to feed him .... I’d done it before and I felt confident 
about that ... so, the fact that it wasn’t working and I couldn’t comfort him ... 
yeah, then it was quite distressing, really’   Rachel (Parent)  
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Four parents spoke of the impact on their life and being unable to do things 
such as return to work, go to baby groups, go shopping and so forth because 
of the regurgitation or the constant crying and distress in their infant. This was 
not what they expected, and it impacted on their daily life as described in the 
excerpts from Susan and Maria below: 
 
‘.... I was planning on going back to work earlier ….  but, there was no way.  
There was no way with what was going on, and we were just completely, 
completely flattened by it.  We had no idea what was going on. We were 
shattered. Our entire lives revolved around, basically, vomit’  
Susan (Parent) 
 
‘He couldn't sleep longer than an hour.  He was just upset all the time and we 
would go to all these baby groups, and he would just be crying. It was just 
frustrating. We couldn't take him in the car, we couldn't take him in the pram ….  
he was just screaming, screaming, screaming the whole time.’   
         Maria (Parent) 
 
Concern for the infant and the perceived distress, discomfort, regurgitation and 
volume of vomit was a key factor in parents seeking help. However, in some 
instances, it seems that the trigger to seek help was for the benefit of the 
parents as much as for the infant. The findings suggest that the symptoms of 




‘Yes, it was really tough. I was just exhausted. My husband – he slept upstairs 
in another room because he needed to be ok for work, but I was just like a 
wreck. I kid you not. I'm sure you must have seen it being a health visitor. I 
was just utterly, utterly exhausted ….’     Louise (Parent) 
 
‘Yeah… Going back to the GP after that, he did say it was more for my health. 
I think he saw me and thought, “Oh, this woman is almost just about to 
collapse and something needs to be done’   Susan (Parent) 
 
On exploring the experience of parents further, the findings suggest that 
symptoms of GOR presented early in the infant’s life and certainly within the 
first 8 weeks of life. Symptoms were reported to subside when weaning 
commenced as indicated by Louise and Susan. 
 
‘I think he was around four months old when I went to see the GP and he said 
that was the classic age when it would be at its peak, and that it would stop 
when he was weaning which was exactly what happened.’  
Louise (Parent)  
 
‘Now, whether it was a coincidence of his reflux symptoms naturally getting a 
bit better, or whether the food helped – I don’t know.’    Susan (Parent)  
 
Regarding symptoms, seven parents reported the infant to spit up, posset, or 
vomit feeds, however the perceived extent of the regurgitation varied. Susan 
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described it as being continuous, and on occasions like a ‘vomit fountain’, 
whereas Louise said that although her baby would regurgitate after every feed, 
he did not seem bothered by it and she was unsure as to whether, or not, it 
really was due to GOR. The experience described by the parents interviewed, 
however, was of infants who were unsettled, agitated, had trouble sleeping, 
screamed a lot, arched their back and appeared to be in pain. For example, Val 
said of her daughter, 
 
‘…. she wasn’t sleeping at night initially. We were up every hour. You know, the 
arching of the back …. the really, really, high-pitched screaming …. although 
she wasn’t constipated or anything because, at that point, we were just 
exclusively breastmilk….’      Val (parent) 
 
Three parents described the experience of caring for their infant with symptoms 
of GOR as being constant and unrelenting as in the excerpt below from Susan: 
 
‘... he was vomiting a huge amount and drinking a huge amount and it was a 
like a vicious cycle. It got to the point where he would feed, he would vomit. He 
was obviously then still hungry because he’d just vomited up his feed. I mean, 
it was all of his feed. It wasn’t just a little mouthful.‘   Susan (Parent) 
 
The intensity and relentlessness of the symptoms were exhausting and very 




Interestingly, one mother (Ursula) whose infant was unsettled overnight and 
caused her husband to be anxious, contacted the ‘Out of Hours’ service for 
support. The infant was diagnosed with GOR and prescribed Infacol, a medicine 
more commonly associated with colic.  
 
‘So, I actually went in to out-of-hours support overnight-wise just for support 
with her and, both times, she fell asleep in the car on the way in, so they didn’t 
see the unsettled baby that we had at home …  but, by two different doctors, 
she was diagnosed as having reflux, and I was given both granules (Nelsons 
granules) and Infacol to help her.’     Ursula (Parent)  
 
Ursula, however, did not consider her infant to suffer from GOR, instead she 
perceived the problem to be related to her mastitis and the pain and difficulty 
experienced when breast feeding. She reported the crying and unsettledness 
of her infant to have begun and resolve about the same time as the mastitis. 
Nobody asked Ursula about her breast-feeding experience or how she was 
coping with breast feeding her baby.  
 
Four parents expressed the perception that friends, family and professionals 
thought they were exaggerating things and didn’t believe the extent of the 
problem and severity of the symptoms until they witnessed it for themselves as 
described by Susan: 
 
‘...and even with family….  as I say, they were all kind of, “Oh, I’ve never seen 
this before.” I remember my mother-in-law …. we were on FaceTime one day, 
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and my husband was speaking to her holding the baby, and he just vomited all 
over him. She went, “Oh, dear. He’s been sick all over you.” ..... and he says, 
“Yeah mum. This is what happens kind of constantly.” .... She went, “Oh! I didn’t 
realise it was like that!”.....  I mean, when you said, the baby has been sick, 
everyone just thought that’s a bit spit-up sick, and we were just kind of over-the-
top first-time parents, rather than instant vomit all the time.’    
Susan (Parent)  
 
Two parents also commented that their own mothers (the infant’s grandmother) 
had not known of GOR nor seen infants vomit as much, or to exhibit such severe 
symptoms when they had been young parents themselves. Penny said of her 
mother: 
 
‘.... my mum had said she’d never really heard of it like, when we were little.  
But she’d said she thought a lot of folk just got misdiagnosed as colic because 
nobody really knew anything about it at that point.  That was about thirty years 
ago …  but she says you heard a lot of babies had colic at that point, but was it 
actually colic, or was it reflux and nobody knew?’  Penny (Parent)  
 
Susan, speaking of her own mother’s experience said: 
 
“… I said, “But mum, you had three children.”  And she said, “None of you had 
anything like this!” …  I said, “How could you cope with three?  I’m struggling to 
cope with one.”  She said, “But none of my children had this” …’  
         Susan (Parent)  
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The advice about conservative or non-pharmaceutical management strategies 
given to parents from health visitors and general practitioners was reported to 
be variable. Some health visitors were reported to give advice about 
conservative or non-medical strategies, others were not. If advice was given by 
health visitors, it tended to focus on raising the head of the cot or keeping the 
infant upright for about 20 minutes after feeding. All the parents (8) interviewed 
reported to get useful tips from family, friends and support groups, whilst seven 
parents sought advice about the symptoms of GOR from the internet, social 
media or internet chat rooms.   
 
‘It was really like reflux, those kinds of things I Googled, and just advice on how 
to position the baby when she was eating, how to position her when she was 
napping, food for me to avoid – those kinds of things.’   Ursula (Parent) 
 
All the parents interviewed said they were offered or prescribed medicine for 
their infant with symptoms of GOR by their general practitioner. A trial period of 
Gaviscon was prescribed to some infants, whilst for other infant’s ranitidine was 
prescribed as the first choice of medicine by general practitioners. In fact, one 
parent, Val, commented that the process of diagnosis and decision to prescribe 
ranitidine was undertaken with the general practitioner over the telephone. 
 
‘.... I got prescribed Ranitidine before that.  I think it was …  and that was over 
a phone consultation …..  so, I hadn’t actually been in to see the doctor, but she 
spoke to me on the phone and said that, if there was no improvement, I would 
have to go in before they would increase the dose or anything like that ....  just 
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so that they can give us the once-over to make sure .... so, it was like 
prescription over the phone which I was a bit shocked at. I thought I would get 
told to go in.‘        Val (Parent)  
 
In this instance, the guidance and recommendations of NICE (2015) were not 
being adhered to. 
 
5.2.2  Emotional and Mental Health Wellbeing 
Caring for an infant with severe symptoms of GOR was a grueling experience 
for parents and created a great deal of stress and anxiety. Five parents 
described feeling tired and exhausted and being at a very low ebb. 
Undoubtedly, caring for an infant with symptoms of GOR impacted on their 
emotional health and mental health wellbeing and this was evident in the 
excerpts from Susan and Louise:  
 
‘There would be days … I mean, I’d be sitting, crying because I was just 
shattered and didn’t know what else to do. In the middle of the night, walk 
through and my husband’s sitting with the baby crying, and he’s crying, and he’s 
just like, “I don’t know what to do. We don’t know what to do to stop this baby 
… We know he’s in distress. We know he is. This can’t be nice to be vomiting. 
We know what it’s like to vomit, and he’s just a baby.” I think it was just that 
complete desperation and despair. We couldn’t do anything and nothing 




‘I just felt stressed. I just felt there was nothing I could do to help him. You feel 
helpless. I was just exhausted. I was also just like, "Why is my baby like this?" 
That's what it felt like. I know there's other babies that have gone through this 
…. but, it just felt, at the time, that it was just me and people would say, "What's 
wrong with your baby?" I couldn't do anything. The amount of times I left 
shopping in the supermarket was just ridiculous. And I just became known as 
the lady with the screaming baby. People would think you're doing something 
wrong and blaming me, or blaming my milk and things like that ...‘   
         Maria (Parent)  
 
In some instances, the feelings of helplessness and despair impacted on 
parent’s self-esteem and self-efficacy and two parents felt they were poor 
parents and were to blame as intimated by Susan. 
 
‘I think the most painful thing for me was to see my child in pain and distress 
and being unable to sort that and to stop it and I was really upset and that just 
… You know, it’s difficult because at the time you think, “What did I do wrong? 
What am I not doing right? Why can’t I make my baby happier? Why is this child 
so upset?” And you do. And I think you’re tired and all these emotions are 
amplified and you’re on your own and you don’t know anyone else who is 
dealing with it, because everyone else you know ….  none of their children had 
this. And you think, “Is it just me? Am I just being a really bad mother, and I 




However, of great concern was the disclosure by one parent that during the 
time that her infant displayed symptoms of GOR, she had thoughts of self-harm. 
Her self-esteem had been low, and she had felt helpless and a failure as a 
parent. 
 
‘When they (health visitors) come over and they make that survey about post-
natal depression and they ask you to circle how many times you’ve thought 
about taking your own life or ....  you know ..... I really fought for survival quite 
a lot, and you do have really down feelings.  When you start to think who to kill 
first – your child or your baby goes first, and I wasn’t able to hurt her, and I 
wouldn’t leave her without being supervised ..... I think that was the only thing 
why I didn’t take my own life!....  You are in such a low place, and it certainly 
isn’t easy.’          Tanya (Parent)  
 
Interestingly, Tanya was not offered any help or support with parenting her 
infant in the early days of parenthood when she felt it would have benefited her 
most. 
 
‘I think my health visitor knew that I was struggling, but she only offered help at 
the time when she was better …. so she said, “Oh, there is that ehm … service, 
the free childcare service that I could maybe refer you for”  … But at the time, I 
didn’t need that referral …I needed the referral, especially, in the first two 
months …. when we had absolutely nobody here to help…. and when I would 
have welcomed any help I would get.  At the time she offered it, she was already 
139 
 
six months.  She was getting better, and I was coping better … so, yeah, that 
was a bit too late for that.’      Tanya (Parent) 
 
Moreover, some parents (4) commented that health professionals were only 
interested in their infant and that he/she was gaining weight. They did not seem 
interested in the parent’s emotional wellbeing and how they were coping. Ursula 
describes her experience following consultation with a doctor at the ‘Out of 
hours’ service. 
 
‘There was no-one who really asked me, “How are you doing?  What is your 
experience?”, and asking me a lot of questions about her over the day.  It was 
really just, “If she’s unsettled.  It is just reflux.  It will pass.  There’s nothing I can 
really do.  It’s not going to change overnight.”  That’s what they kept telling me, 
“It’s not going to change overnight.  There is no miracle pill.”  And then I was 
just expected to go home with her.’     Ursula (Parent)  
 
This suggests that some general practitioners and other medical staff, 
considered the symptoms of GOR that were perceived to be troublesome by 
parents to be normal infant behaviours. 
 
There were mixed responses regarding the support received from health 
professionals. Five parents felt well supported by their health visitor or general 
practitioner. Often in these instances the symptoms of GOR were less severe, 
or the health visitor or general practitioner involved were reported by the parents 
to have had first-hand experience of caring for their own infant with symptoms 
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of GOR and understood how the parents felt. Nevertheless, three parents 
expressed that they felt their concerns were not being listened to. For example, 
Rachel said:  
 
‘I think I was just made to feel that he’s just a baby. This is what babies do …. 
so,  even though I’d had a baby who didn’t do that, that wasn’t … and I was 
like, “Really? I don’t think so because I’ve had a baby, and yeah, babies cry. I 
know that, but they don’t do this, and they don’t vomit like this, and they don’t 
cry like this, and they shouldn’t be.” I even remember saying he’s waking up 
every forty-five minutes, and they’d just be, “Oh, that must be quite hard.” And 
I’m like, “Yeah …” … but that was it. It wasn’t, “Oh, well, maybe we need to find 
out more about this”, or “How can we support you with that?” It was just an “Oh 
dear, that’s terrible.”’      Rachel (Parent)  
 
Tanya had a similar experience: 
 
‘You know they (GPs) were just … I find that they weren’t really interested 
because they didn’t see a problem.  Ehm… I was told that, yes, babies do cry.  
I appreciate this ….  yes, babies cry.  But this wasn’t a cry.  This was a 
scream ..... a very high-pitched scream.  She screamed her lungs out and you 
know when your hormones are all over the place, and your baby screams like 
this, I felt my brain really hurt … you know, like your ears and your brain, and 
you just …  It’s driving me absolutely mental …. So there is a lot of stress and 
a lot of anxiety …. and ehm … sometimes you just don’t know what to do 
anymore.’                Tanya (Parent)  
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Some parents (7), like Tanya in the example below, searched the internet in 
attempt to try and find out what was troubling their infant and what they could 
do to help. 
 
‘I was Googling quite a lot of stuff. My main concern was, not only that she was 
screaming that much, the main concern that I had was that she hasn’t been 
sleeping …. so, I searched through quite a lot of articles (at least two thousand, 
I would say) of both professional and non-professional medical articles and how 
to get her to sleep, and what could prevent her from sleeping.’   
         Tanya (Parent)  
 
Regarding family support, few of the parents (3) interviewed had family living 
locally (see Table 5.01,). Also, some grandparents were reported to still be 
working, whilst others were caring for their own elderly parents (e.g. infants’ 
great grandparents) or were older grandparents and unwell themselves. All 
families had good friends who offered support, others found support from 
attending local baby groups or via social media. Four parents found social 
media such as Facebook groups useful for support, especially during the night 
when they were awake with their infant and even during the day if they felt they 
could not go out. There was always someone on Facebook who they could ask 
a question or converse with on-line. One parent perceived such Facebook 
friends as ‘extended family’ as highlighted in the excerpt from Susan: 
 
‘Well, unfortunately, at the time, my mother-in-law was being treated for cancer, 
so she, obviously, wasn’t able to really help out a lot and she’s an older 
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grandparent anyway …..…………… I suppose that’s why things like Facebook 
groups and things are useful. It means we get some face-to-face with some of 
the other groups when it’s more difficult to get out. They become like an 
extended family, I suppose.’     Susan (Parent)  
 
 ‘ …. my mum couldn’t be here to support us because my mum was the main 
carer to my grandma who has Alzheimer’s, so she wasn’t able to leave her 
mum, and there wasn’t anybody else who could support us.’  
Tanya (Parent)
  
This suggests that young families nowadays are less likely to have support from 
extended family in the early stages of parenthood.    
   
5.2.3 Changes Over Time 
Reflecting on changes over time, the findings suggest that parents are 
increasingly using the internet to access information about unsettled infants and 
symptoms of GOR. This can be positive if reliable web-sites are accessed, 
however unreliable sites may increase anxiety in vulnerable parents. Most 
parents (7) also reported using the internet and social media sites to find 
information about the symptoms GOR in their infant and to contact other parents 
or to seek advice from support groups.  
 
‘I would have just put in Google the search terms, ‘vomiting’, and then, 
actually, maybe because I was aware of it, I would have said, ‘reflux in 
babies’, ‘reflux symptoms’, and then you go down the list and you go, tick, tick, 
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tick – (infants name) has got that; (infants name) has got that …’  
         Rachel (Parent) 
‘….. So, we saw a couple of doctors here and then eventually, through looking 
on the internet, [we said], "Look, could it be silent reflux?"’  
Maria (Parent) 
 
‘Mothercare has a 2 a.m. support group on Facebook – so, at 2 a.m., if you’re 
a member, it will pop up, “Good morning, mums.  How are you feeling?”  So, 
it’s just mum’s up breastfeeding or whatever – unsettled night, sort of thing – 
they can just chat on the Facebook.’    Val (Parent) 
 
‘…as I say, three o’clock in the morning, and you’re feeding, and you’re on 
Facebook trying to keep awake, you can ask questions and see what’s going 
on.’           Susan (Parent) 
 
5.2.4  Conclusion 
In summing up, parents felt the experience of caring for their infant with 
symptoms of GOR to be a challenging and difficult experience and they felt 
helpless in their efforts to comfort and console their infant. Some families did 
not have the support of their extended family in the early days after the birth of 
their baby and valued the support of the health visitor and general practitioner. 
Others (3) did not find health visitors or general practitioners helpful. Parents in 
this study were increasingly accessing internet and mobile technology for 
information, support and advice for a multitude of things including parenting and 
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symptoms of GOR. This may influence perceptions and expectations of 
parenthood. 
 
5.3 Findings from the Analysis of Data from Interviews with Health 
Visitors 
This section presents the findings from the analysis of the data gleaned from 
the semi-structured interviews with health visitors. Analysis of the data helped 
to gain understanding of how health visitors approach the diagnosis of GOR in 
infants, as well as explore influences on their decision making when diagnosing 
and managing symptoms of GOR. None of the health visitors interviewed had 
current prescribing registration, therefore they did not prescribe medicine to 
manage GOR in infants. 
 
5.3.1 The Process of Diagnosing GOR  
The health visitors all understood GOR to involve the effortless regurgitation of 
milk feeds back up the oesophagus. This was perceived to be associated with 
an immaturity of the infant’s gut, or a weakness of the valve at the top of the 
stomach (cardiac sphincter) that keeps contents in the stomach. Whilst most 
infants vomit back, posset or spit out milk feeds, six health visitors did not 
consider the visible evidence of vomit necessary for the diagnosis of GOR and 
seven associated crying, distress and discomfort with symptoms of GOR.  
 
‘…. it would be excessive posseting or vomiting either… ehm.. after a feed or 
in-between feeds which usually causes a degree of distress to the baby… 
ehm… because their vomit would be quite acidic ….ehm..  Sometimes, though, 
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we find that… ehm… babies are unsettled and aren't actually vomiting, but 
there's a suggestion that they're regurgitating… ehm… but not actually getting 
the vomit up, and that is very uncomfortable for them, so they would be 
extremely unsettled in-between feeds …’    Ella (HV)  
 
On further exploration of the cause of the distress and discomfort, the findings 
revealed that four health visitors perceived infants to be in pain due to 
regurgitated acid from the stomach irritating the oesophagus. Seven health 
visitors also spoke of the difficulty of forming a diagnosis due to the symptoms 
of GOR being similar to other common infant conditions such as colic, and cow’s 
milk protein allergy (CMPA). Three health visitors described diagnosis as a 
guessing game, or as a process of trial and error. 
 
‘You know, it's very hard to define between reflux, cow's milk allergies, and colic, 
for example. Everyone gets confused a wee bit and they think the research is 
out there, you know ....  It is quite hard to define what's what ....’  
          Irene (HV)  
 
‘It's difficult because colic ... reflux and intolerance .... the baby cannot tell you 
and you've got to start with the basics and work through and it is, in part, a 
guessing game. It's nay (not), because you're following guidelines but, in actual 
fact, it is trial and error and what works with one doesn't work for the another.’




Nevertheless, in forming a diagnosis of GOR in young infants eight health 
visitors spoke of the importance of taking a full history and listening to the 
parent’s concerns. Only three health visitors spoke of observing the infant 
feeding. However, what the ‘history’ entailed appeared to be variable. For 
example, the interviews with Dawn and Betty suggests that the ‘history’ is 
generic and based on the parent’s perception of the symptoms, whereas the 
history taken by Karen and Irene focuses on how the infant feeds and is 
concerned with observing the feeding technique and how much the infant is 
feeding. 
 
‘It tends to be on ..ehm.. the history that you get from the parent and from your 
clinical … clinical picture that you ...ehm…have of the baby.  A lot of it is on 
parental history… it's what the parents are giving you as that… as that history’
         Dawn (HV)  
 
‘Well, you obviously get a presentation from what mum is saying and you 
obviously listen to the pattern of what mum said.’  Betty (HV) 
 
‘You want their history …  the feeding history...  you want to know how the baby 
is fed from birth and, if possible, you want to observe a feed… ehm… In the 
history you want to know if the volume has gone up, gone down, you want to 
rule out that the mum is overfeeding the baby … because if, obviously, with the 
baby being immature, if the tummy is too full then it is going to lead to excess.’




‘Quite often here, they would want me to watch them do their feed, because 
they want the reassurance.  They want to know they're doing it right, so I do 
that’           Irene (HV) 
 
Nevertheless, there was a perception among the health visitors that if infants 
were developing normally and gaining weight appropriately, the symptoms of 
reflux should not cause undue concern as intimated by Karen.  
 
‘... If a baby vomits, and is still gaining weight and still happy and content within 
himself, then that would lead me to believe that this is just a normal process 
...that the baby is coping fine with it ... that there is no need for treatment.’ 
         Karen (HV)  
 
The health visitors interviewed all commented that the symptoms of GOR 
normally resolved when weaning, or the introduction of complementary foods, 
began at around the age of 6 months. 
 
‘Most of them (infants) would grow out, I would say, about six months once they 
start weaning’       Hannah (HV) 
 
Although local guidelines (NHS Grampian) and NICE (2015) guidelines are 
available, awareness of these guidelines was mixed among the health visitors 
interviewed. Six health visitors were aware of local guidance and/ or NICE 
(2015) guidelines, however four health visitors were not aware of any guidelines 
to support decision-making in the diagnosis and management of GOR. 
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‘Well, there may be (referring to local guidelines), but as I say, I'm not aware of 
them (local guidelines). I don't know if there's NICE guidelines or SIGN 
guidelines’        Carol (HV)  
 
These findings indicate that despite NICE (2015) and local (NHS Grampian, 
2012) guidelines being available, few health visitors accessed them. Those 
health visitors who were aware of guidelines and protocols did use and refer to 
them in their work, however others relied on their own professional judgment, 
or discussed cases with other health visiting colleagues, and / or with general 
practitioners and dieticians.  
 
‘There are no formal guidelines – no – but obviously we liaise with dieticians 
and also with our paediatricians in (hospital) because that's quite a local contact 
and, of course, the GPs.  We discuss it with GPs.  And we discuss it amongst 
ourselves, really, and as a health-visiting team, and look at what do you think 
we can do with this situation that's presented.’   Dawn (HV) 
 
Further exploration found that health visitors’ knowledge of GOR was updated 
from reading journals or attending local training events from dieticians, although 
it appeared to be several years since some health visitors had attended such a 
training event.  
 
‘We've also got a talk from dieticians around milk intolerance, reflux … that type 




5.3.2  Influences on Decision Making in the Diagnosis of GOR in Infants  
In forming a diagnosis of GOR in infants the findings indicate that most health 
visitors (7) perceived infants to be suffering some pain and discomfort resulting 
in the infant crying, being unsettled and appearing distressed. These symptoms 
and behaviours, however, are also typical of other childhood ailments. On 
further exploration, the findings revealed that four health visitors considered the 
perceived pain to be due to acid from the stomach irritating the oesophagus. 
This is interesting as one health visitor (Betty), highlighted learning from a 
dietician and, did not consider stomach contents to be acidic within two hours 
of feeding, thereby refuting the belief that acid from the stomach was the cause 
of pain, distress and discomfort in infants. The belief that regurgitated feeds are 
‘acidic’, and causing pain, may influence diagnostic and prescribing decisions 
in the management of GOR in young infants. 
 
‘........and they (dieticians) also said ....which is quite interesting....that up to two 
hours after a feed, when the milk is brought up, it's the same pH level ...... so it 
shouldn't actually burn .... it shouldn’t burn and that's quite interesting.....’ 
         Betty (HV)  
 
On exploring influences on decision making in the diagnosis of GOR, the health 
visitors interviewed said that they were influenced by the parents’ concerns and 
what the parents told them. The health visitors (10) commented on parents 
making their own diagnosis of GOR, mainly from information gleaned on the 
internet. This can present a challenge to health visitors as indicated by Dawn 
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(below) and may influence decision-making in the diagnosis of GOR in some 
infants.  
 
‘I think now parents are coming to us with ... almost like their own diagnosis.  
They've .... they’ve read all about this ... and they've made an assumption about 
what's going on... and it's quite difficult if they come with that because .... you 
know, you don't want to say, "Well, actually, I don't believe you", but at the same 
time ... ehm ... we also can't just jump in to the ... and make that assumption too 
... so we have to start again with the history and go through it all in a supportive 
way without telling them, you know, that we don't agree with them ... ehm, so 
that's quite difficult sometimes.....’    Dawn (HV)  
 
There was also a sense among the health visitors that some parents were 
anxious, and for the anxiety to transfer to the infant perpetuating the state of 
unsettledness and distress. Many parents were perceived to be under pressure 
to return to work, whilst some health visitors (9) believed that some parents had 
unrealistic expectations of their infant and parenthood. One health visitor 
associated the high expectation of parenthood with postnatal depression, and 
feelings of inadequacy and guilt in parents who believed they were failing in 
their role as a parent. The perception of two health visitors was that these 
parents wanted a label or diagnosis for the symptoms of GOR in their infant so 
as to assuage their feelings of guilt and self-blame. 
 
‘….we do have a high rate of post-natal depression here and I think it is because 
of the area (described as affluent) and because of what their expectations were 
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and I think if they've got high expectations of what it should be like, and then it's 
not how they perceived it to be, then they are almost really blaming themselves 
and once they blame themselves and get into that culture … it's their fault, and 
that's why the baby's being sick because they're not feeding it proper …  so 
they almost want a diagnosis so then they can say, "Well, actually, it's fine, 
because it's not me." …’       Irene (HV)  
 
On probing this further, the interview with Irene (below) suggests that the role 
of extended family in supporting families has changed and may be a factor 
exacerbating the stress of parenting. 
 
‘....back in the olden days, they always had a lot more family support, they had 
a lot more ...  ehm .... there were lots and lots of people around and someone 
would take the baby off you or whatever .... whereas, you know, nowadays ... 
the majority here, anyway ...  they're ready to go back to work at six months.  
They're already juggling everything in their head. Nothing's really changed in 
their whole life, except .... this baby who's changed everything!  But they're still 
expected to do everything, and they're still expected to do the cooking, cleaning, 
and go back to work, juggle a baby that's not sleeping like it's meant to ... or not 
doing what it does in the adverts .... doesn't just have its bottle and go to sleep 
... or doesn't just go on a boob and feed... and quickly and all of a sudden they 
realise this is the reality and it all builds up to make them feel like a failure.’




The findings suggest that parental stress and anxiety does influence health 
visitor’s decision-making regarding the diagnosis and management of GOR in 
infants, and more so if parents appear exasperated and at their wits end as 
experienced by Betty and Dawn. However, the findings also suggest that by 
prioritising the needs of parents in this manner, health visitors may be 
influenced by parents in their decision-making. 
 
‘I think if I see a mum that was completely and utterly drained … and exhausted 
I would probably tell her to go and see the GP sooner….ehm… I'd probably not 
mess about with her and try and do all this other stuff first (referring to non-
pharmaceutical management strategies)…….’   Betty (HV)  
 
‘... I think, truth be told, I think that professionals ….me included ….. are 
influenced by parental presentation …. so, I will respond to a mum who is at the 
end of her tether and it could be that the baby next door has got far worse reflux, 
but the mum's more tolerant of it so that the baby whose mum is intolerant of it 
is going to be treated before the baby whose mum is tolerant of it …. so ... I 
think parental tolerance has got a huge influence on what we do. That's what 
we respond to … it's the parents.’     Dawn (HV)  
 
Three health visitors shared that they had personal experience as a parent 
caring for their own infant with symptoms of GOR. For example, Betty disclosed 
that she found caring for her own infant with symptoms of GOR a terrible 
experience and as a result would never dismiss the possibility of an infant on 
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her caseload suffering from GOR. Personal experience, therefore, may also 
influence the decisions and diagnosis made by health visitors. 
 
‘I'll never dismiss it (referring to GOR) cos my own daughter had it (GOR) ... 
and.... I know exactly what, what it's like ... and you know.... it was horrendous 
– it was absolutely horrendous.... to have a child ... with a diagnosis of that is 
horrendous ... it is really bad. It puts an awful lot of pressure on the families ... 
and sleep you know .... that's one of the biggest things ... just because they tend 
to not sleep .....’       Betty (HV)  
 
Again, this suggests a degree of subjectivity by some health visitors when 
diagnosing GOR in infants and the potential for them to collude with parents. 
 
5.3.3  Changes Over Time 
Four health visitors commented that in years gone by, ranitidine was only 
prescribed to infants with severe symptoms of GOR, that is GORD, following 
outpatient review and advice from a paediatrician, but now prescriptions for 
ranitidine are being initiated by general practitioners in primary care.  
 
‘.......  but you do see far more babies on Ranitidine … early …. rather than a 
few years ago …. we never would have seen a baby on Ranitidine prescribed 
by a GP.’          Ella (HV)  
 
This may reflect changing perceptions of parenting, baby behaviours and GOR 
in infants, as well as a more relaxed approach to prescribing. 
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Other changes over time highlighted within the findings from the interviews with 
health visitors related to weakening of families ties with young families receiving 
less support, or no support, from extended family as indicated in table 5.01. The 
health visitors (10) also noted an increase in the use of the internet and social 
media sources to access information and support about parenting and 
symptoms of GOR. This was perceived to cause some parents to have very 
high or unrealistic expectations of parenting and life with a young infant as 
highlighted below by Fran and Ella. 
‘.... I think they've got a lot of forums to go on like Netmums and then they go in 
and get this whole barrage and sometimes I come in and have a look and I 
think, "Oh, sweet Lord" – somebody just put on a simple comment and they got 
a barrage of things back that they never even thought about, and all of a sudden 
something's gone from something, and all of a sudden they sit and they're 
thinking of a bigger picture and much more anxiety is put onto them .....’ 
             Fran (HV) 
‘A lot of the girls talk about Facebooking people, friends, or peers and saying 
that their baby is sleeping six hours at night and that sort of thing, and 
whenever a baby is not well, it's very depressing for a mum, and all of us here, 
we try and tell that mum who is struggling, that that may well be what that girl 
is saying – that everything is rosy in her garden – but we go into everybody's 
house, and that's not the case all of the time in every house, and to take it at 
face value.  But there is a degree of pressure, socially, and it's so easily 
accessible – just go on their phone and that person is there and they ping off a 
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message.  There's no phoning from the phone box at the end of the road and 
they're not being home.  It's so much more accessible…..’    Ella (HV) 
 
5.3.4 Conclusion 
In summing up the findings from the interviews with health visitors, it seems 
that health visitors have a crucial role in influencing the diagnosis of GOR. 
History taking and assessment were considered important in helping to form a 
diagnosis of GOR, but this practice appears to be variable among the health 
visitors interviewed. Furthermore, not all the health visitors interviewed were 
aware of clinical guidelines therefore, the basis of health visitor’s knowledge of 
GOR is unclear and appears to be subjective and strongly influenced by 
parents.  There is also a perception by some health visitors that young parents 
are influenced by social media and internet sources and as a result had 
unrealistic expectations of parenthood and were less tolerant of fractious 
infants that posset and spit back feeds. 
 
5.4 Findings from the Analysis of Data from Interviews with General 
Practitioners 
5.4.1  The Process of Diagnosing GOR 
In exploring how general practitioners approached their diagnosis of GOR in 
infants, it was important to establish their knowledge and perception of what 
GOR is, its symptoms and the possible causes and consequences. The process 
of diagnosis builds on this knowledge, and explores the steps taken by 
practitioners in forming a diagnosis, as well as how they distinguished 
symptoms of GOR and GORD, and from other conditions such as colic and 
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cow’s milk protein allergy (CMPA). Awareness, and use of protocols and 
guidelines to support the diagnosis and management of GOR in infants was 
also explored. 
 
The general practitioners (4) interviewed understood the physiology of reflux to 
involve the regurgitation of stomach contents, normally milk, back up the 
oesophagus. Regarding severity of symptoms, two general practitioners 
described GOR as being on a spectrum with effortless regurgitation of milk 
feeds at one end and more painful regurgitation and distressed infants at the 
other end.  
 
‘I guess I see it as a bit of a spectrum …  so, maybe a refluxy baby is just kind 
of 'happy spitters', if you like, who do kind of bring up a lot, but they're not 
bothered by it …. they're developing fine…. they're gaining weight and they're 
quite happy …. and then you've got, as I see it, a progression along the 
spectrum.  You then get quite unsettled babies who may not always be spitting 
up or anything, but they seem to be quite distressed a lot of the day….’ 
          Ali (GP)  
 
Three general practitioners, like Ali above, considered GOR to be present 
without visible evidence of the infant vomiting or posseting feeds. Two general 
practitioners interviewed considered the distress and discomfort associated 
with severe symptoms of GOR to be due to acid from the stomach contents 
irritating the oesophagus as described by Lesley below. 
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‘Well, my understanding of it is sort of acid … ehm … coming up from the 
stomach irritating the oesophagus and causing pain and discomfort and can ... 
ehm … lead to vomiting …ehm…  but doesn't always lead to vomiting.’  
         Lesley (GP) 
  
The symptoms of GOR were said by the general practitioners (4) to be similar 
to other conditions such as colic and cow’s milk protein allergy (CMPA) making 
diagnosis difficult and this was reflected in the interviews with Lesley and Lee. 
 
‘Well, I get a little bit lost, if I'm being completely honest, between, like what we 
discussed …ehm.. between milk intolerance and sort of reflux and the sort of 
overlap between the two. Is, actually, what we think of as reflux, actually milk 
intolerance, and vice versa, and that area there is a bit of a grey area – but even 
just a kinda awareness of the fact that … it could be one or the other, I think, is 
good to have …’       Lesley (GP)  
 
‘…… and I see plenty of unsettled babies and if you're honest with the parents, 
it could be a bit of colic, a bit of reflux …. it could be a bit of intolerance, all 
mixed in.  That’s often my chat …. a bit of everything going on here …  a little 
bit of trial and error.’        Lee (GP)  
 
This suggests the criteria for diagnosing symptoms of GOR is unclear and the 
diagnosis dependent on the subjective experiences of the general practitioners. 
Nevertheless, in forming a diagnosis, the general practitioners highlighted the 
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importance of taking a good history of the presenting symptoms and situation 
from parents as indicated below by Lesley and Lee. 
 
‘But a lot of it comes from the history I think …. from the mum …  you know and 
sometimes you can sort of ehm …  see that the baby is groaning and unsettled 
and when it is picked up …  sort of upright … it just immediately seems calmer… 
ehm but no I would definitely want to, you know, examine ehm …  feel the 
abdomen ...  You know, you wouldn't want something like pyloric stenosis or 
something like that…. a vomiting baby …  although they tend to present much 
younger ……... The history is the main thing, with reasonable weight gain ...’
         Lesley (GP) 
 
‘So, yes, gathering all that information first of all to get a clear picture, and then, 
obviously, assessing the child to see, is it likely to be reflux, or is it something 
else?’            Lee (GP) 
 
Lee also valued the time spent with parents listening to their concerns and 
offering reassurance during consultations and commenting on such 
consultations said: 
 
‘…….. but it is time-consuming because often that consultation does take a bit 
of time….. to examine the baby,  make sure you're happy with its growth 
development …. but even that process is quite valuable ….  spending time 
because often the baby is not even examined.  It is just a bit of reflux.  Yeah, 
here's some whatever……  If you can actually ...  The parents appreciate that, 
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and then I can say, "Well, actually, here's another way to go at the 
moment.  Let's just hold back’’ …..I do lots of these consultations.  There's a 
cost to that, if you like, there's a resource implication but, you know, that's fine 
– that's what I do.’        Lee (GP) 
 
Regarding awareness of guidelines and protocols to guide the diagnosis of 
GOR, the general practitioners (4) interviewed were aware of local guidelines, 
although they did not use these local guidelines or conceded that it had been 
quite some time since they had accessed them.  
 
‘Well, there's NHS Grampian guidelines…. ehm ….there are some sort of 
guidelines there as such.  I wouldn't say I kind of rigidly stick to that though. 
Again, I draw on a lot of personal experience which maybe is the right or wrong 
thing to do …  I don't know.’      Ali (GP)  
 
None of the general practitioners (4) interviewed had accessed the NICE (2015) 
guideline. On pursuing this further, it appeared that the general practitioners in 
this study drew on their own personal and subjective experience or liaised with 
other health professionals for support as indicated by Lee below. 
 
‘We have an old guideline from the Children's Hospital and we have that on our 
formulary and a link from our own practice formulary to that guideline, but it 
hasn't been updated for quite some time – but, again, we work quite closely with 




Further investigation revealed that the general practitioners updated their 
knowledge of GOR by undertaking ‘GP Hot Topics’ courses, or as evidenced 
by Lesley by attending local training events on the topic of GOR. One general 
practitioner accessed informal support from medical friends and colleagues 
within their own social network.  
 
‘I heard a talk (about GOR) from the dietician at the Children's Hospital to a 
group of GPs.  It's a few years ago now…..’    Lesley (GP)  
   
‘I'm happy to phone up my paediatric buddies and say, "I have a kid I'm just not 
sure about", and they're often fine and give me some advice, but that's a very 
informal kind of way of doing it, but the parents like that as well.  They like the 
fact that you've had a chat with some specialist about their kid …  put your 
heads together and came up with a plan … they like that’  Lee (GP)  
 
This raises the question of where dieticians and paediatricians get their 
information and evidence about GOR to inform their practice and / or teaching. 
 
5.4.2 Influences on Decision Making in the Diagnosis of GOR in Infants 
Although history taking was considered important in forming a diagnosis, further 
exploration revealed that in some instances health visitors influenced decision-
making in the diagnosis of GOR in young infants by general practitioners.  
 
 ‘I think by the time a health visitor refers someone on to me, they've done a fair 
bit of work with that family, and they have just decided it's reflux …. make an 
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appointment with the GP….  We, as GPs, have to be sensitive to that as well.’
          Lee (GP)  
 
In some cases, it seems that it may be the health visitor that makes the initial 
diagnosis of GOR, or strongly influences the general practitioner’s decision to 
diagnosis GOR. On exploring this further, the general practitioners 
acknowledged the expertise and time invested by health visitors to promote 
non-pharmaceutical strategies to manage symptoms of GOR and to support 
anxious parents. They also recognised, as general practitioners, they 
encountered much fewer infants with symptoms of GOR than health visitors and 
were also more likely to see the more severe end of the spectrum of GOR.  
All the general practitioners reflected back on their own experience of caring for 
their own unsettled infant with symptoms of GOR. Caring for their own unsettled 
infant changed one general practitioners’ perception of GOR and subsequently 
may have influenced their professional judgement, and decision-making 
regarding the diagnosis of GOR. 
 
‘As I say, I think kinda the first time I became aware of it (GOR) was …. finding 
out when my own young one was unsettled and ….. something’s not right and 
… and I think … being a medic I was like, "Ach, I'm fine, you know….  it's just 
one of these … an unsettled child …. you know we see them all the time … 
they’re fine" (laugh)… ehm but I think there's just that kind of instinct about you 
like… that something’s not right …ehm and I think that's how I came about it. 
…cos I didn’t know it (GOR) existed … that was a potential thing…’  
          Ali (GP)  
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Interestingly, Ali was the only general practitioner interviewed with less than 5 
years’ experience as a general practitioner (see Table 5.03). Moreover, one 
mature general practitioner who, as part of a return to general practice 
programme, joined a group of young trainee general practitioners on a training 
event about GOR in infants, commented that a large number of trainee general 
practitioners in the group had given their own infant medicine to relieve 
symptoms of GOR. 
 
‘I was returning to work and doing a trainee post, I was training alongside much, 
much younger GPs …  a lot of them female, and I still go to an annual learning 
group.  We all meet up once a year and get together and we go through some 
educational lectures and things like that … and a chap came to speak to us 
from The Sick Children's Hospital here ………… and he was speaking to us 
about this (GOR) and it became apparent, around the table of about 15 to 
20 GPs, most of whom were young females, that a huge number of them had 
medicated their own children … their own babies …. and, as a .. (age).. (parent) 
of teenage children, I found it quite shocking, and I did wonder …  It would be 
interesting to look back at me sitting with a cohort of my contemporaries when 
I was having my babies, if they were all GPs (and a lot of them would have been 
GPs at that time), how many of them were medicating their babies, and it would 
have been zero at that time.’       Jo (GP)  
 
This suggests that attitudes to unsettled infants with symptoms of GOR among 
general practitioners is changing. It seems that infant behaviours that were 
previously perceived as normal, are now being considered as an illness 
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requiring treatment with medication, and therefore being diagnosed as GOR. It 
also suggests that medication is perceived by some parents (within the general 
practitioner population in this instance) to be a resource or asset that enables 
them to return to their normal working life and daily routines. 
 
The findings also identified that there was a perception among the general 
practitioners that parents were anxious, therefore, this may be a factor 
influencing diagnostic decisions.  All the general practitioners in the study 
attributed parental anxiety to the transition and adaptation to parenthood and 
the responsibility of caring for a new baby. They also associated the anxiety 
with high or unrealistic expectations of life with a new infant, and lack of support 
from extended family. Background anxiety was also highlighted as an issue. 
This centered on the pressure on parents to return to work early due to 
mortgages and other financial commitments. Parents were considered to have 
busy working lives and busy home lives that added to their anxiety and stress.  
 
‘I think it kinda all depends on what the parents are saying ehm (referring to 
making the diagnosis of GOR) ….cos a lot of the time, there may be quite a lot 
of parental anxiety about it.’      Ali (GP)  
 
‘I also think…. I wonder … if it’s (referring to parents presenting babies with 
symptoms of reflux) to do with their background levels of anxiety in a lot of these 
parents, you know that ehm…. they're all busy working… busy lives ehm…. and 
I think when there is a background ….. of just anxiety… not significant anxiety, 
but just sort of health anxieties….’      Lee (GP)  
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‘….. I think probably a lot of the mums that I see that are well-educated and 
working, maybe don't have the family around – the family support. I mean, I'm 
making sweeping assumptions here, but just kind of thinking about it – maybe 
they don't have a mum in the background helping out. It's just them there with 
the baby themselves and you can see how you can be tearing your hair out if 
it's getting .....’       Lesley (GP)  
 
This differs from the perception of parents. However, it also suggests that some 
parents consciously or unconsciously attend their general practitioner when 
their infant is unsettled and has symptoms of GOR when in reality, these 
parents may be finding it hard to cope with their own personal stress and 
anxiety, as well as caring for a young infant, and may be in more need of help 
themselves. By conferring a diagnosis of GOR in infants in instances where 
parents are perceived to be stressed, general practitioners could be argued to 
be colluding with parents. Parents, therefore may influence general 
practitioner’s decision-making in the diagnosis of GOR in young infants. 
 
5.4.3 Influences on Prescribing Decisions Regarding GOR in Infants  
Regarding influences on prescribing decisions, the findings suggest that 
decisions made on whether, or not, to prescribe medicine were influenced by 
the general practitioners understanding of the cause of the symptoms of reflux 
and their own subjective personal and professional experience. The lack of 
clarity in forming a diagnosis also led to a process of trial and error in the 




‘I think it can be quite difficult to know whether to try … If they're quite distressed 
with, what you'd say, reflux, then you often try maybe just a wee bit of Ranitidine 
to see if it helps. I do find that often it (Ranitidine) helps in the short term.  Even 
if they increase in weight, there seems to be a point …. where it (Ranitidine) 
doesn't seem to be as effective … but I would often suggest maybe trialling a 
diary-free diet quite early on.  Again, part of that is personal experience ……’
          Ali (GP)  
 
‘… and I see plenty of unsettled babies and if you're honest with the parents, it 
could be a bit of colic, a bit of reflux …. it could be a bit of intolerance all mixed 
in…. that happens often… a bit of everything going on here … a little bit of trial 
and error.’          Lee (GP)  
 
Other influences on prescribing that emerged from the interviews with general 
practitioners centred on parent’s expectation that medicine be prescribed to 
manage their infants’ symptoms of GOR, the acquiescence of GPs to prescribe, 
and the concept of defensive medicine. Health visitors were also found to have 
a role in influencing decisions to prescribe medicine to manage symptoms of 
GOR. Regarding health visitors, the findings revealed that not only do health 
visitors influence the diagnosis of GOR by general practitioners, but in some 
instances they influence general practitioners’ decision to prescribe medication. 
 
‘Most of the babies that we will see where there is a query diagnosis of reflux, 
will have been seen by health visitors and they will have been advised to come 
and see us to… ehm.. to perhaps, explore things a bit further, often already with 
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a suggestion from the health visitors of something that we may wish to 
prescribe…. ehm… Sometimes we'll get messages on our ….. doctor screen 
just asking us to prescribe …. You know suggesting that we prescribe 
something based on a diagnosis having been made by the health visitor.’  
           Jo (GP)  
 
On discussing the medical management of GOR further and the length of time 
infants with symptoms of GOR were prescribed medicine, it was disclosed that 
in some instances decisions regarding the continued prescribing of medicines, 
such as ranitidine, were made by health visitors. 
 
‘I think, in my mind and consciousness, I'm sort of leaving some of the follow-
up and decision-making about Ranitidine to a health visitor, but it is ultimately 
me that's prescribing it, but if you put it on our system with just one repeat on it, 
they can't go off and give it to the baby for two years.’   Jo (GP)  
 
This suggests that general practitioners value the knowledge, skills and 
expertise of health visitors in supporting families caring for infants with 
symptoms of GOR and the decisions and recommendations they make.  
 
The influence of parents on prescribing decisions was interesting. All the 
general practitioners interviewed highlighted the importance of spending time 
listening to, talking to and reassuring parents about their infant, the symptoms 
of GOR and non-pharmaceutical management strategies as well as the 
potential medicines available as intimated by Lee: 
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I'll give a little bit of reassurance about the natural history of it – so, they've often 
had some advice about nursing, posture, feeding and may have had advice 
about thickeners as well.        Lee (GP) 
 
However, on further investigation the findings revealed that all the general 
practitioners had felt under pressure to prescribe medicine by parents, or that 
parents expected a prescription for medicine to manage the symptoms of GOR 
in their infant. 
 
‘I'm not aware, when they come to see me, that they've got a great 
understanding of the natural history of the reflux problem and the sort of 
treatments available, but many of them do come in knowing that there are drugs 
like Ranitidine and Omeprazole and they have those words and you know that, 
obviously, that's their expectation ….  that they know there's a drug that can 
cure their baby's problem.’       Lee (GP)  
 
‘….. so, by the time they're sitting in front of us, there's a different expectation 
and often …  we're now seeing the next …  the second and the third babies in 
the same family with mum sitting in front of us saying, "Gaviscon sorted this 
one", or "Ranitidine sorted that one, can we just have it?"  They're absolutely 
asking for it outright.’        Jo (GP) 
 
On exploring where parents sourced information on the symptoms of GOR and 
the medicines available, all the general practitioners (4) believed parents to 
learn about GOR from health visitors whilst three commented on parents 
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sourcing information on-line. This suggests that some parents may ‘self-
diagnose’ GOR in their infant, based on information on the internet and consult 
their general practitioner with the expectation of getting a prescription for 
medicine. 
 
‘They've usually Googled something, or they've been on forums like Mumsnet 
and that kind of thing. They're quite popular sites to go on, so if they come in 
with some problem, they've already kind of … they've got an expectation there 
or they have an idea in their heads.’      Ali (GP)  
 
Nevertheless, the findings indicate that general practitioners were aware that 
some parents were anxious, and that caring for an unsettled infant with 
symptoms of GOR can be stressful and exhausting, therefore, some general 
practitioners, as highlighted by Lesley, are acquiescent and willing to prescribe 
medicine to manage GOR in infants whose parents are perceived to be stressed 
and have difficulty coping. One general practitioner raised the notion of 
defensive medicine which suggests that subliminally, some general 
practitioners may be colluding with parents or feel under pressure to prescribe 
medicine for their infants’ symptoms of GOR or do something to help stressed 
and anxious parents. In such instances the prescribed medicine may act as a 
placebo. 
 
‘The importance is to reassure parents because… you know…  if they have a 
screaming, unsettled child it’s… especially if it's a first child and….. what you're 
doing with a new baby, "Am I doing this right?", and it can really affect one's 
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confidence …. you know…  and have an impact on their mental health….  That’s 
why I think…. that it’s one of the reasons why I think if administering Ranitidine 
in any small way might help, I tend to be quite happy to prescribe it.’ 
         Lesley (GP)  
 
‘We're guilty of ...  Defensive medicine as well ...  You think, "Well, I'd better do 
something."  It's easier to prescribe…. keep them happy… they want 
something….fair enough.  Perhaps it's harder, and takes longer to say, "Maybe 
that's not the right way to do it."‘      Lee (GP)  
 
5.4.4  Changes Over Time  
Regarding changes over time, the findings from general practitioners suggest 
that the increasing use of the internet by parents may be a factor leading to a 
rise in the prescribing of medicines for GOR in infants. It appears that some 
parents are active consumers in their health care, and during the consultation 
share their learning from the internet with the general practitioner and actively 
engage and participate in the decisions made regarding the diagnosis and 
management of GOR in their infant. The changing role and reliance on 
extended family for support in the early days following the birth of the baby may 
also be a factor influencing parental coping as well as diagnostic and 
prescribing decisions by general practitioners. The findings also suggest a 
change in the criteria by which a diagnosis of GOR is made. This may be linked 




Two general practitioners, however, expressed concerns about prescribing 
practices and the increase in prescribing. For example, one general practitioner 
commented that the more widespread a prescribing practice is, the more 
relaxed practitioners become about prescribing medicines such as ranitidine. 
This was likened to the prescribing of thalidomide to pregnant women in the 
1960’s when it became socially accepted to prescribe medicine to manage 
morning sickness. Another general practitioner alluded to ‘defensive medicine’, 
meaning that on occasions it may be easier to prescribe medicine, as they feel 
under pressure to do something to alleviate the symptoms of GOR for anxious 
parents. This suggests that some parents expect to get a prescription when 
attending their general practitioner and that prescribing medicine to manage 
symptoms of GOR by some general practitioners is be becoming normal 
practice. 
  
‘But the more widespread a practice is, the less reticence there will be among 
practitioners to engage in that practice and to do that prescribing, perhaps 
without stopping and thinking enough about the fact that it's not been validated 
in the longer, longer, longer term and, presumably, if mothers were fully aware 
…’          Jo (GP)  
 
This general practitioner also expressed concern about the impact of drugs 
such as ranitidine on the gastric mucosa of young infants. 
 
‘My own concern is that this is a drug (ranitidine) that acts on the lining of the 
stomach and, is that what tiny wee physiological gastric mucosa’s need, or can 
171 
 
they withstand that sort of interference in terms of the longer term …. you know, 
the maturation process of these cells, and of the baby's digestive and immune 
system? I don't know. There must be some scientists in the world who are 
concerned about this.’        Jo (GP) 
 
5.4.5 Conclusion 
The lack of clear criteria on which to make a diagnosis of GOR creates 
challenges for general practitioners in diagnosing and managing infants with 
symptoms of GOR, resulting in a reliance on their own tacit knowledge and 
subjective experience. Parental expectations were also found to influence 
diagnostic and prescribing decisions by general practitioners, whilst other 
parents were perceived by general practitioners to suffer underlying anxiety and 
stress. The findings also suggest that health visitors may influence general 
practitioner’s decision making in the diagnosis and management of GOR in 
infants. Furthermore, it appears, that over the years prescribing practice has 
become more relaxed and it has become socially acceptable and normal for 
infants to be prescribed medicines to manage symptoms of GOR. 
 
5.5 Conclusion 
Stage two of the study focused on NHS Grampian and explored why there was 
an increase in the prescribing of medicines to manage symptoms of GOR. The 
aim was to understand the situation from the perspective of health visitors and 
general practitioners as well as from parents of infants with symptoms of GOR 
and try to unveil what, if anything, had changed over time to help explain the 
rise in prescribing of medicines in the management of symptoms of GOR. 
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The findings reflect a lack of clarity in the diagnosis of GOR with many of the 
health visitors and general practitioners relying on their own personal 
experiences rather than clinical guidelines and evidence-based sources when 
diagnosing GOR in young infants. Other influences identified include parental 
anxiety. However, whilst health visitors, general practitioners and parents 
acknowledged that parents of infants with symptoms of GOR experienced 
stress and anxiety, the cause of the stress and anxiety was understood 
differently between the health professionals and the parents. Health visitors and 
general practitioners alluded the stress and anxiety to be attributed to high or 
unrealistic expectations of parenthood, the pressure to return to work and the 
absence of support from grandparents and extended family as well as reliance 
on the internet and social media. The parents interviewed, considered their 
stress due to the incessant screaming and distress of their infant and their 
inability to console the infant. This led to sleepless nights, exhaustion and a 
feeling of isolation, particularly if grandparents were not at hand to lend support, 
and support from other sources such as health professionals was lacking. 
Pressure from parents and parental anxiety, therefore, influences health visitors 
and general practitioner’s decision making regarding the diagnosis and 
management of GOR in infants.  
 
The findings also revealed some changes over time that may be relevant and 
have an influence on the management and prescribing decisions of health 
professionals when faced with infants with symptoms of GOR. A change 
identified in the findings relates to the diagnosis of GOR and the understanding 
now that the presence of overt regurgitation, posset or vomit is no longer a 
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requirement in the diagnosis of GOR. Family networks and family support is 
also reported to be changing. Most families in the study lived at a distance from 
extended family and grandparents. This suggests a weakening of family support 
networks and was also reflected in the interviews with health visitors and 
general practitioners. Another change of interest that may have influenced 
management strategies and prescribing practices concerns the increasing use 
of the internet and social media. Several parents reported to access the internet 
and social media for information and support, whilst health visitors and general 
practitioners also commented on the increasing use of social media by patients 
and clients. Interestingly the findings also suggested that there is a perception 
amongst some parents that the symptoms of GOR may be more severe or 
exaggerated nowadays compared to previous generations. This is interesting 






CHAPTER 6: DISCUSSION OF FINDINGS FROM STAGE ONE AND 
STAGE TWO   
 
6.0 Introduction 
This chapter interprets the findings and explores influences on the diagnosis 
and management of symptoms of GOR in infants. Essentially, the findings 
reveal a rise in prescribing of Gaviscon (alginate), omeprazole (PPI) and 
ranitidine (H2RA) to manage symptoms of GOR in infants, as well as potential 
factors that may be contributing to this rise. Analysis of the data in stage one 
indicates this trend is likely to continue, whilst the data from stage two highlight 
that the decisions and actions of health visitors and general practitioners 
regarding symptoms of GOR are strongly influenced by parents. Furthermore, 
the unclear diagnostic pathway regarding GOR has led to some general 
practitioners relying on the opinion of health visitors whom they perceive to be 
experts in infant and early child care, or on their own personal and professional 
experiences. This is contrary to the recommendations of current guidelines 
(NICE, 2015; Rosen et al., 2018), and suggests that normal infant behaviour, 
such as symptoms of GOR, has become medicalised. This chapter, therefore, 
will begin with a discussion of the findings of the study in relation to the literature 
on the diagnosis and management of GOR by health visitors and general 
practitioners, and the parents’ experience of caring for infants with symptoms 
of GOR. Thereafter the theoretical framework, the medicalisation of normality, 
will be discussed in relation to everyday child care and the symptoms of GOR 
and the contribution of the study to this literature. Finally, strengths and 




6.1 Patterns of Prescribing of Medicines in the Management of GOR in 
Infants 
 
The findings from stage one identified that the number of infants aged 0-1year 
in Scotland and prescribed alginate, omeprazole and ranitidine increased over 
the 7-year study period and that the prescribing rates for these medicines in this 
age group in Scotland also increased. Whilst the findings highlight a rise in the 
number of infants aged 0-1-year prescribed these medicines, population 
statistics from the National Records of Scotland indicate that over the study 
period there was a decline in the overall number of infants aged 0-1 year. 
Therefore, reflecting on these demographic changes, the proportion of infants 
aged 0-1-year in Scotland prescribed these medicines to manage symptoms of 
GOR may be rising more sharply than the study data suggests. 
 
The data revealed that in Scotland, both the number of infants prescribed 
omeprazole, and the prescribing rate for omeprazole increased over three-fold 
between the years 2010 and 2016. These findings replicate data from other 
studies (Table 6.1) in New Zealand, Australia, Belgium and the United States 
that reported an increase in the use of PPI medicines, including omeprazole, in 
infants aged 0-1 year (Hudson et al, 2012; Blank and Parkin, 2017; Bell et al., 
2018;  Illueca et al., 2014; De Bruyne et al., 2014; Chen et al., 2012; Barron et 
al., 2007). The findings of this study indicate that the upward trend in prescribing 
of omeprazole is likely to continue with regression coefficients indicating 






Table 6.1 International Comparison of Change in Use of PPI Medicine in 0-1-year infants  
Country Publication Change in use of PPI medicine  Years of study 
Scotland Cowie et al. 2018 Omeprazole (PPI) > over 3-fold  2009 - 2016 
United States Illueca et al., 2014 PPI > over 2-fold 2004 - 2008 
 Chen et al., 2014 PPI > 11-fold 2002 - 2009 
 Barron et al., 2007 PPI > 4-fold 2000 - 2003 
Australia Bell et al., 2018 PPI > over 2-fold 2006/8 – 2014/16 
New Zealand Blank and Parkin, 2017 PPI > over 2-fold 2005 - 2010 
 Hudson, 2012 Omeprazole (PPI) > over 4-fold 2005 - 2010 
 Reith, 2011 Omeprazole (PPI) > 2-fold 2006 - 2010 
Belgium De Bruyne et al., 2014 PPI > 30-fold 1997 - 2009 
 
The picture is similar for ranitidine. The findings revealed that the number of 
infants in Scotland prescribed ranitidine, and the prescribing rate of ranitidine 
both increased almost four-fold between 2010 to 2016. Studies investigating 
prescribing patterns of ranitidine and other H2RA medicines, however, are 
limited. This study, therefore, adds to the body of literature regarding ranitidine 
use in infants aged 0-1 year. Of the studies available, De Bruyne et al (2014) 
reported an increase in prescribing of H2RA medicine (i.e. ranitidine) in infants 
age 0-1 year in Belgium, whilst Bell et al., (2018) reported that in Australia the 
prescribing rate of H2RA medicine (i.e. ranitidine) declined from 2012. The 
reason for the decline in prescribing of H2RA medicines in Australia is unclear, 
however it may be linked to the reported rise in the rate of diagnosis of GORD 
and decline in the diagnosis of GOR in infants aged 0-1 from 2012 (Bell et al, 
2018). Bell et al., 2018), indicate that there was a preference among 
practitioners to prescribe PPI medicines (i.e. omeprazole) to infants diagnosed 
with pathological GORD, and HR2A medicine (i.e. ranitidine) to infants 
diagnosed with physiological GOR. As with the findings of this study, the 
findings of the study by Bell et al. (2018) suggest that symptoms of physiological 
GOR in infants has become medicalised. Regarding the current study, the 
177 
 
findings indicate that the upward trend in prescribing of ranitidine shows no sign 
of abating with regression coefficients indicating estimated annual increases of 
1.3% for prescribing of ranitidine in Scotland. In NHS Grampian, the area 
selected for further study in stage two, the prescribing rate for ranitidine 
consistently exceeded the national average throughout the study period. 
Furthermore, the regression coefficient estimated an annual increase of 1.4% 
for prescribing of ranitidine in NHS Grampian which is greater than the national 
estimated increase of 1.3%.  
 
As discussed in the literature review evidence of the efficacy of omeprazole and 
ranitidine to manage symptoms of GOR is weak, and neither medicine is 
licensed for use in the 0-1-year age group, the population of interest in this 
study. Therefore, the reason for the increase in the use of these medicines to 
manage symptoms of GOR in infants needed to be explored further in stage 
two of this study. 
 
6.2 Influences on Decisions to Diagnosis GOR in Infants  
Parents were found to have a key influence on decisions regarding the 
diagnosis of GOR. However, what drove parents to seek a ‘label’ or diagnosis 
for the symptoms of GOR in their infant exposed new insights into the 
medicalisation of normality (Zola, 1972; Jutel 2011a). 
 
6.2.1 Parental Stress and Anxiety  
Analysis of the findings revealed parents of infants with symptoms of GOR to 
be anxious and stressed. There was a perception among health visitors and 
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general practitioners in this study that parents nowadays want to carry on with 
life and social activities as it was before the infant was born. For example, the 
health visitors and general practitioners interviewed reported that nowadays 
women need to return to work soon after their infant is born to maintain financial 
commitments such as mortgage repayment, whereas in previous generations 
many women gave up paid work to raise their family (Cornwell, 1984; Giddens 
and Sutten, 2014). According to the health visitors and general practitioners 
interviewed, this creates stress and feelings of failure in parents who cannot 
achieve this ideal. Furthermore, such parents were perceived by the health 
visitors and general practitioners in this study to be less tolerant of symptoms 
of GOR such as crying, distress and regurgitation, that they generally 
considered to be normal infant behaviours. The findings, therefore, suggest that 
the impact of these symptoms of GOR on the parent’s lifestyle and stress levels 
is a key driver for some parents seeking medical help, and a diagnosis to 
confirm the symptoms. A confirmed medical diagnosis facilitated access to 
prescription medicine, that is perceived to relieve symptoms of GOR and allow 
parents to return to their normal routines and activities. 
 
In contrast to the findings from the health visitors and general practitioners, 
parents in this study indicated that they were optimistic about parenthood. They 
expected sleepless nights and for their infant to posset and be unsettled at 
times. However, they did not anticipate these symptoms being as frequent or 
as intense as they were and for their infant to be upset and distressed. Even 
those parents who had older children were not prepared for the unrelenting 
persistence of the symptoms and distress, or their inability to console and 
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comfort their infant. This suggests that the symptoms of GOR that are perceived 
by parents to be troublesome, severe and distressing to the infant are generally 
considered to be normal infant behaviours by some health visitors and general 
practitioners. Consequently, this may have influenced decision-making and led 
to less infants being diagnosed with GOR.  
 
The reason for the dissonance in views between health professionals and 
parents is unclear but may be linked to the older maternal age of women when 
having their first child (ISD Scotland, 2018, 2018b) that will be discussed further 
in section 6.2.2. For example, a study by McConachie et al (2008) that focused 
on maternal wellbeing reported older and more educated mothers to find 
parenting more stressful than younger mothers. Compared to younger mothers 
McConachie et al (2008) found that older (over the age of 30 years) and more 
educated mothers perceived ‘daily hassles’ such as cleaning up the mess of 
their infant posseting or being sick, and unpredictable baby behaviours, such 
crying and unsettledness that are typical of symptoms of GOR, to be more 
severe and frequent. 
 
According to the health visitors and general practitioners interviewed, it seems 
that attitudes and expectations of parenthood have changed and that some 
parents have a reduced tolerance of these ‘unexplained symptoms’ that are 
typical of GOR, and previously considered normal infant behaviours. 
Consequently, this adds to their feelings of stress and anxiety, as well as 
feelings of inadequacy and a failure as a parent if they cannot alleviate the 
symptoms or soothe and comfort their baby. Some parents, therefore, are 
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driven to find a medical diagnosis or medical explanation for their infants 
behaviour or ‘unexplained symptoms’. Having the medical diagnosis of GOR 
exonerates them from blame and failure as a parent. It also reinforces their 
rationale and demand for a prescription for medicine that is perceived to 
alleviate the symptoms of GOR and in turn allow them to resume their normal 
routine and lifestyle. Furthermore, having a medical diagnosis of GOR 
increases the likelihood that medicine will be prescribed. This is reflected in the 
steady increase in the prescribing of medicine that is evident in the findings in 
stage one of this study. Consequently, this suggests that it is parents rather 
than health professionals who are driving the medicalisation of these normal 
infant behaviors, and the increase in prescribing of medicines for symptoms of 
GOR. 
 
Interestingly, some infants in this study who were reported, by their parents, to 
be very distressed and to exhibit severe symptoms of GOR were later 
diagnosed with cow’s milk protein allergy (CMPA). This indicates the need for 
health visitors and general practitioners to exclude other conditions with similar 
symptoms, such as CMPA, when making diagnostic decisions regarding 
symptoms typical of GOR in infants and lead them to seek out medical 
approaches to address this issue. 
 
Reflecting on their experience, some parents expressed that the stress of caring 
for their infant and symptoms of GOR resulted in them feeling exhausted, low 
in mood and in extreme cases feeling depressed and suicidal. This accords with 
the existing evidence base that associates maternal mood, anxiety and 
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depression with unsettled and crying behaviours in infants (Don et al., 2002; 
Matthies et al., 2017; Petzoldt, 2018). However, the direction of the causal effect 
appears to be two-way with maternal mood influencing infant behaviours, and 
infant behaviours influencing maternal mood (Don et al., 2002). Whilst the 
health visitors and general practitioners were aware of links between low 
maternal mood and depressive illness with unsettled infants, the parents in this 
study perceived that health professionals were only interested in the infant and 
were not concerned about their maternal health, emotional wellbeing or coping.  
 
The health visitors and general practitioners interviewed all stated that they 
listened to parents and their concerns, however some parents whose infants 
had severe symptoms of GOR, reported poor experiences in their encounters 
with health professionals, claiming that they (health visitors, general 
practitioners, accident and emergency paediatricians) did not listen to them or 
were not interested in their concerns. This resonates with literature regarding 
medically unexplained symptoms in adults, whereby people with symptoms that 
have no pathological underpinning and no scientific or evidence based medical 
explanation, such as myalgic encephalomyelitis, feel disbelieved and 
discredited by health professionals (Page and Wessely, 2003; Nettleton et al., 
2006; Werner and Malterud 2003). Symptoms of GOR in infants are medically 
unexplained as there is no definitive diagnostic test, and diagnostic criteria in 
clinical guidelines are vague and open to interpretation (NICE, 2015; Rosen et 
al., 2018). Furthermore, existing evidence suggests that people with medically 
unexplained symptoms are generally dissatisfied with encounters with medical 
practitioners (Johansen and Risor, 2017; Nettleton, 2006; Werner and Malterud, 
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2003). This was also the experience of some parents in this study but by proxy, 
or regarding their infant’s symptoms of GOR. 
 
The data from this study also identified that for some parents, labelling the 
symptoms with the diagnosis of GOR, served to authenticate their concerns 
about their infant’s symptoms and to remove feelings of inadequacy, blame and 
failure as a parent. In contrast, those parents in this study who experienced 
diagnostic uncertainty regarding their infant’s symptoms of GOR felt 
despondent and powerless to help their child and this impacted on their self-
esteem. This mirrors the experience of adults with medically unexplained 
symptoms (Nettleton et al., 2005; Nettleton, 2006; Page and Wessely, 2003). 
The need for a diagnosis and to have their infants’ symptoms of GOR validated 
and their experience and stress of caring for their infant and the symptoms 
acknowledged, is a key factor driving parents to seek a medical diagnosis. 
Furthermore, Nettleton (2006) highlights that people with medically unexplained 
symptoms are often highly motivated to find a diagnosis, and Werner and 
Malterud (2003) in their study of women with unexplained back pain, found that 
the women in their study went to great efforts to be perceived as credible and 
have their symptoms acknowledged as being genuine by doctors. Motivation by 
some parents to have a diagnosis of GOR for their infants’ symptoms, and 
access to prescription medicine, was evident in this study and was a factor 
driving the diagnosis of GOR and the subsequent rise in prescribing of ranitidine 





6.2.2 Shifting Social Support Structures 
Why parents are perceived to be more stressed nowadays than in previous 
generations is interesting and may be linked with changing family support 
structures and increasing use of the internet and social media. 
 
According to the findings many new parents lack family support compared to 
previous generations when grandmothers supported their daughters to look 
after and care for their children (Cornwell, 1984). In this study, the findings 
indicate that many families do not have support from extended family in the 
early days with a new baby due to extended family living at a distance, 
grandparents still being in employment, being a carer for their own parents, or 
being elderly themselves and in poor health. This finding suggests changing 
family and social support structures.  Interestingly, ISD Scotland (2018, 2018b) 
data, indicates that between the years 1998 and 2017, the birth rate among 
women aged 30 – 34 remained relatively stable whilst the birth rate among 
women aged 35 – 39 rose substantially by around 40% (1998: 6677 births; 
2017:9379 births). Furthermore, the birthrate in women aged 25 years and 
under declined during this period (1998:10174 births; 2017: 8128 births). 
According to ISD Scotland (2018, 2018b) women are now older when having 
their first baby. In the year 2017-2018, 54% of first-time mothers were aged 30 
years or older, and 46% of first-time mothers were younger than 30 years of 
age. Therefore, as first-time mothers are older, it is logical to assume that 
grandparents will also be older. Whilst many older grandparents will be in good 
health and look forward to the role of grandparent, others will be in poor health 
and unable to support their offspring (Margolis and Iciaszczyk, 2015). Also 
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impacting on the role of grandparents is the deferment of the age of retirement 
and eligibility for the State Pension in the UK. This is particularly pertinent to 
women who in some cases may have their pension deferred by up to 7 years 
beyond the age of 60 (Gov.UK, 2018). Furthermore, the Scottish Government 
(2017) highlights that divorce rates increase after the age of 45. Consequently, 
this has implications for the ability of some grandmothers to support their 
offspring with grandchildren. Not all grandmothers will be financially secure and 
may need to continue working till they reach retirement age; therefore, some 
may not be available to support or share child care responsibilities. As the age 
of retirement is set to rise further, this may have longer term implications on 
family structures and support. Furthermore, the inability of grandparents, 
especially grandmothers, to be actively involved in caring for their grandchildren 
may result in valuable tips and parenting skills not being shared or passed down 
generations. The findings of this study suggest that lack of family support may 
add to the stress and anxiety of being a new parent thereby pushing parents to 
seek a medical diagnosis and explanation for the symptoms of GOR from health 
professionals, along with a prescription for medicine to treat it. 
 
Whilst extended family ties may be diminishing, it appears from this study that 
parents are seeking support from other sources such as parenting support 
groups, the internet and social media sites. This reflects Scottish Government 
(2017) data that indicates the use of the internet by adults for personal use 
increased from 62.7% in 2007 to 83.4% in 2016. Furthermore, health visitors, 
general practitioners and parents in this study reported the use of Facebook as 
a communication medium, with parents regularly posting pictures and sharing 
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experiences of their ‘perfect' infant with family and friends. However, for those 
parents with unsettled infants it was acknowledged, by the health visitors, 
general practitioners and parents interviewed, that this can have a negative 
impact leaving parents feeling inadequate, incompetent and that they are to 
blame for their infant bringing up feeds and being upset and unsettled. Several 
parents in the study accessed online support groups and chat rooms on 
Facebook and social media that can be accessed day and night, and offer 
immediate support to stressed parents, particularly at night-time. One mother 
even likened her ‘Facebook’ friends to extended family. This suggests a social 
and cultural change regarding the support available to, and sought by, parents 
and may reflect diminishing ties between parents and grandparents (Giddens 
and Sutten, 2014).  
 
Diminishing family ties may be a factor impacting on the stress and coping 
strategies of new parents and their ability to resume their normal daily routines. 
It may also be linked to parents using the internet and social media to seek 
health information and support. Moreover, to shift blame and remove feelings 
of inadequacy, some parents use the information gleaned from the internet or 
social media to find a medical diagnosis, that they then present to their general 
practitioner to purport a prescription for medicine to manage their infants’ 
symptoms of GOR. 
 
6.2.3 Sources of ‘Medical’ Knowledge 
It was also evident in the findings that some parents use the internet to fulfil 
their natural curiosity and learn more about their infant and parenting, whilst 
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others use the internet and social media because they are dissatisfied with the 
advice and support offered by health professionals. This reflects the experience 
of people with medically unexplained symptoms discussed earlier and their 
efforts to find a diagnosis by searching the internet for information, evidence or 
research to support a medical diagnosis and access to treatment (Nettleton, 
2006). With technological advances and increasing use of technology in the 
home, several parents in this study searched for, and accessed information 
about the symptoms of GOR on the world wide web (Dumit, 2012). Parents in 
this study reported to use Google to search for information about the symptoms 
of GOR, and in many instances to make their own diagnosis of the condition, 
that they then presented to their general practitioner along with a request for a 
prescription for medicine. This suggests a shift in the balance of power between 
health professionals and patients, with patients becoming active consumers of 
health information rather than passive participants (Wald et al., 2007; McMullen, 
2005). Alternatively, it may be linked to the unclear criteria for diagnosing GOR 
in the NICE (2015) guideline, along with the motivation of parents to seek a 
medical diagnosis and explanation for their infant’s symptoms as discussed by 
Nettleton (2006). Furthermore, Johansen and Risor (2017) highlight that 
general practitioners often feel uncomfortable, helpless and frustrated when 
confronted with symptoms that are vague or medically unexplained, thereby 
shifting the power balance in favour of patients. Consequently, this suggests 
that the unclear guidance for diagnosing GOR, along with parents ‘new 
knowledge’ gained from the internet, is enabling parents to self-diagnosis GOR 
in their infant. In turn, pressure from parents to have their internet informed self-
diagnosis of GOR validated by their general practitioner has driven the 
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diagnosis of GOR in infants and the subsequent rise in prescribing of medicine 
that is identified in stage one of this study. 
 
Whilst most health practitioners in this study considered the use of the internet 
by parents positively and engaged with parents regarding the diagnosis and 
management of their infant, it was also recognised that some parents cannot 
discern between good and bad sources of information. Prasad (2013) highlights 
that although the internet and social media are useful tools to support health 
care a lot of health-related information on the internet is unregulated and 
therefore should be used wisely and with caution. For example, Netmums was 
highlighted by health visitors in this study as a social media resource that aimed 
to support parents but, in some instances, served to heighten anxiety as it 
presented anxious parents with a list of minor ailments and serious conditions 
that parents then perceive their infant to have. Netmums also suggests that a 
trial of medicine may be helpful in the management of GOR and names the 
drugs domperidone, omeprazole and ranitidine. This could be argued to be a 
subtle form of advertising by pharmaceutical companies. For example, 
evidence from the US (Tyrawaski and DeAndrea, 2015; Mogull and Balzhiser, 
2015) highlights increasing use of social media sites such as Facebook to 
promote pharmaceutical products. Furthermore, findings from stage one of this 
study identified a steady increase in prescribing of omeprazole and ranitidine in 
infants aged 0-1 year over the 7-year study period.  
 
Although direct to consumer advertising is restricted in the UK, parents and 
other consumers can readily access Facebook as well as US based websites 
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such as ‘Healthline’ and ‘BabyCentre’. Both these US websites and Netmums 
state that the regurgitated stomach contents are acidic in nature. This is 
misleading to parents and a form of pharmaceuticalisation (William et al., 2008; 
Harvey, 2013), as research has found that regurgitated stomach content in 
young infants is not acidic (Garza et al., 2011; Mitchell et al., 2001). Accessing 
poor or biased sources of information on the internet, therefore, not only creates 
anxiety in parents but can present a challenge to the power balance of health 
professionals, when parents self-diagnose the condition of GOR in their infant 
and then demand a prescription for medicine to treat the symptoms of GOR. 
Pharmaceutical companies, therefore, by using subtle advertising strategies on 
social media and the internet have a powerful impact on parents’ perceptions 
of GOR in their infant. In turn this strengthens the motivation and power of 
parents to influence diagnostic and prescribing decisions by health visitors and 
general practitioners. Subtle marketing of pharmaceutical products on the 
internet is influencing parents understanding of GOR and driving their demand 
for medicine and contributing to the rise in prescribing of medicine to manage 
symptoms of GOR in young infants. 
 
6.3 Professionals Approach to Diagnosis 
Although a national guideline (NICE, 2015) is available to support health 
professionals to diagnose and manage symptoms of GOR in infants, health 
visitors and general practitioners in this study appeared to either not know about 
the guideline or chose not to refer to it.  Instead the health visitors and general 
practitioners preferred to rely on their own professional judgement and 
subjective experiences when diagnosing GOR in infants. Of those in this study 
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who were aware of the guideline, some practitioners did not find the guideline 
useful. This reflects evidence on the use of guidelines in an international study 
by Quitadamo et al. (2014) that found that paediatricians did not adhere to the 
2009 NASPGHAN - ESPGHAN guideline.  Furthermore, McCracken (2014) 
considers poor implementation of clinical guidelines to be due to poor promotion 
and awareness raising, or because practitioners do not consider the guideline 
effective or useful. Guidance on the diagnosis of physiological GOR and 
pathological GORD in infants is unclear in current clinical guidelines (NICE, 
2015; Rosen et al., 2019). This leads to health professionals relying on their 
own tacit knowledge and subjective experiences. 
 
In this study decisions by general practitioners to diagnose GOR in infants were 
strongly influenced by the views of health visitors, as well as by parents, and 
the general practitioners own personal experience and intuition. Some general 
practitioners, for example, considered infant feeding, and related issues, to be 
within the domain of health visiting and as such they relied on the knowledge 
and expertise of health visitors in this area. General practitioners often assumed 
that health visitors had undertaken a full feeding history and thorough feeding 
assessment prior to an infant being referred to them. However, the findings 
suggest variance in obtaining and undertaking a feeding history and 
assessment by health visitors. For example, some health visitors focused on 
the clinical symptoms of GOR that presented and took a generic history from 
the parents, whereas others were more focused on observing the feeding 
technique and assessing how infants feed, and in obtaining a full feeding 
history. Consequently, this may have influenced diagnostic decisions. 
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Furthermore, whilst health visitors in this study relied on tacit knowledge, the 
findings also revealed that they are strongly influenced by the concerns of the 
parents.  
 
Parents in this study consulted the internet to gain medical knowledge and self-
diagnose GOR in their infant. The internet, therefore, is a powerful medium that 
influences people’s beliefs and understanding of a multitude of issues, including 
health and GOR in infants (Prasad 2013). The internet is now an integral part 
of daily life (Eckler et al., 2010) allowing parents easy access to a vast array of 
health-related information which may be biased and unreliable, but which 
parents trust. In turn, this new ‘medical’ knowledge from the internet appears to 
empower parents to form their own self-diagnosis of GOR in their infant, and to 
challenge the knowledge and expertise of health visitors and general 
practitioners and demand medicine to treat the symptoms. The findings, 
therefore, indicate that general practitioners are being influenced in their 
diagnosis and prescribing of GOR by health visitors who, in turn, are being 
influenced by parents who gain their information from the internet. This 
suggests that in some instances it is parents and not health professionals who 
are driving the diagnosis and medicalisation of GOR in infants, and the 
subsequent rise in prescribing of medicines. 
 
6.4 Influences on Prescribing Decisions 
The perception and interpretation of an infants distressed behaviour by parents, 
is a factor influencing the diagnosis of GOR in infants by health visitors and 
general practitioners. As chapter 5 reveals, this also appears to influence the 
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prescribing of medicines to manage symptoms of GOR in infants. Some 
decisions made by general practitioners regarding the diagnosis of GOR are 
influenced by health visitors or made based on the perceived effectiveness of 
the medicine prescribed. Interestingly views on the efficacy of ranitidine in this 
study was mixed among parents and practitioners. Ranitidine was effective in 
managing symptoms of GOR for some infants but not for others. This reflects 
the findings of a Cochrane systematic review (Tighe et al., 2014) that found the 
available evidence supporting the use of alginates (Gaviscon), and H2RAs 
(Ranitidine), and PPI (Omeprazole) limited and conflicting, particularly in 
relation to infants under one year of age. This process of ‘trial and error’ in the 
diagnosis and management of GOR is unscientific and surprising given the 
weak evidence base underpinning the efficacy of these medicines. 
Nevertheless, the findings did highlight that some health visitors, general 
practitioners and parents perceived the regurgitated stomach contents to be 
acidic in nature. This belief that the regurgitated stomach contents are acidic 
may have attributed to the increase in prescribing of acid suppressant drugs 
such as ranitidine (H2RA) and omeprazole (PPI). Of interest, however, is 
research from Garza et al. (2011), and Mitchell et al. (2001) that found milk 
(breast and formula) to have a buffering and neutralising effect on gastric acidity 
for up to two hours post prandial. The parents interviewed in this study reported 
symptoms of GOR to occur within 20 – 30 minutes after feeding, therefore 
according to Garza et al. (2011) and Mitchell et al. (2001) the regurgitated feeds 
would not be acidic in nature. This suggests that the perceived pain and 
discomfort experienced by some infants may not be due to gastric acid burning 
the oesophagus, but due to something else and therefore acid suppressant 
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medicines (ranitidine and omeprazole) are not required. This may, in part, 
explain the findings of the Cochrane systematic review (Tighe et al., 2014) that 
found the evidence of the effectiveness of ranitidine and omeprazole to manage 
symptoms of GOR in infants to be weak. Nevertheless, these acid suppressant 
drugs, ranitidine and omeprazole, are unlicensed in the 0-1-year age group and 
are being prescribed off-label to neutralize perceived ‘acid reflux’ in infants. 
Furthermore, Crawford et al. (2018) highlights that calculating and measuring 
accurate dosage of unlicensed medicines for young children can be challenging 
and, in some instances, may lead to overdosing of some medicines. In their 
examination of UK National Poisons Information Service data, Crawford et al. 
(2018) found 79% of cases of ranitidine overdose in children under 5 years of 
age, involved infants aged 0-6 months. The lack of evidence supporting the use 
of these medicines in this age group is a concern and clearly contravenes the 
advice from the GMC (2013) that requires the prescriber to be convinced of the 
safety and efficacy of the medicine being prescribed.  
 
As with the diagnosis of GOR, the findings indicate that general practitioners’ 
decisions to prescribe medicine to manage symptoms of GOR are influenced 
by health visitors. There was also a perception among general practitioners that 
a range of conservative management strategies had been advised by health 
visitors and tried by parents to manage symptoms of GOR prior to the infant 
being presented or referred to them for consultation and, therefore, the infants 
presented for consultation had more extreme symptoms of GOR. The findings 
also reveal that some health visitors and general practitioners did not consider 
conservative measures or treatment with Gaviscon to be effective and 
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expressed a preference for ranitidine as the first line of treatment. This is 
contradictory to the advice from NICE (2015). Furthermore, the findings 
highlight that in some instances follow-up of the infant and the decision to 
continue treatment with ranitidine is made by health visitors. Health visitors 
were perceived to have more frequent contact with families and to have built 
good rapport and relationships with parents, and to have the skills to review the 
infant and symptoms of GOR. This contravenes the GMC (2013) and Medicines 
and Healthcare Products Regulatory Agency (2014) prescribing guidance which 
clearly states that when medicines, such as ranitidine, are prescribed off-label 
(or unlicensed), the prescriber is responsible for follow-up and monitoring of the 
patient. This raises questions about the evidence base for diagnostic and 
prescribing decisions and the source and depth of the health visitors and 
general practitioners’ knowledge. Nevertheless, the findings indicate that 
general practitioners rely on the expertise of health visitors to inform their 
prescribing decisions, and that health visitors are influenced by parents who are 
influenced by information from the internet, therefore, this suggests that it is 
parents who are instigating the medicalisation of GOR and the increasing use 
of medicine that is evident in the findings in stage one of this study. 
 
Along with the lack of clarity, subjectivity and ‘trial and error’ approach to forming 
a diagnosis, the findings suggest complacency in prescribing medicine by some 
general practitioners. On deeper analysis of the data the findings suggest that 
the perceived complacency in prescribing ranitidine, an unlicensed medicine, is 
linked to pressure from some parents to get medicine to manage the symptoms 
of GOR in their infant. However, it may also be influenced by the current 
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emphasis on shared decision making in health care policy and practice 
(Scottish Government, 2018; Da Silva, 2012; Waneless, 2002). Health 
professionals are encouraged to actively involve patients in decision-making 
regarding their treatment and care (Scottish Government, 2018). Therefore, 
rather than having a passive role in their health care, patients are becoming 
more active and engaged in health care decisions (Wald et al., 2007; McMullen, 
2006). As discussed, many parents access health information on the internet 
prior to the consultation with their general practitioner.  Using information from 
the internet, they often have their own perception of their infants’ symptoms and 
have formed a diagnosis of GOR prior to consultation with their general 
practitioner, and present with an expectation that a prescription for medicine will 
be prescribed. On exploring the influence of patients on prescribing practice, 
Britten (2008) highlights that patient expectation strongly influences prescribing 
decisions. According to Britten (2008) patients who expect a prescription are 
twice as likely to receive one, however the chance of getting a prescription is 
seven times higher in situations where the general practitioner perceives the 
patient to expect a prescription. This may help explain the rise in prescribing in 
this study whereby parents expected or demanded a prescription for their 
infants’ symptoms of GOR. The practice of prescribing acid suppressant 
medicines such as ranitidine and omeprazole to young infants may be likened 
to the prescribing of antibiotics. Similar to the findings of this study, a systematic 
review (Bosley et al., 2018) found many parents expected to be prescribed 
antibiotics for their children, and that practitioners felt pressured by parents to 
prescribe antibiotics. In situations where antibiotics were prescribed, parents 
felt their concerns about their child’s condition were validated. Arguably this is 
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reflected in this study where parents who self-diagnosed GOR, and demanded, 
and were prescribed ranitidine for their infant, had their concerns reinforced and 
their diagnosis of GOR ratified. Subsequently this has contributed to the rise in 
prescribing of medicines and the medicalisation of normal infant behaviours that 
are typical of symptoms of GOR. 
 
As discussed earlier, some parents were perceived by general practitioners to 
suffer underlying anxiety and stress that was masked by parents seeking 
support for their unsettled infant and their symptoms of GOR. In such instances 
where medicine was prescribed to manage the infant’s symptoms of GOR, 
general practitioners could be argued to be acquiescent or colluding with 
parents. This acquiescence and collusion with parents, therefore, may be a 
factor influencing the prescribing of medicines to manage symptoms of GOR in 
infants 
 
6.5 Changes Over Time 
Reflecting on changes over time that may have influenced the diagnosis and 
management of GOR and prescribing practices, several factors have been 
identified. Firstly, there appears to have been a change in the criteria used to 
diagnose GOR. According to current clinical guidelines (Rosen et al., 2018; 
NICE, 2015), overt regurgitation and vomiting is no longer required as evidence 
for the diagnosis of GOR. Previously these symptoms were a hallmark sign of 
GOR in infants (Paton et al., 1988; Vandenplas et al., 1993; Vandenplas and 
Hegar, 2000). This suggests a broadening of criteria on which to determine 
GOR and may have contributed to a rise in the diagnosis of GOR in infants. 
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Secondly, expectations and attitudes to parenthood are perceived to have 
changed. The findings suggest that mothers now want to resume their previous 
lifestyle or return to work quite soon after the infant is born. Consequently, some 
parents are stressed and less tolerant of symptoms of GOR. Furthermore, 
among parents within the general practitioner population, there was a 
perception that medication is a resource that supports them to return to work 
and their daily routine. This may be a factor influencing the perception of 
complacency in prescribing by general practitioners. Another change relates to 
ranitidine now being prescribed in primary care, whereas in years gone by 
ranitidine was only prescribed in secondary care following referral to a 
consultant paediatrician.  
 
The increasing use of the internet and social media by parents is another factor 
that may have influenced the diagnosis and management of symptoms of GOR 
in infants. In some instances, information from the internet and social media 
sites has led to parents self-diagnosing GOR in their infant and expecting, or 
demanding medicine be prescribed. This also suggests a shift in the power 
balance between health professionals and patients. In previous generations 
patients were passive participants in the consultation with their general 
practitioner, whereas nowadays, patients are ‘active-consumers’ and want to 
be involved in the decisions made regarding their health care (Scottish 
Government, 2018). Furthermore, social media depicts an idyllic image of 
parenthood that can be demoralising and unachievable for some parents whose 




Another shift relates to the perception that symptoms of GOR are more severe 
or frequent nowadays than was experienced in previous generations and this 
may be linked to the change in the age recommended to introduce 
complementary foods or to start weaning. In this study some parents reported 
that their own parents (the infants’ grandparents) had not known of GOR when 
they were young parents themselves. Other grandparents were reported to 
perceive the symptoms of GOR to be worse nowadays, or more severe and 
frequent than they had experienced 25 - 30 years ago with their own infants. 
This may be linked to changing trends in infant feeding and weaning practices 
over time. For example, Koplin and Allen (2013) highlight that in the 1960’s most 
infants were introduced to solid food at 12 - 16 weeks of age. However, the 
COMA Report (Department of Health, 1994) later recommended that weaning 
be delayed till between 4 and 6 months. This recommendation remained until 
2003 when the Department of Health following the advice of the World Health 
Organisation (2001) recommended that infants be exclusively breast fed for 6 
months and the introduction of complementary / solid foods, or weaning, begin 
from the age of 6 months. Consequently, the introduction of solid food to infants 
is now up to 10 weeks later than in the 1990’s, therefore it is assumed that older 
and larger infants will want to consume larger volumes of milk to satiate their 
appetite. It may be that milk feeds are not enough to quell the appetite in some 
infants with the result that older and hungrier infants demand volumes of milk 
greater than the capacity of their stomach and therefore regurgitate or vomit the 
excess feed. This may, in part, explain the perception that symptoms of GOR 
are more severe now than in previous generations. Older, larger and hungry 
infants will consume larger volumes of milk and therefore regurgitate larger 
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volumes of milk feed. Furthermore, participants in this study reported symptoms 
of GOR to subside when weaning commenced. Therefore, it may that by 
delaying weaning till 6 months, symptoms of GOR persist for longer giving the 
impression that more infants have GOR nowadays compared to previous 
generations.  
 
Evidence from Nelson et al. (1997) and Martin et al. (2002) found the peak age 
for symptoms of GOR to occur was 4 months. However, when these studies 
were conducted, the recommendation was for solid food to be introduced at 16 
weeks. Furthermore, a survey by Hamlyn et al. (2002) conducted in 2000, found 
that almost 50% of mothers, at that time, introduced solids to their infant earlier 
than 16 weeks. As solid food is now recommended to be introduced to infants 
when they are older (around 6 months/ 26 weeks) this may be a reason for the 
perception that more infants are displaying symptoms of GOR. Also, it may be 
that the peak age of GOR has shifted and infants now older. If replicated today 
it would be interesting to see if the studies by Nelson et al. (1997) and Martin et 
al. (2002), would produce the same result and peak age for symptoms of GOR 
in infants.  
 
The Department of Health (2003) in recommending that the introduction of solid 
foods be delayed till the age of 6 months, also recognise that infants are all 
individual, have individual needs and grow and develop at a different pace. 
Health professionals, therefore, are permitted to use their professional 
judgement to inform their decisions regarding the earlier introduction of solid 
foods to infants. This clause, however, appears to be largely ignored by health 
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professionals. Nevertheless, when making decisions about the earlier 
introduction of solid food, health professionals are advised to take cognisance 
of the stage of development, and nutritional needs of each infant. They also 
need to heed the recommendation of the Comma Report (Department of 
Health, 1994) that advised solid food to be introduced between 4 and 6 months. 
The introduction of solid food before 17 weeks / 4 months is not recommended 
as infants may not have the neuromuscular coordination or physiological 
maturity to cope with the weaning diet (Department of Health, 1994). The British 
Dietetic Association (2013) and ESPGHAN Committee on Nutrition (2008) 
agree with the Comma Report recommendation (Department of Health, 2003), 
and support its flexibility. Furthermore, the British Dietetic Association (2013) 
and ESPGHAN Committee on Nutrition (2008) highlight that there is limited 
evidence that the introduction of solid food between 4 and 6 months is harmful 
to infants.The findings of this study highlighted weaning, or the introduction of 
solid foods, as a time when symptoms of GOR subsided, therefore the later 
onset of weaning may be factor contributing to the medicalisation of GOR and 
the subsequent rise in prescribing. 
 
6.6 Medicalisation of GOR 
It is evident from the findings of this study that normal infant behaviours such 
as regurgitation, crying and unsettledness have been given the diagnostic label 
of GOR and become medicalised. Several factors have contributed to the 
medicalisation of GOR in infants. However, unlike other literatures in this field 
that focus on the dominance of the medical profession (Clark, 2010; McLaren, 
2015; Szasz, 2007), the findings of this study point to parents as being the 
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driving force propelling the medicalisation of GOR in infants. The findings of this 
study, therefore, adds new theoretical knowledge and insight to the 
medicalisation of normality. 
 
A key factor influencing the medicalisation of GOR is the changing power 
balance between parents and health professionals. According to Cornwell 
(1984), decades ago medical practitioners were held in high esteem, and 
deemed to be superior due to their scientific and medical knowledge. 
Consequently, patients tended to adopt a passive role with doctors being more 
authoritative. In recent years, however there has been growing interest in 
shared decision-making between health care practitioners and patients 
(Scottish Government, 2018). This change from passive patient to ‘active 
consumer’ is evident in the findings of this study with parents consulting their 
general practitioner having first formed their own diagnosis of GOR in their 
infant from information gleaned from the internet and social media.  
Furthermore, the reason for regurgitation, crying and unsettledness in infants is 
not always known, therefore these symptoms are medically unexplained. As 
highlighted by Nettleton et al. (2005) and evident in the findings, some parents 
are determined to find a medical explanation for these unexplained infant 
behaviours and scour the internet in search of a medical diagnosis, such as 
GOR, that they then present to their general practitioner with the expectation of 
getting a prescription for medicine. According to Jutel (2009), ‘diagnosis’ is a 
sophisticated and powerful skill that allows medical practitioners to interpret 
symptoms and assign a label as appropriate. However, the findings indicate 
that this skill, that traditionally has been within the domain and power of the 
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medical profession, is now being challenged and tested by parents. 
Furthermore, having the diagnosis of GOR, validates parent’s concerns about 
their infant, and according to Jutel (2011a, 2011b) justifies their insistence and 
expectation of medicine to treat it, thereby driving the rise in prescribing of 
medicines and the resultant medicalisation of normal everyday behaviour in 
infants. 
 
In forming a diagnosis of GOR, several health visitors, general practitioners and 
parents in this study believed the infants regurgitated stomach contents to be 
acidic in nature. Some even referred to the regurgitation as ‘acid reflux’. This is 
interesting and supports the concept of pharmaceuticalisation proposed by 
Williams et al. (2012) and the suggestion from Hassell (2012) that in the US 
advertising products to manage ‘acid reflux’ in adults by pharmaceutical 
companies has transposed to children and now influences perceptions of GOR 
in infants. Suggesting that refluxed stomach contents are acidic implies the 
need for acid suppressant medicines such as ranitidine and omeprazole to 
neutralise the acid. In the UK pharmaceutical companies are only permitted to 
advertise ‘over the counter drugs’ or drugs that do not require a prescription 
(MHRA, 2012). Nevertheless, the internet and social media sites are widely 
available and easily accessible, and it is recognized that control of advertising 
on the internet is very difficult, therefore, parents are highly likely to be exposed 
to, and to be influenced by such advertising (Mintzes, 2016). Parents in this 
study accessed the internet and engaged with social media to gain medical 
knowledge and were exposed to this form of subtle advertising by 
pharmaceutical companies. For example, Netmums was cited as a website 
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commonly accessed by parents. Netmums is a sponsored website that claims 
to be the most influential and trusted parenting brand in the UK, to have 5 million 
unique followers each month, and a following of 1.2 million on social media. 
Netmums, therefore is a powerful platform that is tremendous in its reach to 
parents. Information on Netmums implies that the regurgitated stomach 
contents in infants are acidic. This is misleading and a subtle form of 
pharmaceuticalisation (Williams et al., 2012) that leads parents to believe that 
their infant needs acid suppressant medicine to neutralise the acid. Netmums 
also suggests a trial of medicine naming the acid suppressant medicines 
omeprazole and ranitidine. Armed with this information from Netmums, or other 
internet sources, parents in this study believing their infant has ‘acid reflux’, 
challenged the authority and expertise of the medical profession insisting their 
infant has GOR and needed a prescription for medicine, often naming ranitidine. 
Consequently, this has contributed to the steady rise in prescribing of medicine 
in the 0-1-year age group that is evident in the findings.  It also suggests that 
parents are being influenced by unreliable information and subtle advertising on 
the internet. Parents then use this ‘medical’ knowledge to challenge health 
professionals, and pressurise them to diagnose GOR in their infant and to 
prescribe medicine. Parents, therefore, are driving the medicalisation of GOR 
in infants. 
 
The findings also highlighted weaning, or the introduction of solid foods, as a 
time when symptoms of GOR subsided. The Department of Health (2003) 
advise the introduction of solid food from 6 months of age.The later onset of 
weaning may lead to some infants being hungry and it is possible that the 
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distress, crying and unsettledness associated with hunger is now being 
misdiagnosed as being symptomatic of GOR, and deemed to require treatment 
with medicine, thereby contributing to the rise in prescribing of medicines 
evident in this study. This reflects the concept of social diagnosis proposed by 
Brown et al. (2011), in that the diagnosis of GOR is influenced by social, cultural 
and political factors and by social actors. For example, the WHO (2001) and 
Department of Health (2003) as social actors, are political stakeholders 
recommending that weaning be delayed till the age of 6 months. This expert, or 
political, opinion is then promoted by other social actors (health professionals) 
to mothers as being the best for their infant. Other social actors reinforcing this 
social diagnosis of GOR include parenting groups and the wide array of internet 
and social media sites that are readily accessible, and bombard parents with 
parenting information. Equally parents are contributing to the medicalisation of 
every day by accessing and using information from the internet to find a 
diagnosis and to demand medicine for their infants’ ‘hunger’ or symptoms of 
GOR from their general practitioner, and this is evident in the findings. 
 
6.7 Strengths and Limitations of the Study 
A strength of this study is that it is the first to analyse prescribing data for 
medicines used in the management of GOR in the 0-1-year age group in 
Scotland. It is also the first to explore factors contributing to the rise in the 
diagnosis and prescribing for GOR from the perspective of both practitioners 
and parents. It is also the first to highlight the influence of parents as a driving 




In stage one, the prescribing data obtained for secondary analysis from ISD 
Scotland is the most accurate, robust and reliable in Scotland (ISD Scotland, 
2010, 2012b). This is because ISD Scotland routinely gather prescribing data 
nationally from across Scotland. Furthermore, this study is the first to examine 
patterns of prescribing to manage symptoms of GOR in the 0 to 1-year age 
group in Scotland and therefore has added new knowledge that has the 
potential to influence practice in the treatment and management of GOR in 
infants. Nevertheless, stage one of the research is not without limitations. 
Firstly, as some alginate preparations for young infants can be bought over the 
counter, it is possible that the use of alginate (Gaviscon) in infants aged 0-1 
year is higher than the ISD Scotland data would imply. A second limitation 
concerns the age of the infants prescribed alginate, domperidone, omeprazole 
and ranitidine. It is acknowledged that GOR is a self-limiting condition that 
resolves of its own accord as the child grows (Cohen et al., 2015; Hassell, 2012; 
Bhsavar et al., 2011). NICE (2015) indicate that at least 40% of infants 
experience symptoms of GOR, however by the age of six or seven months only 
14% of infants continue to exhibit symptoms (Nelson et al., 1997) and by one 
year of age symptoms of GOR persist in less than 10% of infants (NICE, 2015; 
Martin et al., 2002; Nelson et al., 1997). The data from ISD Scotland do not 
detail the actual age in months of the infant prescribed these medicines, 
therefore it is not known whether these medicines were prescribed consistently 
for 12 months or if prescribing peaked at set ages. A further limitation concerns 
the reason for prescribing the medicines. Whilst alginate (Gaviscon), H2RA 
(ranitidine) and PPI (omeprazole) are medicines used primarily in the 
management of GOR, it cannot be assumed that all prescriptions were written 
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in this regard. Despite these limitations, the results do clearly show a rise in the 
use of all three medicines but particularly the unlicensed medicines, ranitidine 
and omeprazole. 
 
Stage two of the study aimed to explore why the use of medicines to manage 
symptoms of GOR was increasing and this a strength in that this study appears 
to be the first to do this. Most research to date, has focused on the efficacy of 
these medicines and/ or made comparisons between medicines (Tighe et al., 
2014; Chen et al., 2012; Gieruszszak-Bialek et al., 2015). A second strength of 
the study is that it explores perceptions of GOR in infancy from the perspective 
of the key players involved in the management of GOR within the community, 
that is health visitors, general practitioners and parents. It also explores 
potential predisposing factors and influences on decision making regarding the 
diagnosis and management of symptoms of GOR in infants. On exploring the 
literature, there is a dearth of evidence focusing on parents’ perceptions and 
experience of caring for an infant with symptoms of GOR, and there is little 
evidence of research exploring factors that may influence practitioners’ 
decisions regarding the diagnosis and management of GOR in young infants in 
day to day practice. The use and flexibility of semi-structured interviews was 
also a strength in that it allowed both the researcher and the interviewee to 
explore and discuss key issues relevant to the diagnosis and management 
GOR in infants. A further strength of the study was my experience as a nurse, 
midwife and health visitor. Often in qualitative research there is a risk that the 
researcher’s personal knowledge and experience can influence the behaviour 
and responses of participants, however this was not so in this study. Instead, 
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my knowledge of GOR and experience as a health visitor gave me better 
understanding of what the participants were saying and to explore pertinent 
issues further. For instance, I understood medical terminology and jargon used 
by practitioners, and could speak in layman terms to parents about their infant’s 
GOR and the impact on their family. For example, one parent commented that 
their infant was prescribed ‘Infacol’ (simethicone) for the symptoms of GOR, 
however Infacol (simethicone) is a remedy associated with infant colic rather 
than GOR. This was probed further and suggested lack of understanding of the 
symptoms, diagnosis and management of GOR by the practitioner consulted. 
A researcher without health visiting experience may not have been aware of 
this. This reflects the experience of ethnography by Goodwin et al. (2003) who 
highlight the value to the outcome of research by the researcher being closely 
associated with the population being studied. Another strength of the study is 
the focus on changes over time. This appears to be the first study that explores 
change over time and what triggered or underlies this change in prescribing 
practice and management strategies for infants aged 0-1 year presenting with 
symptoms of GOR.  
 
Limitations of stage two concern the focus on one NHS Board only. Initially the 
study focused on two research sites (NHS Board areas) but unfortunately due 
to recruitment difficulties one research site was closed. This was a great pity as 
the research site that was closed had the highest prescribing rate for 
omeprazole (PPI) whilst the site included in the study, NHS Grampian, was the 
highest prescriber of ranitidine (H2RA). Comparison between the two areas and 
exploration of factors influencing drug choice may have strengthened the study. 
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The second limitation relates to the number of general practitioners recruited to 
the study. Only four general practitioners were recruited and three were from 
the same medical centre. However, although the themes identified from the 
analysis of the general practitioner interview data was similar to that of the 
health visitors, it may be that recruitment of more general practitioners may 
have strengthened the study. The third limitation relates to the combination of 
research participants. Recruitment of participants to the study was challenging, 
therefore the health visitors, general practitioners and parents came from 
throughout Grampian and were not aligned to the same medical practices or 
health centres. Recruitment of participants aligned to the same medical 
practices may have strengthened the study and facilitated further probing of 
particular issues in later interviews, or during analysis to expose deeper 
understanding. A fourth limitation concerns the focus on health visitors and 
general practitioners as the only health professionals, as inclusion of 
paediatricians may have provided useful data, particularly in relation to 
prescribing omeprazole as participants in the study indicated that omeprazole 
was generally prescribed following consultation with a paediatrician at the 
Children’s Hospital. Despite these limitations, this research study does provide 
some valuable insight of parent’s experiences of caring for an infant with GOR, 
as well as factors influencing health professionals’ decisions regarding the 
management and prescribing of medicines to manage symptoms of GOR in 








This study adds new empirical knowledge in that it identifies that prescribing of 
Gaviscon (alginate), omeprazole (PPI), and ranitidine (H2RA) in the 0-1-year 
age group is steadily rising in Scotland, and there is regional variation in the 
patterns of prescribing. Although several factors are contributing to this rise in 
prescribing, the findings point to parents, and their use of the internet and social 
media, as being the key driving force. Diagnostic and prescribing decisions by 
general practitioners are being informed by health visitors whom they assume 
have expert knowledge and expertise. However, health visitors’ diagnostic 
decisions are strongly influenced by parents. In turn, parents’ expectations of 
parenthood and perceptions of normal infant behaviours are being shaped by 
information on the internet and from social media. Subtle advertising by 
pharmaceutical companies on the internet and social media shapes parent’s 
medical knowledge. Consequently, regurgitation in infants is now being referred 
to as ‘acid reflux’ implying that acid suppressant medicine is required. Believing 
their infant is unsettled and upset due to ‘acid reflux’ parents presented to health 
visitors and general practitioners with their own diagnosis of GOR. Validating 
the diagnosis of GOR confirmed the parent’s concerns and supported their 
demand and expectation of a prescription for acid suppressant medicine such 
as ranitidine. This study adds to the body of theoretical knowledge by 
highlighting that rather than the medical profession, it is parents that are driving 




CHAPTER 7: CONCLUSION 
In concluding this thesis, it is evident that the aim and objectives set at the 
outset of the study have all been addressed and that the research provides new 
knowledge and greater insight of factors that have shaped the diagnosis, 
management, and prescribing of medicines for symptoms of gastro-
oesophageal reflux (GOR) in infants aged 0-1year. 
 
Analysis of national prescribing data in stage one provides evidence of a steady 
increase in prescribing of alginate, omeprazole and ranitidine in infants aged 0 
to 1 year in Scotland as well as regional variation in patterns of prescribing over 
the 7-year study period. This steady rise in prescribing shows no sign of abating.  
 
The findings of stage two of the study unveiled several factors that may have 
influenced and shaped management and prescribing practice over time and 
contributed to the rise in prescribing. For example, the lack of scientific evidence 
and robust criteria within clinical guidelines (NICE, 2015; Rosen et al., 2018) 
led many practitioners to rely on tacit knowledge and subjective experiences 
when diagnosing GOR in infants. The findings also revealed that general 
practitioners relied on the knowledge and expertise of health visitors to inform 
their diagnostic and management decisions, but health visitors in this study 
appeared to rely heavily on information from parents as well as their own tacit 
knowledge. Furthermore, the findings highlighted that while a feeding history is 
important to assessing and diagnosing GOR in infants, its application as part of 




The process of diagnosing therefore, appears to be influenced by social and 
cultural factors that are influencing contemporary parenting behaviours, 
especially changing perceptions of parenthood and parental expectations, with 
the result that over time there appears to be a shift in what is considered 
acceptable and within the parameters of normal infant behaviour. Baby 
behaviours previously considered as ‘normal’ such as those displayed in 
symptoms of GOR are now seen as an illness by parents and, as highlighted 
by Jutel (2011a), now legitimised by being assigned the label of GOR. The 
desire to have a medical resolution for this baby behaviour is in part driven by 
changing family networks. Nowadays, many young parents no longer have the 
same close support of grandparents from whom they may learn valuable 
parenting skills and conservative approaches to the management of GOR. 
Consequently, many families look to other sources of support, such as the 
internet and social media, many of which promote a medical approach. 
Furthermore, with the increasing use of the internet and social media, parents 
are unwittingly exposed to subtle advertising strategies by pharmaceutical 
companies that influence their understanding of common and unexplained baby 
behaviours. Whilst normal infant behaviours such as crying, unsettledness and 
regurgitation are now being recognised as symptoms of GOR, internet sources 
were found to refer to GOR as ‘acid reflux’ suggesting the need for medicine to 
neutralise the acid, and in some cases naming the acid suppressant medicines, 
omeprazole and ranitidine. Armed with ‘medical’ information from the internet 
and social media, parents take this new-found knowledge to health visitors and 
general practitioners forming their own diagnosis of GOR and expect or demand 
to get a prescription for medicine. The findings of this study therefore add to the 
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body of theoretical knowledge by highlighting that the medicalisation of GOR in 
infants, rather than be led by the medical fraternity, is in fact being driven by the 
changing expectations and demands of parents. 
 
7.1 Recommendations: 
1. To reduce the use of medicines in the management of GOR in infants 
aged 0-1 year it is recommended that: 
• A new practice standard should be introduced that requires 
conservative strategies to be adopted as the primary approach to 
the management of symptoms of GOR in infants. Medical 
approaches should only be considered as a last resort when all 
non-medical strategies have been tried and proven non-effective, 
or when clinically indicated i.e. weight loss in the infant 
• Practice guidelines should clearly set out: 
o The process to be followed and tools to be used by health 
professionals to ensure a robust and consistent approach 
when undertaking a feeding history and assessment of an 
infant with symptoms of GOR. 
o Conservative strategies to be recommended to parents to 
try in the first instance to comfort their infant and to alleviate 
the symptoms of GOR. 
 
2. To reduce the dissonance between health professionals and parents and 
help health professionals to better understand the experience and 
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context of a family caring for an infant with symptoms of GOR and what 
is important to them, it is recommended that: 
• The ‘What matters to you?’ conversation (Healthcare 
Improvement Scotland, 2019) be adopted as an integral part of 
day-to-day practice for health visitors and general practitioners to 
encourage them to: 
o Listen to what parents are saying, hear their concerns and 
what matters to them. 
o Practice in a person-centred way. 
 
3. Research be undertaken to: 
• Explore the extent to which the findings of this small study in one 
NHS Board holds relevance in other areas of Scotland. 
• Understand why there is variation in the medicines prescribed for 
GOR in infants across the NHS Boards in Scotland. 
• Establish the effectiveness of weaning as a management strategy 
for GOR 
 
4. General practitioners and health visitors be upskilled regarding common 
infant behaviours, GOR and use of ‘off-label’ medicines by: 
• Strengthening this learning within health visitor and general 
practitioner programmes. 
• Implementing a programme of continuing professional 
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Quality Appraisal – Systematic Reviews 
 
Quality Appraisal – Systematic Review 
Author(s) 
 




Pharmacological treatment for children with gastro-oesophageal reflux 
Abstract 
 Background: Gastro-oesophageal reflux (GOR) is a common disorder, 
characterised by regurgitation of gastric contents into the oesophagus. 
GOR is a very common presentation in infancy in both primary and 
secondary care settings. GOR can affect approximately 50% of infants 
younger than three months old (Nelson 1997). The natural history of 
GOR in infancy is generally that of a functional, self-limiting condition 
that improves with age; < 5% of children with vomiting or regurgitation 
continue to have symptoms after infancy (Martin 2002). Older children 
and children with co-existing medical conditions can have a more 
protracted course. The definition of gastro-oesophageal reflux disease 
(GORD) and its precise distinction from GOR are debated, but consensus 
guidelines from the North American Society of Gastroenterology, 
Hepatology and Nutrition (NASPGHAN-ESPGHAN guidelines 2009) define 
GORD as 'troublesome symptoms or complications of GOR.' 
Objectives: This Cochrane review aims to provide a robust analysis of 
currently available pharmacological interventions used to treat children 
with GOR by assessing all outcomes indicating benefit or harm. 
Search Methods: We sought to identify relevant published trials by 
searching the Cochrane Central Register of Controlled Trials (CENTRAL) 
(2014, Issue 5), MEDLINE and EMBASE (1966 to 2014), the Centralised 
Information Service for Complementary Medicine (CISCOM), the 
Institute for Scientific Information (ISI) Science Citation Index (on BIDS-
UK General Science Index) and the ISI Web of Science. We also searched 
for ongoing trials in the metaRegister of Controlled Trials (mRCT) 
(www.controlled-trials.com).Reference lists from trials selected by 
electronic searching were handsearched for relevant paediatric studies 
on medical treatment of children with gastro-oesophageal reflux, as 
were published abstracts from conference proceedings (published in Gut 
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Quality Appraisal – Systematic Review 
and Gastroenterology) and reviews published over the past five years.No 
language restrictions were applied. 
Selection Criteria: Abstracts were reviewed by two review authors, and 
relevant RCTs on study participants (birth to 16 years) with GOR 
receiving a pharmacological treatment were selected. Subgroup analysis 
was considered for children up to 12 months of age, and for children 12 
months to 16 years of age, and for those with neurological impairment. 
Data Collection And Analysis: Trials were critically appraised and data 
collected by two review authors. Risk of bias was assessed. Meta-analysis 
data were independently extracted by two review authors, and suitable 
outcome data were analysed using RevMan. 
Main Results: A total of 24 studies (1201 participants) contributed data 
to the review. The review authors had several concerns regarding the 
studies. Pharmaceutical company support for manuscript preparation 
was a common feature; also, because common endpoints were lacking, 
study populations were heterogenous and variations in study design 
were noted, individual drug meta-analysis was not possible. Moderate-
quality evidence from individual studies suggests that proton pump 
inhibitors (PPIs) can reduce GOR symptoms in children with confirmed 
erosive oesophagitis. It was not possible to demonstrate statistical 
superiority of one PPI agent over another. Some evidence indicates that 
H₂antagonists are effective in treating children with GORD. 
Methodological differences precluded performance of meta-analysis on 
individual agents or on these agents as a class, in comparison with 
placebo or head-to-head versus PPIs, and additional studies are required. 
RCT evidence is insufficient to permit assessment of the efficacy of 
prokinetics. Given the diversity of study designs and the heterogeneity of 
outcomes, it was not possible to perform a meta-analysis of the efficacy 
of domperidone. In younger children, the largest RCT of 80 children (one 
to 18 months of age) with GOR showed no evidence of improvement in 
symptoms and 24-hour pH probe, but improvement in symptoms and 
reflux index was noted in a subgroup treated with domperidone and co-
magaldrox (Maalox(®) ). In another RCT of 17 children, after eight weeks 
of therapy. 33% of participants treated with domperidone noted an 
improvement in symptoms (P value was not significant). In neonates, the 
evidence is even weaker; one RCT of 26 neonates treated with 
domperidone over 24 hours showed that although reflux frequency was 
significantly increased, reflux duration was significantly improved. 
Diversity of RCT evidence was found regarding efficacy of compound 
alginate preparations(Gaviscon Infant(®) ) in infants, although as a result 
of these studies, Gaviscon Infant(®) was changed to become aluminium-
free and has been assessed in its current form in only two studies since 
1999. Given the diversity of study designs and the heterogeneity of 
outcomes, as well as the evolution in formulation, it was not possible to 
perform a meta-analysis on the efficacy of Gaviscon Infant(®) . Moderate 
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evidence indicates that Gaviscon Infant(®) improves symptoms in infants, 
including those with functional reflux; the largest study of the current 
formulation showed improvement in symptom control but was limited 
by length of follow-up. No serious side effects were reported. No RCTs 
on pharmacological treatments for children with neurodisability were 
identified. 
Authors' Conclusions: Moderate evidence was found to support the use 
of PPIs, along with some evidence to support the use of H₂ antagonists in 
older children with GORD, based on improvement in symptom scores, pH 
indices and endoscopic/histological appearances. However, lack of 
independent placebo-controlled and head-to-head trials makes 
conclusions as to relative efficacy difficult to determine. Further RCTs are 
recommended. No robust RCT evidence is available to support the use of 
domperidone, and further studies on prokinetics are recommended, 
including assessments of erythromycin. Pharmacological treatment of 
infants with reflux symptoms is problematic, as many infants have GOR, 
and little correlation has been noted between reported symptoms and 
endoscopic and pH findings. Better evidence has been found to support 
the use of PPIs in infants with GORD, but heterogeneity in outcomes and 
in study design impairs interpretation of placebo-controlled data 
regarding efficacy. Some evidence is available to support the use of 
Gaviscon Infant(®) , but further studies with longer follow-up times are 
recommended. Studies of omeprazole and lansoprazole in infants with 
functional GOR have demonstrated variable benefit, probably because of 
differences in inclusion criteria. No robust RCT evidence has been found 
regarding treatment of preterm babies with GOR/GORD or children with 
neurodisabilities. Initiation of RCTs with common endpoints is 
recommended, given the frequency of treatment and the use of multiple 





















Quality Appraisal – Systematic Review 
 
 
 Yes No Don’t Know 
Did the review address a clearly focused issue?  √   
Did the authors look for the right papers? √   
Do you think all the important, relevant studies 
were included? 
√   
Did the review’s authors do enough to assess the 
quality of the included studies? 
√   
It the results of the review have been combined, 
was it reasonable to do so? 
√   
What are the overall results of the review? √   
How precise are the results? √   
Can the results be applied to the local population, 
or in your context? 
√   
Were all important outcomes considered? √   
Are the benefits worth the harms and costs? √   
 Good Moderate Weak 
Overall quality of research? √   
Comments: 
 
Robust systematic review of studies focused on the effectiveness of medicines used in the management 
of GOR in infant. Gaviscon (alginate), domperidone (motility stimulant), omeprazole (PPI) and ranitidine 
(H2RA) included within the systematic review. 
Systematic review process clearly outlined. Inclusion and exclusion criteria identified. 
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Author(s) 
 




Effect of Gaviscon Infant on gastro-oesophageal reflux in infants 
assessed by combined intraluminal impedance/ pH 
Abstract 
 
Background: Gaviscon Infant (GI) has been recommended for gastro-
oesophageal reflux (GOR) in infants. Its efficacy has not been examined 
with a physiologically appropriate denominator to define the degree of 
GOR. 
Aim: To investigate the influence of Gaviscon Infant on GOR in infants 
using combined pH and intraluminal impedance measurement. 
Methods: Twenty infants (mean age 163.5 days, range 34–319 days) 
exclusively bottle fed, with symptoms clinically suggestive of GOR, 
underwent 24 hour studies of intra-oesophageal 6 channel impedance 
and dual channel pH monitoring, during which six random 
administrations (3+3) of Gaviscon Infant (625 mg in 225 ml milk) or 
placebo (mannitol and Solvito N, 625 mg in 225 ml milk) were given in a 
double blind fashion. Impedance/pH reflux data were recorded and 
analysed blind by one observer. 
Results: The median number of reflux events/hour (1.58 v 1.68), acid 
reflux events/hour (0.26 v 0.43), minimum distal or proximal pH, total 
acid clearance time per hour (time with pH below pH 4), and total reflux 
duration per hour were not significantly different after GI than after 
placebo. Reflux height was marginally lower after GI (median 66.6% v 
77.3% oesophageal length) compared with placebo. 
Conclusions: Results showed a marginal but significant difference 
between Gaviscon Infant and placebo in average reflux height, and raises 









Quality Appraisal - RCT 
 Yes No Don’t Know 
Did the trial address a clearly focused issue?  √   
Was assignment of patients to treatments 
randomized? 
  √ 
Were all patients who entered the trial properly 
accounted for at its conclusion? 
  √ 
Were patients, health workers and study 
personnel ‘blind’ to treatment? 
  √ 
Were the groups similar at the start of the trial? √   
Aside from experimental intervention, were the 
groups equally treated? 
  √ 
How large was the treatment effect?   √ 
How precise was the estimate of the treatment 
effect? 
√   
Can the results be applied to the local 
population, or in your context? 
√   
Are all clinically important outcomes considered? √   
Are the benefits worth the harms and costs?  √  
 Good Moderate Weak 






Randomisation method unclear 
Small sample 
Funded by Reckitt Benckisor – Manufacturer of 
Gaviscon 





Studies Included in Literature Review 
 
Included Literature: Prevalence 
 
Author /Country Publication Title Method/ design/sample Quality 
Nelson SP, Chen EH, Synair GM, 
Christoffel KK. 
United States 
Archives of Pediatric and 
Adolescent Medicine 
1997. Vol. 151 (6) pp 569-72 
Prevalence of Symptoms of 
Gastroesophageal Reflux During Infancy 
Cross-sectional survey 
Sample size 948 
Good 
Martin AJ, Kennedy JD, Pratt, N, Ryan P, 
Ruffin RE, Miles H, Marley J. 
Pediatrics 
2002. 109:6 pp1061 
Natural History and Familial 
Relationships of Infant Spilling to 9 Years 
of Age 
Prospective study 
Sample size 693 infants 
Good 
Miyazawa R, Tomomasa T, Kaneko H, 
Tachibana A, Ogawa T, Morikawa A. 
Pediatrics International.  
2002. 44, pp 513–516 
 
Prevalence of gastro-esophageal reflux-
related symptoms in Japanese infants 
Survey 
Sample: 921 mothers of infants 
aged 0-1 in one area interviewed  
Fair 
Hegar B, Dewanti NR, Kadim M, Alatas S, 
Firmansyah A, Vandenplas Y. 
Indonesia 
Acta Paediatrica 
2009. 98, pp1189- 1193 
Natural evolution of regurgitation in 
health infants. 
1-year Prospective study  




Campanozzi A, Boccia G, Pensabene L, 
Panetta F, Marseglia A, Strisciuglio P, 
Barbera C, Maguzzu G, Pettoello-
Mantovani M, Staiano A 
Italy 
Pediatrics. 
2009. 123: 3, pp779 – 783 
Prevalence and Natural History of 
Gastroesophaeal Reflux: Pediatric 
Prospective Survey 
Prospective survey 
Sample: 2642 infants aged 0-1 
year 
Fair 
Sun H, Peters RL, Allen KJ, Dharmage SC, 
Tang MLK, Wake, M, Foskey R, Heine 
RG. 
Australia 
Journal of Paediatrics and Child 
Health 
2015. 51, pp 515 -523 
Medical intervention in parent-reported 
infant gastro-oesophageal reflux: A 
population-based study. 
Longitudinal population based 
study 








Included Studies: Guidelines 
 
Author /Country Publication Title Method/ design/sample Quality 
Quitadamo P, Papadopoulou A, Wenzl T, 
Urbonas V, Kneepkens F, Roman E, Orel 
R, Pavkov DJ, Dias JA, Vandenplas Y, 
Kostovski A, Miele E, Villani A, Staiano A. 
11 Countries in Europe 
Journal of Pediatric 
Gastroenterology and Nutrition. 
2014. 58:4 , pp505 -509 
European Pediatricians’ Approach to 
Children with GER Symptoms: Survey of 
the Implementation of the 2009 
NASPGHAN-ESPGHAN Guidelines 
Survey 
Sample: 567 (42% response rate) 
paediatricians from 11 European 
countries 
Good 
Quitadamo P, Miele E, Alongi A, Brunese 
FP, Di Cosimo ME, Ferrara D, Gambotto 
S, Lamborghini A, Mercuri M, Pasinato, 
A, Sansone R,  Staiano A.Vitale C, Villani 
A, 
Italy 
European Journal of Pediatrics. 
2015. 174, pp91-96 
Prevalence and Natural History of 
Gastroesophaeal Reflux: Pediatric 
Prospective Survey 
Prospective study 
Questionnaires given to 
paediatricians 
 
Sample: 100  
Good 




2017. 106. pp316-321 
Questionnaire-based survey in a 
developing country showing 
noncompliance with paediatirc gastro-
oesophageal reflux practice guidelines. 
Survey 



















Grey Literature: Guidelines 
 
Author /Country Year Title 
Rosen R, Vandenplas Y, Singendonk M, Cabana M, 
DiLorenzo C, Gottrand F, Gupta S, Langendam M, 
Staiano A,Thapar N, Tipnis N, 
2018 Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the 
North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the 
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition  
 
National Institute for Clinical Excellence (NICE) 2015 Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young 
people. NICE Guideline 
NHS Lothian, Paediatric Gastroenterology and 
Nutrition Department 
2014 Management Guidelines for Paediatric Gastroenterology 
NHS Grampian 2012 Infant Feeding Guidelines for Health Professionals 
Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassell E, 
Liptak G, Mazur, L, Sondheimer J, Staiano A, 
Thomson M, Veerman-Wauters G, Wenzl TG. 
2009 Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the 
North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) 
and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
Sherman PM, Hassall E, Fagundes-Neto U, Gold BD, 
Kato S, Koletzko S, Orenstein S, Rudolph C, Vakil N, 
Vandenplas Y. 



















Included Studies: Conservative Management 
Author /Country Publication Title Method/ design/sample Quality 
Kwok TC, Ojha S, Dorling JKwok TC, Ojha 
S, Dorling J 
Cochrane Database of 
Systematic Reviews  
2017, Issue 12. Art. No.: 
CD003211. 
ReviewsFeed thickener for infants up to 
six months of age with gastro-
oesophageal reflux 
Systematic Review Good 
Neu M, Pan Z, Workman R, 
Marcheggiani-Howard C, Furuta G, 
Laudenslager ML. 
United States 
Biological Research for Nursing 
2014., 16:4, pp387-397 
Benefits of Massage Therapy for Infans 
wwith Symptoms of Gastroesophageal 
Reflux Disease 
Randomised controlled trial 
Sample 43 
Good 
Huang RC, Forbes D,  Davies MW.  
 
Cochrane Database of 
Systematic Reviews. Issue 1 
2009 
Feed thickener for newborn infants with 
gastro -oesophageal reflux (Review). 
 
Systematic review of RCTs Good 
Horvath A, Dziechciarz A, Szajewska H. Pediatrics.  
2008., Vol. 122 
The Effect of Thickened-Feed 
Interventions on Gastroesophageal 
Reflux in Infants: Systematic Review and 
Meta-analysis of Randomized,  
Controlled Trials. 
Systematic review and meta-
analysis of RCTs 
14 studies 
Good 
Orenstein SR, McGowan  JD. 
United States 
The Journal of Pediatrics. 
2008 
Efficacy of Conservative Therapy as 
Taught in the Primary Care Setting for 




Sample size =37 
Fair 
Chao HC, Vandenplas Y. 
Belgium 
Diseases of the Esophagus 
2007., 20, pp 155 -160 
Comparison of the effect of a cornstarch 
thickened formula and strengthened 
regular formula on regurgitation, gastric 




Sample size = 81 
Fair 
Xinias NM, Le Luyer B, Spiroglou K, 
Demertzidou V, Hauser B, Vandenaplas 
Y. 
Greece, Morocco, France, Belgium 
Digestive and Liver Disease 
2005., 37, pp 23-27 
Cornstarch thickened formula reduces 
oesophageal acid exposure time in 
infants 
Blinded, prospective, randomized 
trail - intervention study 
96 infants 
Fair 
Khoshoo V, Ross G, Brown S, Edell E. 
United States 
Journal of Pediatric 
Gastroenterology and 
Nutrition. 
2000., Vol. 31 (5). 
Smaller volume, thickened formulas in 
the management of gastroesophageal 
reflux in thriving infants. 
 
Oesophageal pH monitoring 




Included Studies: Medical Management 
 
Author /Country Publication Title Method/ design/sample Quality 
Bell JC, Schneuer FJ, Harrison C, Trevena 
L, Hiscock H, Elshaug AG, Nassar N. 
Australia 
Archives of Disease in 
Childhood 
2018., 103, pp660-664 
Acid suppressants for managing gastro-
oesophageal reflux and gastro-
oesophageal reflux disease in infants: a 
national survey 
Cross sectional survey of GP 
activity  
Good 
Crawford C, Anderson M., Cooper G., 
Jackson G., Thompson J., Vale A., 
Thomas SHL., Eddleston M., Bateman 
DN 
United Kingdom 
Human and Experimental 
Toxicology 
2018., 37: 4., pp343 - 349 
Overdose in young children treated with 
anti-reflux medications: Poisons enquiry 
evidence of excess 10-fold dosing errors 
with ranitidine  
Analysis of data routinely 
collected by UK’s National 




Salvatore S., Ripepi A., Huysetrust K., 
vande Maele K., Nosetti L., Agosti M. 
Pediatric Drugs   
2018., 20. pp. 575–583  
The Effect of Alginate in 
Gastroesophageal Reflux in Infants  
Prospective, pharmacological, 
observational case–control study  
Sample size = 43  
Good 
Blank M., Parkin L. 
New Zealand 
Journal of pediatric 
gastroenterology and nutrition  
2017., 65: 2, pp. 179- 184 
National Study of Off-label Proton-Pump 
Inhibitor Use Among New Zealand 
Infants in the First Year of Life (2005-
2012) 
Population based study using 
routinely gathered dispensing 
data 
Sample size:  
22,643 
Good 
De Mattos AZ., Marchese GM., Fonseca 
BB., Kupski C., Machado MB. 
Arq Gastroenterology 
2017., 54:4, pp271-280 
Antisecretory treatment for pediatric 
gastroesophageal reflux disease- a 
systematic review.  




Azizollahi, H.R., Rafeey, M Korean Journal of Pediatrics. 
2016., 59:5, pp.226-230. 
 
Efficacy of proton pump inhibitors and 
H2 blocker in treatment of symptomatic 
gastroesophageal reflux disease in 
infants. 
Randomized double blind trial 
and parallel-group study. 
Sample size = 60  
Fair 
Gieruszczak-Bialek D, Konarska Z, Skorka 
A, Vandenplas Y, Szajewska H. 
The Journal of Pediatrics 
2015., 166, pp 767-770. 
No Effect of Proton Pump Inhibitors on 
Crying and Irritability in Infants: 
Systematic Review of Randomized 
Controlled Trials 
Systematic Review 
5 RCT studies 
Good 
Kierkus J, Oracz G, Korczowski B, 
Szymanska E, Wiernicka A, 
Woynarowkski M.   
Drug Safety.  
2014; 37: 309 – 316. 
 
Comparative Safety and Efficacy of 
Proton Pump Inhibitors in Paediatric 
Gastroesophageal Reflux Disease 
Comparative Review  




Tighe M, Afzal NA, Bevan A, Hayen A, 
Munro A, Beattie RM.  
Cochrane Database of 
Systematic Reviews  
2014, Issue 11   
Pharmacological treatment of children 
with gastro-oesophageal reflux. 
Systematic review of RCTs Good 
De Bruyne P, Christiaens T, Vander 
Stichle R, Van Winckel M. 
Belgium 
Journal of Pediatric 
Gastroenterology and Nutrition 
Changes in Prescription Patterns of Acid-
Suppressant Medications by Belgian 
Pediatricians: Analysis of the National 
Database, [1997-2009] 
Analyis of national prescribing 
data 
Good 
Chen I, Gao W, Johnson A, Niak A, 
Troiani J, Korvick J, Snow N, Estes K, 
Taylor A, Griebel D.  
Journal of pediatric 
gastroenterology and nutrition  
2012., Vol. 54 (1) 
Proton pump inhibitor use in infants: 
FDA reviewer experience."  
Systematic review of RCTs 
 
Good 
Scott, B. Archives of Disease in 
Childhood.  
2012., 97, 
How effective is domperidone at 
reducing symptoms of gastro-
oesophageal reflux in infants? 
Systematic review  Fair 
Van der Pol RJ., Smits MJ., van Wijk MP., 
Omari TI., Tabbers MM., Bennings MA. 
Pediatrics  
2011., 127:5., pp. 925 -935. 
Efficacy of Proton-Pump Inhibitors in 
Children With Gastroesophagea Reflux 





Cresi F, Marinaccio C, Russo MC., 
Miniero R., Silvestro L. 
 
Journal of Perinatology  
2008., 28, pp. 766–770  
 
Short-term effect of domperidone on 
gastroesophageal reflux in newborns 
assessed by combined intraluminal 
impedance and pH monitoring  
Prospective randomized 
controlled study model  
Sample 26 (13 of which were 
controls) 
Fair 
Barron J, Tan H, Spalding J, Bakst AW, 
Singer J. 
United States 
Journal of Pediatric 
Gastroenterology and Nutrition. 
2007., Vol. 45, pp 421- 427 
Proton Pump Inhibitor Utilization 
Patterns in Infants 
Retrospective observational 
study 
Sample size 2469 
Good 




2007. 120 (5) p946 -9 
Are we overprescribing Antireflux 
Medications for Infants With 
Regurgitation? 
Retrospective review of medical 
records 
Sample size 64. 
Fair 




2006., 96, pp176-181 
Oral ranitidine and duration of gastric 
pH>4.0 in infants with persisting reflux 
symptoms. 
Two-channel pH study 
103 infants 
Fair 
Del Buouno R., Wenzl, TG., Ball G., 
Keady S., Thomson M.. 
United Kingdom 
Archives of Disease in 
Childhood.  
2005. 90: 460 – 463. 
Effect of Gaviscon Infant on gastro-
oesophageal reflux in infants assessed 
by combined intraluminal 
impedence/pH 
Randomised placebo controlled 
double blind study 
Sample  20 
 Weak 
Pritchard DS, Baber N, Stephenson T. British Journal of Clinical 
Pharmacology. 
Should domperidone be used for the 
treatment of gastro-oesophageal reflux 
Systematic review of RCTs 




2005., Vol. 59 (6) in children? Systematic review of 
randomized controlled trials in children 
aged 1 month to 11 years old. 
Moore, D. J., Tao, B. S., Lines, D. R., 
Hirte, C., Heddle, M. L., Davidson, G. P.   
Journal of Pediatrics.  
2003., 143:2,  pp. 219 - 223. 
Double-blind placebo-controlled trial of 




placebo- controlled crossover 
trial. 
Sample size 64 
Fair 
Cucchiara S, Minella R, Lervolino C, 
Franco M T, Campanozzi A, Franceschi 
M, et al.  
Italy 
Archives of Disease in 
Childhood. 1993; 69: 655–9. 
 
Omeprazole and high dose ranitidine in 
the treatment of refractory reflux 
oesophagitis. 
RCT 





Current Medical Research and 
Opinion.  
1999. 15:3, 160-168  
Comparison of the Efficacy and Safety of 
a New Aluminium-free Paediatric 
Alginate Preparation and Placebo in 
Infants with Recurrent 
Gastroesophageal Reflux, 
Double-blind, randomised, 
parallel-group study  
























Research Study: Factors influencing and shaping the diagnosis and management of gastro-
oesophageal reflux in babies 
 
I am undertaking a research project as part of my studies towards a PhD in Public Health. The study aims to 
explore patterns of prescribing behaviours amongst health professionals and to develop an understanding of 
the factors that have shaped and influenced decision making with regard to the diagnosis and management of 
gastro-oesophageal reflux in infants. As part of this study I invite you to take participate in an interview that 
would last no longer than one hour. I have enclosed a participant information sheet with further details of the 
study that may help you decide whether or not to take part in the interview. 
 
If you are willing to take participate, please contact me by e-mail or telephone to arrange a suitable date, time 
and venue for the interview to take place. My contact details are below. 
 
Should you require more information about the research study or the actual interview please do not hesitate 
to contact me. 
 






PhD Student, Lancaster University 
 
Educational Projects Manager – Health Visiting 
NHS Education for Scotland, 
Aberdeen Dental Education Centre (ADEC), 
Argyll House, Cornhill Road, 
Aberdeen, AB25 2ZR. 
 










Participant Information Sheet 
 
 
Factors influencing and shaping the management of, and prescribing practices for infants aged 0-




My name is Jean Cowie and I am conducting research into, ‘Factors influencing the management of, 
and prescribing practices for infants presenting with symptoms of gastro-oesophageal reflux (GOR)’, 
for my PhD in Public Health at Lancaster University, Lancaster, UK. 
 
 
What is the study about? 
The purpose of this study is to explore patterns of prescribing behaviours amongst health 
professionals and to develop an understanding of the factors that have shaped and influenced their 
decision making with regard to the diagnosis and management of GOR in infants. 
 
Why have I been approached? 
You have been approached because the study requires information from health professionals who 
regularly come in contact with infants presenting with symptoms of GOR and make decisions 
regarding the diagnosis and treatment of the symptoms. 
 
Do I have to take part? 
No.  It’s completely up to you whether or not you take part. If you decide to take part you will be 
given this information sheet to keep and asked to sign a consent form. If at any time you change your 
mind about taking part, you will still be free to withdraw from the study up to 2 weeks after the 
interview without giving a reason. Your participation in the study, however, will be of great value and 
hopefully add to the body of knowledge regarding best practice in the diagnosis and management of 
symptoms of GOR in infants. Your participation will be greatly appreciated as it will help to develop a 
better understanding of the factors that shape the management of GOR in infants. 
 
What will I be asked to do if I take part? 
If you decide to take participate, you will be invited to take part in an interview to explore the factors 
that influence and shape decision making with regard to the diagnosis and management of GOR in 
infants. The interview will be last no longer than 60 minutes and will take place on a day, time and 
location that is convenient to you.  The interviews will be audio recorded then transcribed to ensure 
the information provided by you is recorded and documented accurately. I will conduct the interview 
and transcribe the data with the support of another transcriber.  
 
Will my data be confidential? 
The information you provide is confidential. All data collected will be stored electronically and be 
password protected in order to maintain confidentiality as defined by the Data Protection Act (1998). 
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The interviews will be audio recorded then transcribed with the collected data anonymised, 
encrypted and stored electronically. Within 5 years of completion of the research study all data 
including the transcriptions and audio recordings will be destroyed by me. Assurance is also given 
that the data collected will be used solely for the purpose of this research study and will not be used 
in any other study or passed on to any third parties.  
 
The data collected for this study will be stored securely and only the researchers conducting this 
study will have access to this data: 
 
o Audio recordings will destroyed and/or deleted after they have been transcribed and checked.   
o The files on the computer will be encrypted (that is no-one other than the researcher will be 
able to access them) and the computer itself password protected.  All data will be erased 
within 5 years of completion of the study. 
o The typed version of your interview will be made anonymous by removing any identifying 
information including your name. Anonymised direct quotations from your interview may be 
used in the reports or publications from the study, so your name will not be attached to them. 
 
There are some limits to confidentiality: if what is said in the interview makes me think that you, or 
someone else, is at significant risk of harm, I will have to break confidentiality and speak to my 
research supervisor about this.  If possible, I will tell you if I have to do this. 
 
What will happen to the results? 
The results will be summarised and reported in a thesis and may be submitted for publication in an 
academic or professional journal such as the Journal of Advanced Nursing or the British Medical 
Journal.  The findings of the study may also be presented at conferences and to colleagues in the 
NHS. 
 
Are there any risks? 
There are no risks anticipated with participating in this study.  However, if you experience any 
distress following the interview you are encouraged to inform the researcher and contact the 
resources provided at the end of this sheet   
 
Are there any benefits to taking part? 
Although you may find participating interesting, there are no direct benefits in taking part. However, 
you should note that the project aims to inform policy so although there are no immediate benefits 
there may be some benefit to practice in the longer term. 
 
Who has reviewed the project? 
This study has been reviewed by the Faculty of Health and Medicine Research Ethics Committee, and 
approved by the University Research Ethics Committee at Lancaster University and NHS Grampian, 
Research and Development Office. 
 
Where can I obtain further information about the study if I need it? 
If you have any questions about the study, please contact the main researcher: 
 
Jean Cowie 
PhD Public Health Student 
Lancaster University 
E-mail: j.cowie@lancaster.ac.uk  / Jean.Cowie@nes.scot.nhs.uk 






If you wish to make a complaint or raise concerns about any aspect of this study and do not want to speak to 
the researcher, you can contact:  
 
Director of Research: Dr Katherine Froggatt 
Tel: (01524) 593308 
Email: k.froggatt@lancaster.ac.uk 
Division of Health Research 





If you wish to speak to someone outside of the Public Health Doctorate Programme, you may also contact:  
 
Professor Roger Pickup Tel: +44 (0)1524 593746  
Associate Dean for Research Email: r.pickup@lancaster.ac.uk  
Faculty of Health and Medicine  
(Division of Biomedical and Life Sciences)  
Lancaster University  
Lancaster  
LA1 4YG 
Thank you for taking the time to read this information sheet. 
 
 
Resources in the event of distress 
Should you feel distressed either as a result of taking part, or in the future, the following resources 




































I am undertaking a research project as part of my studies towards a PhD in Public Health. The study aims to 
explore perceptions, and experiences, of gastro-oesophageal reflux in infants, and to develop an 
understanding of the factors that have shaped and influenced its the diagnosis and management in infants. As 
part of this study I invite you to take participate in an interview that would last no longer than one hour. I have 
enclosed a participant information sheet with further details of the study that may help you decide whether or 
not to take part in the interview. 
 
If you are willing to take participate, please contact me by e-mail or telephone to arrange a suitable date, time 
and venue for the interview to take place. My contact details are below. 
 
Should you require more information about the research study or the actual interview please do not hesitate 
to contact me. 
 







PhD Student, Lancaster University 
 
Educational Project Manager 
NHS Education for Scotland 

















Participant Information Sheet 
 
 
Factors influencing and shaping the management of, and prescribing practices for infants aged 0-




I am conducting research into, ‘Factors influencing the management of, and prescribing practices for 
infants presenting with symptoms of gastro-oesophageal reflux (GOR)’, for my PhD in Public Health at 
Lancaster University, Lancaster, UK. 
 
 
What is the study about? 
The purpose of this study is to explore parents perceptions, and experiences, of gastro-oesophageal 
reflux in infants, and to develop an understanding of the factors that have shaped and influenced its 
diagnosis and management in infants.  
 
Why have I been approached? 
You have been approached because the study requires information from parents / carers of infants 
who have experienced symptoms of reflux (vomiting, regurgitation and bringing back feeds). 
 
Do I have to take part? 
No.  It’s completely up to you whether or not you take part. If you decide to take part you will be given 
this information sheet to keep and asked to sign a consent form. If at any time you change your mind 
about taking part, you will still be free to withdraw from the study up to 2 weeks after the interview 
without giving a reason. Your participation in the study, however, will be of great value and hopefully 
add to the body of knowledge regarding best practice in the diagnosis and management of symptoms 
of GOR in infants. Your participation will be greatly appreciated as it will help to develop a better 
understanding of the factors that shape the management of GOR in infants. 
 
What will I be asked to do if I take part? 
If you decide to take participate, you will be invited to take part in an interview to explore parental 
perceptions, and experiences, of gastro-oesophageal reflux in infants, and to develop an 
understanding of the factors that have shaped and influenced its diagnosis and management. The 
interview will be last no longer than 60 minutes and will take place on a day, time and location that is 
convenient to you.  The interviews will be audio recorded then transcribed to ensure the information 
provided by you is recorded and documented accurately. I will conduct the interview and transcribe 
the data with the support of another transcriber.  
 
Will my data be confidential? 
The information you provide is confidential. All data collected will be stored electronically and be 
password protected in order to maintain confidentiality as defined by the Data Protection Act (1998). 
The interviews will be audio recorded then transcribed with the collected data anonymised, encrypted 
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and stored electronically. Within 5 years of completion of the research study all data including the 
transcriptions and audio recordings will be destroyed by me. Assurance is also given that the data 
collected will be used solely for the purpose of this research study and will not be used in any other 




The data collected for this study will be stored securely and only the researchers conducting this study 
will have access to this data: 
 
o Audio recordings will destroyed and/or deleted after they have been transcribed and checked.   
o The files on the computer will be encrypted (that is no-one other than the researcher will be 
able to access them) and the computer itself password protected.  All data will be erased 
within 5 years of completion of the study. 
o The typed version of your interview will be made anonymous by removing any identifying 
information including your name. Anonymised direct quotations from your interview may be 
used in the reports or publications from the study, so your name will not be attached to them. 
 
There are some limits to confidentiality: if what is said in the interview makes me think that you, or 
someone else, is at significant risk of harm, I will have to break confidentiality and speak to my 
research supervisor about this.  If possible, I will tell you if I have to do this. 
 
What will happen to the results? 
The results will be summarised and reported in a thesis and may be submitted for publication in an 
academic or professional journal.  The findings of the study may also presented at conferences and to 
colleagues in the NHS. 
 
Are there any risks? 
There are no risks anticipated with participating in this study.  However, if you experience any distress 
following the interview you are encouraged to inform the researcher and contact the resources 
provided at the end of this sheet   
 
Are there any benefits to taking part? 
Although you may find participating interesting, there are no direct benefits in taking part. However, 
you should note that the project aims to inform  
policy so although there are no immediate benefits there may be some benefit to practice in the 
longer term. 
 
Who has reviewed the project? 
This study has been reviewed by the Faculty of Health and Medicine Research Ethics Committee, and 
approved by the University Research Ethics Committee at Lancaster University and NHS Grampian, 
Research and Development Office. 
 
Where can I obtain further information about the study if I need it? 
If you have any questions about the study, please contact the main researcher: 
 
Jean Cowie 








If you wish to make a complaint or raise concerns about any aspect of this study and do not want to speak to 
the researcher, you can contact:  
 
Director of Research: Dr Katherine Froggatt 
Tel: (01524) 593308 
Email: k.froggatt@lancaster.ac.uk  
Division of Health Research 





If you wish to speak to someone outside of the Public Health Doctorate Programme, you may also contact:  
 
Professor Roger Pickup Tel: +44 (0)1524 593746  
Associate Dean for Research Email: r.pickup@lancaster.ac.uk  
Faculty of Health and Medicine  
(Division of Biomedical and Life Sciences)  





Thank you for taking the time to read this information sheet. 
 
 
Resources in the event of distress 
Should you feel distressed either as a result of taking part, or in the future, the following resources 




493 Union Street 
Aberdeen 
AB10 1RX 








INTERVIEW SCHEDULE FOR HEALTH PROFESSIONALS     
 
1. I’ll start by first asking you some general questions about you, your career history and place of 
work? 
a. When you first qualified? 
b. How long have you worked as a GP / HV? 
c. How long have you worked at this practice? 
d. What drew you to become a GP / HV? 
e. A bit about your caseload/ population you serve 
 
2. Infant Reflux (Ob 2, 3) 
What is your understanding of ‘reflux’ in young babies? 
What terms are used to describe it - (reflux)? 
Are these terms used interchangeably or do they have different meanings with regard to reflux? 
What, in your opinion, are the key symptoms of reflux? 
If different terms used - how do you distinguish between the terms used? 
     ie when GOR become GORD 
What leads you to your decision that an infant has reflux? 
Are there any tools/ guidelines/ protocols used to guide your decision making? 
If tool used - how effective? 
Are there political, economic, cultural or social influences? 
In the time that you have been a HV/ GP, have you noticed any change in the pattern, or number of 
babies that are presenting with symptoms of reflux? Why do you think this is? 
 
1. Parents of infants with reflux (Ob 2, 3) 
Can you tell me about the parents of babies presenting with symptoms of reflux? 
Have you noticed any pattern among the parents of the babies with symptoms of reflux? 
  ie  Family networks / support; Single, couples; Young/mature; Culture; Nationality; 
    Employment status; Rural/ city dweller etc 
How would you describe their parenting skills, adaptation to parenthood/motherhood? 
How do the parents react to their baby with the symptoms of reflux? 
What coping strategies do they have? 
Do you have experience of the parents getting information/ support from elsewhere? Where? How do 
you feel about this 
How would you describe your relationship with the parents? 
  
2. Management (Ob 4,) 
What management strategies do you use to support parents with infants presenting with symptoms of 
reflux?  / How do you manage infants presenting with symptoms of reflux? 
What influences your management decisions? - social, cultural, economic, political; Marketing/ 
Advertising 
Do the parents have any influence on your management decisions?  why? 
How would you describe your relationship with the GP / HV? Does this influence the management? 
How do you feel about the support you give to parents of infants with symptoms of reflux? 
Is there anything you would like to do differently? 
 
5.  Effectiveness and Efficacy (Ob 4,5) 
What are your thoughts on the management options available and their efficacy and effectiveness? 
ie Conservative management , pharmaceutical products etc 
 
6. What do you think has contributed to the rise in the number of parents presenting babies 
with reflux and the increase use of medicines? (Ob 3,4,5) 
 Changing expectations of parenthood / motherhood?; Availability of pharmaceutical 
 products?; Internet, social media? Advertising etc? 






PARTICIPANT INTERVIEW SCHEDULE (PARENTS) 
 
As I don’t know much about you, it would be good if you could tell me a bit about yourself, your baby…. your family…  Ie  work – 
type of work, full-time/ part-time etc 
  Baby – age, feeding, first, second baby etc 
  Family – partner, children, extended family etc  
 
Can you tell me about your experiences of being a parent to…….. (new baby 
- Is it what you expected?  
- How does being a parent and caring for…. (new baby)….. compare to being a parent and caring for your other children when 
they were this young? 
 
Your baby has been vomiting and bringing up feeds – can you tell me about this?  
- What’s been happening? 
- How often are feeds been brought up / vomited? 
- When did it start? How long it’s been going on for / how long went on for? 
- Are there any other symptoms? Ie weight loss 
- How does the regurgitation of feeds affect your baby? 
- Any pattern – timing, link to feed, nappies (wet/ dirty nappies) 
 
What’s your experience of looking after your baby when he / she is vomiting or bringing up feeds? (and/ or unsettled / distressed) 
- Can you tell me how did this make you feel? (vomiting, ?unsettledness etc) 
- To what extent does this affect you and your family? (sleep, social activities, relationship with partner etc) 
 
What did you think’s happening with your baby …… or causing him/ her to bring back feeds……. or cry or be unsettled and distressed? 
(may be opportunity here to probe or explore source of information – family, friends, internet, health professionals etc) 
 
Can you tell me how you tried to comfort and care for your baby when he/ she was vomiting…………and/or crying or unsettled and 
distressed? 
- Was there anything else happening in your life that may have impacted on how you managed and coped with the 
regurgitation and vomiting……… and crying / distress/ unsettledness? 
Ie pressure of work – full-time/ part-time employment? Managing time and plans to go out etc 
 
At what point did you feel you needed to seek help and support to manage the vomiting and regurgitation? 
- Where, or from whom, did you seek help? 
  Family, friends, HV, GP, internet, social media etc. 
  What influenced this decision? 
  What were your expectations from the HV, GP…. or others? 
 
Can you tell me about the advice, support, reassurance …. that you received  
- What was your experience of the advice, support reassurance given……  
- To what extent did you feel your concern was addressed?  
- How satisfied were you with the advice, support, reassurance received? 
- Was a condition or illness diagnosed? 
 
Can you tell me of any medicines or remedies that you are aware of to alleviate the symptoms for your baby? 
- How did you know about these medicines / remedies? Ie family, friends, internet, health professional  
- Can you tell me how these medicines/ remedies can be accessed? Are they available over the counter from the 
pharmacist? Do you need a prescription? 
- How did you access these medicines? Were you offered a prescription for these medicines? Did you ask for a 
prescription? 
 
Can you tell me about the support you received from health professionals ie HV / GP’s etc? 
- How satisfied did you feel with the support you received? 
 






Example of list of initial themes & sub-themes from interviews with General 
Practitioners 
 
Understanding of reflux:  
 What it is / physiology 
 Diagnosis - mis/over/ under 
 Terms used 
 Prevalence 
 Duration 
 Colic/ CMPA 
 Protocols & Guidelines 
 
Parents:  
 Social class 
 Culture 
 Family support/ social support networks 
 Parenting skills/ attachment 
 Coping strategies 
 Expectations 
 Anxiety 
 Finncial / social pressure 
 
Source of Information: 
 HV 
 Magazines – parenting & baby 
 Internet 
 Social media 




 Decision to prescribe  
 Practice 
 Efficacy of medicine 
 Reason for increase 
 
Health Visitors  
 Role of HV – some referring to GP. Some asking for prescriptions, Some reviewing 




 Impact of medicines on mucosa 
 Parallel to anti-emetics in pregnant women ie thalidomide 
 Attitude / practice of medical profession when evidence to use drugs not strong. 





Example of some early themes, sub-themes mapped to research aim and underpinning theoretical framework (medicalisation) 
 
Themes Sub-theme Description Research Question Theoretical Framework / 
Literature Review 
Parent     
 Educated / Professional 
Parent 
Thought to be more 
educated Professional 
parents presenting babies. 
Young parents / parents 
from lower SEG seem to 
cope better or to accept 
GOR. 
3. To explore factors 
influencing health 
professionals decision 
making in the diagnosis of 
GOR in infants.  
Social diagnosis 
Scientific motherhood 
  Parental anxiety Pressure to return to work, 
mortgages to pay etc 
3. To explore factors 
influencing health 
professionals decision 
making in the diagnosis of 
GOR in infants.  
Social diagnosis 
 Parental Expectations, 
Attitudes 
Parents thought to have 
unrealistic expectation of 
baby and parenthood.  
Parents thought to have 
low intolerance to crying 
and sicky baby 
5. To assess changes over 
time in the management 
strategies for dealing with 
GOR in infants and what 
underpins these changes 
Social diagnosis 
 Self Blame Maternal feelings of guilt or 
self-blame - failing to 
manage to sooth baby. 
Looking for a label ie GOR 
to remove blame 
3. To explore factors 
influencing health 
professionals decision 
making in the diagnosis of 




Themes Sub-theme Description Research Question Theoretical Framework / 
Literature Review 
Social Media     
 Self-diagnosis Many parents using 
technology to explore 
problem and to self-
diagnose 
Many parents using 
technology to explore 
problem and to self-
diagnose 
 
5. To assess changes over 
time in the management 
strategies for dealing with 
GOR in infants and what 
underpins these changes 
Internet & Social media 
Social diagnosis 
 Increasing use of 
technology 
Parents always on mobile 
phone or laptop 
5. To assess changes over 
time in the management 
strategies for dealing with 
GOR in infants and what 
underpins these changes 
 
Internet & Social media 
Social diagnosis 
  Use of Facebook, 
netmums, google etc 
5. To assess changes over 
time in the management 
strategies for dealing with 
GOR in infants and what 




Internet & Social media 
Social diagnosis 
 
Diagnosis of Reflux     
 Understanding of reflux Variety of descriptions 
/perceptions of reflux in 
babies 
2. To understand how 
health professionals 
approach their diagnosis of 





Themes Sub-theme Description Research Question Theoretical Framework / 
Literature Review 
 Under, over & mis 
diagnosis; colic intolerance 
etc 
Some no change in 
symptoms and babies but 
difference is related to 
under or over diagnosis. Or 
perhaps mis diagnosis 
2. To understand how 
health professionals 
approach their diagnosis of 
GOR and GORD in infants. 
5. To assess changes over 
time in the management 
strategies for dealing with 
GOR in infants and what 




 Guidelines / Protocols Not all are aware of, or 
refer to, protocols or 
guidelines 
2. To understand how 
health professionals 
approach their diagnosis of 




 Incidence / Prevalence Some think it is much more 
common. Some think reflux 
is the new colic 
Others think it is better 
diagnosed now 
Some think it is increased 
due to parental 
expectations and 
intolerances 
Seems more common in 
white Scottish / British 
 
5. To assess changes over 
time in the management 
strategies for dealing with 
GOR in infants and what 







































Example of part of Data Summary and Display: Influence on Diagnosis 
Name Symptoms Parents Parental Anxiety 
 
Ali (GP) I think it all depends on 
what the parents are 
saying because, a lot of 
the time, there might be 
quite a lot of parental 
anxiety about it – so, I 
think if the child is quite 




I think, I'd probably say 
most people I see about it 
are working middle class 
who seem to be reasonable, 
sensible people. Whether 
they've got, maybe, too 
much expectation in a way, 
that they should have a nice 
lovely child and baby, and 
remain in control of their 
work environment and 
suddenly they've got a child 
who's doing nothing that is 
in their control and that's 
again – certainly from a 
personal perspective – this 
was a complete change. I'm 
usually in control of things, 
and suddenly you're like, 
"What is going on?" I think 
that causes a lot of stress 
and anxiety when they're 
not in control of a situation. 
 
I think … I don't know – there's lots of social 
media going around; everyone's posting 
their pictures of their perfect little bundles 
who … You know, I guess the pictures 
portray these perfect little things. You don't 
actually know what's going on, so I think 
everyone has that kind of expectation that 
they should have perfect children who don't 
cry, who sleep well, who feed well and so, I 
think there is maybe more of an expectation 
that children should be like that, and get 
into a routine – and that's not really the 
case, though. So, maybe, there's a wee bit 
more anxieties about what is normal, I 
guess. A lot of people just come with 
normal kind of problems, but they're maybe 
thinking it's not right. I don't know if social 
media had anything … 0:12:21.9 
 
Yes, an 'unsettled' child, and you kind of feel 
you're on your own and you kind of feel a 
bit isolated – I think that doesn't make it 
any easier and makes it a wee bit more 
pressured and you maybe don't go out as 
much and stuff. I do think that is, maybe, 
with people who don't have that kind of 
family support – it might be a bit more 
difficult for them. So, maybe them having 
support groups and stuff. I think that's 
maybe lacking a wee bit. I don't think 
there's much in this area in terms of 
support groups and kind of social things 
that……. I think if there's maybe more of 
that – maybe…. 0:33:01.2 
Ella 
(HV) 
Often there is an impact 
on weight in that there 
would be a faltering 
growth and which would 
have been a failure to 
thrive before, or slow 
weight gain. The stool, I 
think, can vary from a 
very loose stool to a 
constipated stool, 
really… 
The big difference might 
be …. but whether it makes 
a difference on the 
management of reflux …. 
would be the lack of 
extended family support for 
a large proportion of my 
client group and that is 
certainly wearing for 
parents……. It's the mum's 
ability to manage and cope 
with it, and trying to keep 
the stress levels down 
because, obviously, that's an 
impact then as well on the 
baby. 0:15:12.8 
 
The partners would feel that mum's job is to 
care for the baby and look after herself, 
whereas the local men – white Western 
men would be expecting the house cleaned, 
and dinner on the table, and just carry on as 
per normal – so, that may well have an 
impact because that's all extra stress.  If 
you've had a rough night, and then you try 
to get your baby fed and changed, and it 
vomited and is upset – how can you get 
anything done?  And it just adds stress to 
the whole set-up then as well.  So, that, 
certainly ... 0:42:41.4 
 
I think, maybe mums now expect the babies 
to fit into their lifestyles as opposed to the 
whole lifestyle changing once you've had a 
 275 
 






The weight. I think if 
they're not actually 
putting on weight, or the 
weight is ….  they're not 
actually putting on a 
minimum amount of 
acceptable weight-gain, 
then I'd be considering 
that they need 
something to help them 
keep that milk down, or, 
if they're a very 
unsettled baby with all 
this possetting and 
refluxing, I would say 
again, we could do a trial 
with Gaviscon with that. 
It is more the weight I'm 




 Sometimes you find it's anxiety on the 
mum's behalf that's adding to it as well 
because I think there must be nothing 
worse for a mum who has been looking 
forward to this baby and then find out 
they've got a baby that cries an awful lot 
and they're looking for ways to answer why 
that crying is, rather than it just being 
maybe their baby and it's something you 
kind of sit and think, "Maybe you just have 
one of those babies that's doing really well 
and appears to be thriving every time I 
come in."   
 
I think the idea of just doing well, and being 
a mum and having this contented baby, and 
when it doesn't happen like that, that is 
quite distressing for the mum as well.  It 
doesn't help the situation because you're 
trying to tell them, "Look, if you're feeling 
maybe anxious and you're holding your 
baby, your baby will pick up from all these 
queues as well."  And it's just going to be a 
revolving circle for them. 
0:11:50.0 
 
0:24:30.6Yes, a lot of it (referring to 
parental anxiety) I think is due to 
technology – the fact that they're looking 
up everything; they're trying to solve 
problems themselves; and they're often 
doing stuff.  I mean, twenty years ago, when 
I had my children, you would Google up 
stuff and you would go on, but it wasn't as – 
you know, just go and do, "Oh, yeah, I'll do 
that, I'll just go and look it up."  I think a lot 
of them dwell on it.  They don't get the 
answer they want.  I think they've got a lot 
of forums to go on like Netmums and then 
they go in and get this whole barrage and 
sometimes I come in and have a look and I 
think, "Oh, sweet Lord" – somebody just put 
on a simple comment and they got a 
barrage of things back that they never even 
thought about, and all of a sudden 
something's gone from something, and all 
of a sudden they sit and they're thinking of 
a bigger picture and much more anxiety is 
put onto them then at that particular time. 
 
You do get a lot of parents that don't feel 
they have the same support networks that 
they had and they do look around them for 
what's out there on a computer.  
Sometimes they may ask somebody to do 














Jo (GP) I think that, within the 
practice, there is an 
expectation amongst our 
population and amongst 
our health visitors that 
we prescribe for reflux 
simply on the basis of 
pain, wriggling, perhaps 
difficulty winding, and I 
think that is probably 
happening within the 
practice. I don't know if 
it's happening on a wider 
scale. 
 
We're learning now what 
we've been told now is 
that they don't 
necessarily have to 
posset or vomit with any 
degree of force or 
volume or regularity; 
that pain and discomfort 
may be a sign of what is 
now accepted to be a 
diagnosis of gastro-
oesophageal reflux.  
 
Sometimes we'll get 
messages on our doctor 
screen suggesting that 
we prescribe something 
based on a diagnosis 
having been made by a 
health visitor. 
 
My own feeling is it might 
be the kind of middle class 
to lower social class parents 
who are living in a new 
house in our area and their 
expectations are quite high 
as to how things might go 
with a new baby and what 
life might be like with a new 
baby. That may be just a 
prejudice within myself in 
deciding that there is a core 
of mums who are finding it 
difficult to accept that it is 
difficult. 0:09:47.1 
And like I say, I'm not … It's 
not the poor souls that you 
think do need support …. 
perhaps the single teenage 
mums etcetera who are 
coming to us looking for a 
better pattern here; looking 
for a better, more 
manageable situation. It's 
the ones, most often, it's 
people who have all the 
expected benefits in place. 
They have a partner, they 
have their own house, they 
have separate bedrooms for 
a child and many of their 
other children and they 
have a car that they can 
transport a child in to 
necessary appointments 
etcetera. So, is this just a bit 
of the jigsaw that doesn't fit 
the expectation? I do 
wonder about that. I feel 
quite strongly that that may 
well be a driving force in 
some of this health-seeking 
behaviour amongst young … 
yes, perhaps professional or 
semi-professional mums. 
0:22:39.4 
My own feeling is it might be the kind of 
middle class to lower social class parents 
who are living in a new house in our area 
and their expectations are quite high as to 
how things might go with a new baby and 
what life might be like with a new baby. 
That may be just a prejudice within myself 
in deciding that there is a core of mums 









Study Title: Factors influencing and shaping the management of, and prescribing 
practices for infants aged 0 -12 months presenting with symptoms of gastro-
oesophageal reflux (GOR). 
 
I am asking if you would like to take part in a research project that aims to explore factors 
influencing the management of, and prescribing practices for infants presenting with 
symptom of gastro-oesophageal reflux (GOR). 
Before you consent to participating in the study we ask that you read the participant 
information sheet and mark each box below with your initials if you agree.  If you have any 
questions or queries before signing the consent form please speak to the principal 
investigator, Jean Cowie. 
 
Please initial box after each statement: 
 
1. I confirm that I have read the information sheet and fully 
understand what is expected of me within this study  
2. I confirm that I have had the opportunity to ask any 
questions and to have them answered.  
3. I understand that my interview will be audio recorded and 
then made into an anonymised written transcript. 
4. I understand that audio recordings will be kept until the 
research project has been examined. 
5. I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving any reason, 
without my legal rights being affected.  
6. I understand that once my data have been anonymised and 
incorporated into themes it might not be possible for it to be 
withdrawn, though every attempt will be made to extract my 
data, up to the point of publication. 
7. I understand that the information from my interview will be 
pooled with other participants’ responses, anonymised and 
may be published 
8. I consent to information and quotations from my interview 
being used in reports, conferences and training events.  
9. I understand that any information I give will remain strictly 
confidential and anonymous unless it is thought that there 
is a risk of harm to myself or others, in which case the 
principal investigator will need to share this information with 
her research supervisor.  
10. I consent to Lancaster University keeping written 
transcriptions of the interview for 5 years after the study has 
finished.                                      

































Applicant: Jean Cowie 
Supervisor: Christine Milligan 
Department: Health Research 
FHMREC Reference: FHMREC16096 
 
 




Re: Factors influencing and shaping the management of, and prescribing practices 
for infants aged 0 -12 months presenting with symptoms of gastro oesophageal 
reflux. 
 
Thank you for submitting your research ethics amendment application for the above 
project for review by the Faculty of Health and Medicine Research Ethics 
Committee (FHMREC). The application was recommended for approval by FHMREC, 
and on behalf of the Chair of the Committee, I can confirm that approval has been 
granted for the amendment to this research project. 
As principal investigator your responsibilities include: 
 
- ensuring that (where applicable) all the necessary legal and regulatory 
requirements 
in order to conduct the research are met, and the necessary licenses and approvals 
have been obtained; 
 
- reporting any ethics-related issues that occur during the course of the research or 
arising from the research to the Research Ethics Officer at the email address below 
(e.g. unforeseen ethical issues, complaints about the conduct of the research, 
adverse reactions such as extreme distress); 
 
- submitting details of proposed substantive amendments to the protocol to the 
Research Ethics Officer for approval. 
 
Please contact me if you have any queries or require further information. 





Dr Diane Hopkins 




Applicant: Jean Cowie 
Supervisor: Christine Milligan 
Department: Health Research 
FHMREC Reference: FHMREC16035 
 




Re: Factors influencing and shaping the management of, and prescribing practices 
for infants aged 0 -12 months presenting with symptoms of gastro oesophageal 
reflux. 
 
Thank you for submitting your research ethics amendment application for the above 
project for review by the Faculty of Health and Medicine Research Ethics 
Committee (FHMREC). The application was recommended for approval by FHMREC, 
and on behalf of the Chair of the Committee, I can confirm that approval has been 
granted for this research project. 
 
As principal investigator your responsibilities include: 
 
- ensuring that (where applicable) all the necessary legal and regulatory 
requirements 
in order to conduct the research are met, and the necessary licenses and approvals 
have been obtained; 
 
- reporting any ethics-related issues that occur during the course of the research or 
arising from the research to the Research Ethics Officer at the email address below 
(e.g. unforeseen ethical issues, complaints about the conduct of the research, 
adverse reactions such as extreme distress); 
 
- submitting details of proposed substantive amendments to the protocol to the 
Research Ethics Officer for approval. 
 
Please contact me if you have any queries or require further information. 





Dr Diane Hopkins 




Applicant: Jean Cowie 
Supervisor: Christine Milligan and Paula Holland 
Department: Health Research 
FHMREC Reference: FHMREC15084 




Re: Factors influencing and shaping the management of, and prescribing practices 
for infants aged 0 -12 months presenting with symptoms of gastro oesophageal 
reflux. 
 
Thank you for submitting your research ethics amendment application for the above 
project for review by the Faculty of Health and Medicine Research Ethics Committee 
(FHMREC). The application was recommended for approval by FHMREC, and on 
behalf of the Chair of the University Research Ethics Committee (UREC), I can confirm 
that approval has been granted for this research project. The approval is given with 
the caveat that NHSREC ethical approval be sought as appropriate. 
 
As principal investigator your responsibilities include: 
 
- ensuring that (where applicable) all the necessary legal and regulatory 
requirements in order to conduct the research are met, and the necessary licenses 
and approvals have been obtained; 
 
- reporting any ethics-related issues that occur during the course of the research or 
arising from the research to the Research Ethics Officer (e.g. unforeseen ethical 
issues, complaints about the conduct of the research, adverse reactions such as 
extreme distress); 
 
- submitting details of proposed substantive amendments to the protocol to the 
Research Ethics Officer for approval. 
 
Please contact the Diane Hopkins (01542 592838 
fhmresearchsupport@lancaster.ac.uk ) if 




Dr Diane Hopkins 
Research Development Officer 





Research and Development Foresterhill House Annexe 
      Foresterhill 
      ABERDEEN 




Miss Jean Cowie  Date  07/01/2015 
The Robert Gordon University  Project No 2014GA002 
School of Nursing and Midwifery  Enquiries to 
Garthdee Campus    Extension 53846 
Garthdee Road    Direct Line 01224 553846 
AB10 7QG     Email     




Dear Miss Cowie 
 
Management Permission for Non-Commercial Research 
 
 
STUDY TITLE: Factors influencing and shaping the management of, and 
prescribing practice for infants aged 0 - 12 months presenting 
with symptoms of gastro-oesophageal reflux (GOR)   
PROTOCOL NO: Research Proposal 
REC REF: N/A  
NRS REF:  N/A 
 
 
Thank you very much for sending all relevant documentation.  I am pleased to confirm 
that the project is now registered with the NHS Grampian Research & Development 
Office.  The project now has R & D Management Permission to proceed locally.  This 
is based on the documents received from yourself and the relevant Approvals being in 
place. 
 
All research with an NHS element is subject to the Research Governance Framework 
for Health and Community Care (2006, 2nd edition), and as Chief or Principal 
Investigator you should be fully committed to your responsibilities associated with this. 
 
It is particularly important that you inform us when the study terminates. 
 
The R&D Office must be notified immediately and any relevant documents forwarded 
to us if any of the following occur: 
 
▪ A change of Principal Investigator, Chief Investigator or any additional research 
personnel 
▪ Premature project termination 
▪ Any amendments – substantial or non-substantial (particularly a study 
extension) 





We hope the project goes well, and if you need any help or advice relating to your R&D 




























































Prescribing rate of Alginate (per 100) and confidence intervals (lower – upper) for infants aged 0-1 year in each NHS Board (2010-2016    APPENDIX 10 
 
* The number of patients is < 20 therefore the confidence interval may be unreliable. 
NHS Board 2010 2011 2012 2013 2014 2015 2016 








































































































































































































Prescribing rate of domperidone (per 100) and confidence intervals (lower – upper) for infants aged 0-1 year in each NHS Board (2010-2016) 
 
* The number of patients is < 20 therefore the confidence interval may be unreliable. 
 
NHS Board 2010 2011 2012 2013 2014 2015 2016 










































































































































































































Prescribing rate of omeprazole (per 100) and confidence intervals (lower – upper) for infants aged 0-1 year in each NHS Board (2010-2016) 
 
* The number of patients is < 20 therefore the confidence interval may be unreliable. 
NHS Board 2010 2011 2012 2013 2014 2015 2016 










































































































































































































Prescribing rate of ranitidine (per 100) and confidence intervals (lower – upper) for infants aged 0-1 year in each NHS Board (2010-2016) 
 
* The number of patients is < 20 therefore the confidence interval may be unreliable. 
NHS Board 2010 2011 2012 2013 2014 2015 2016 














































































































































































































Ranking* of NHS Boards for prescribing of alginate in infants age 0-1 year (2010-2016) 





Ranking* of NHS Boards for prescribing of domperidone in infants age 0-1 year (2010-2016) 
 
NHS Board Year  
 2010 2011 2012 2013 2014 2015 2016 Mean 
rank 
Ayrshire & Arran 11 7 5 6 8 11 13 8.71 
Borders 4 3 3 2 2 3 1 2.57 
Dumfries & Galloway 10 8 6 5 5 6 9 7.00 
Fife 1 1 1 3 3 2 3 2.00 
Forth Valley 5 4 4 4 4 4 10 5.00 
Grampian 6 5 7 7 9 9 7 7.14 
Greater Glasgow & 
Clyde 
13 12 11 11 13 13 11 12.00 
Highland 12 11 10 12 11 7 6 9.86 
Lanarkshire 8 10 9 9 12 12 12 10.29 
Lothian 2 2 2 1 1 1 2 1.57 
Orkney  7 13 13.5 10 6 10 4 9.07 
Shetland 3 14 13.5 13 10 14 14 11.64 
Tayside 9 6 8 8 7 5 8 7.29 
Western Isles 14 9 12 14 14 8 5 10.86 
*Ranking: 1= highest rank 
NHS Board Year  
 2010 2011 2012 2013 2014 2015 2016 Mean 
rank 
Ayrshire & Arran 12 13 12 12 10 9 9 11.0 
Borders 9 9 11 10 12 13 8 10.3 
Dumfries & Galloway 11 10 10 6 6 4 4 7.3 
Fife 6 5 4 4 5 5 5 4.9 
Forth Valley 3 3 1 1 2 3 6 2.7 
Grampian 1 1 2 3 4 6 7 3.4 
Greater Glasgow & 
Clyde 
4 4 5 2 1 1 2 2.7 
Highland 7 7 6 9 7 8 11 7.9 
Lanarkshire 2 2 3 5 3 2 1 2.6 
Lothian 8 6 8 7 9 11 10 8.4 
Orkney  14 11 13 13 11 14 14 12.9 
Shetland 5 12 9 8 13 7 3 8.1 
Tayside 10 8 7 11 8 10 12 9.4 






Ranking of NHS Boards for prescribing of omeprazole in infants age 0-1 year (2010-2016) 
 
NHS Board Year  
 2010 2011 2012 2013 2014 2015 2016 Mean 
rank 
Ayrshire & Arran 12 13 11 12 12 11 12 11.83 
Borders 5 4 4 6 5 6 8 5.50 
Dumfries & Galloway 4 5 3 2 2 3 2 2.83 
Fife 3 3 5 4 3 2 3 3.33 
Forth Valley 9 6 6 7 7 9 6 6.83 
Grampian 10 9 10 10 11 10 10 10.00 
Greater Glasgow & 
Clyde 
7 8 7 5 6 4 5 5.83 
Highland 8 7 8 9 8 7 7 7.67 
Lanarkshire 2 2 2 3 4 5 4 3.33 
Lothian 1 1 1 1 1 1 1 1.00 
Orkney  13.5 10 13.5 8 9 14 13 11.25 
Shetland 6 12 12 13 14 12 11 12.33 
Tayside 11 11 9 11 10 8 9 9.67 
Western Isles 13.5 14 13.5 14 13 13 14 13.58 






Ranking* of NHS Boards for prescribing of ranitidine in infants age 0-1 year (2010-2016) 
 
NHS Board Year  
 2010 2011 2012 2013 2014 2015 2016 Mean 
rank 
Ayrshire & Arran 14 13 11 12 12 12 11 11.83 
Borders 11 5 10 11 9 11 12 9.67 
Dumfries & Galloway 12 10 12 13 13 14 13 12.50 
Fife 6 7 4 8 8 8 8 7.17 
Forth Valley 3 3 2 3 2 2 3 2.50 
Grampian 1 1 1 1 1 1 2 1.17 
Greater Glasgow & 
Clyde 
9 8 9 9 10 4 6 7.67 
Highland 7 4 6 6 7 3 4 5.00 
Lanarkshire 13 12 7 10 11 10 5 9.17 
Lothian 8 9 8 5 6 9 7 7.33 
Orkney  4 14 13 4 3 6 9 8.17 
Shetland 2 2 3 2 4 5 1 2.83 
Tayside 5 6 5 7 5 7 10 6.67 
Western Isles 10 11 14 14 14 13 14 13.33 
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